

Ali I. Shamseddine, M.B., CH.B., FRCP, ESCO

I. PERSONAL EXPERIENCE

ADDRESS:

Professor of Clinical Medicine
Hematology-Oncology Division
American University of Beirut – Medical Center
Department of Internal Medicine
P.O. Box: 113-6044
Beirut – Lebanon
Telephone: 961 1 374374/ Ext: 5390
Fax: 961 1 342517
E-mail: as04@aub.edu.lb

MARITAL STATUS:

Married to Randa Ghosn.
Have 2 children, Ashraf 1987 and Lama 1990

CITIZENSHIP:

Lebanon. Belgium

LICENSURE:

Lebanese Licensure
Egyptian Licensure

DEGREES:

M.B., Ch.B.	Nov. 1980
FRCP	May 2012
Faculty of the European School of Oncology ESCO	June 2020

MEDICAL COLLEGE:

Alexandria University – Egypt

POST GRADUATE TRAINING:

i. INTERNSHIP

Rotating	March 1, 1981
Alexandria University Hospital	February 28, 1982
Alexandria, Egypt	

ii. RESIDENCY

PGY1, Department of Radiotherapy & Medical Oncology	April 25, 1982
Alexandria University Hospital	July 1, 1983
Alexandria, Egypt	

PGY1, PGY2, PGY3	July 1, 1983
Department of Internal Medicine	June 30, 1986
Makassed General Hospital affiliated With the American University of Beirut	

iii. FELLOWSHIP

Fellow I, Hematology – Oncology	July 1, 1986
American University of Beirut	June 30, 1987

Fellow II, Hematology – Oncology
American University of Beirut

July 1, 1987
June 30, 1988

ACADEMIC APPOINTMENTS:

- A. Professor of Clinical Medicine** Oct. 1, 2005- Present
Department of Internal Medicine
Head Hematology – Oncology Division (until November 2017)
American University of Beirut – Medical Center
- B. Associate Professor of Clinical Medicine** Oct. 1 2000- Sep. 30 2005
Department of Internal Medicine
Hematology – Oncology Division
American University of Beirut – Medical Center
- C. Assistant Professor of Medicine** July 1, 1994-Sept 30, 2000
Department of Internal Medicine
Hematology – Oncology Division
American University of Beirut – Medical Center
- D. Instructor** Aug. 1, 1991- June 30, 1994
Department of Internal Medicine
Hematology – Oncology Division
- E. Clinical and Research Associate** July 21, 1988 – July 31, 1991
Department of Internal Medicine
Hematology – Oncology Division
American University of Beirut – Medical Center

ACADEMIC POSITIONS:

Head, Hematology – Oncology Division Sept. 1, 2000- Nov 2017
Department of Internal Medicine
American University of Beirut – Medical center

Director,

Gastrointestinal and genitourinary Oncology Services March 2011-Present

Director, Data Management and Clinical Research Unit Oct. 2012 – June 2018

Data management unit July 2018- present

NK Basile cancer Institute

HONORS AND AWARDS:

- 1. AUB Faculty Recognition Among the World's Most-Cited researchers**
Stanford University's Science-wide Author Databases of Standardized Citation Indicators Dec 2024
- 2. Sigma XI**
The scientific research honor society Nov 2023
- 3. King Hussein Award for Cancer Research**
Lifetime achievement award Sep 2023
- 4. Appreciation trophy and Award for Service Excellence**
For Department of Medicine May 2018
- 5. Certificate of appreciation**
For participation in writing and reviewing the National Guidelines for Cancer Treatment in Lebanon (GI section) Jan. 2018
- 6. Appreciation trophy for Leading Hematology – Oncology Division**
Pathway of Steady Growth and Prosperity 2000-2017 Dec. 2017
- 7. Certificate of Appreciation** March 2013
For the contribution in the National Cancer Treatment Guidelines
- 8. Statement of Appreciation Military Jordanian Services**
As a leader in Medical Oncology Dec. 2009

- 9. Medal of Appreciation** Nov. 2008
 Lebanese Society of Medical Oncology
 For the Service as a president of the Society 2006-2008
- 10. Leading Scientists and Engineers** May 2006
 OIC Member States
 (Organization of Islamic Conference Standing Committee on Scientific and Technological Cooperation)
- 11. 2000 outstanding Scientists of the 21st Century** March 2003
 International Biographical Center Cambridge, England
- 12. Medal of Appreciation** May. 2004
 Lebanese Order of Physician
 Lebanese Society of Medical Oncology
 (For Cancer incidence study in Lebanon, the first national Based study since 4 decades)
- 13. Dean`s Honor List** Nov. 1981

II. RESEARCH

A. BOOKS

- 1. Colorectal Cancer Screening in the Middle East: What, Why, Who, When, and How?**
 Shamseddine A, Chehade L, Al Mahmasani L, Charafeddine M.
 Book Chapter Am Soc Clin Oncol Educ Book. 2023
- 2. Cancer Control Eastern Mediterranean Region Special Report : Cancer surveillance in the Eastern Mediterranean Region**
 Al Zahrani Ali, Shamseddine A, Basu P, Hamadeh R, Abdel-Razq H, Charafeddine M, Altahan F, A Alessy S, Znaor A, Shen Z, Fouad H, Zendeheel K, Eser S, Abdul-Sater Z, Al-Lawati J, Fadhil I
 Book Chapter. 2022

3. **Cancer Control Eastern Mediterranean Region Special Report : Cancer prevention: Infection and environment as risk factors**
Al Zahrani Ali, Shamseddine A, Basu P, Hamadeh R, Abdel-Razq H, Charafeddine M, Altahan F, A Alessy S, Znaor A, Shen Z, Fouad H, Zendejdel K, Eser S, Abdul-Sater Z, Al-Lawati J, Fadhil I
Book Chapter. 2022
4. **Holland And Frei's Cancer Medicine Book: Parasites and Cancer**
El Azouri M, El Matar C, Galal R, Jabra E, Shamseddine A
Book Chapter. 2021
5. **Hcc/Liver Cancer Un The Middle East: Radiotherapy for Hepatocellular Carcinoma**
Mahmoud D, Mohammad M, Zeidan Y, Shamseddine A
Book Chapter. 2021
6. Tumor Registry: 20 years of service. American University of Beirut Medical center.
Shamseddine, A. Editor in Chief. Muhieddine Seoud, Associate editor, Maya Charafeddine, Managing editor. (2004)
7. Cancer Report of Asian – Pacific Region 2010, May 2010, 5.2.23:361-3
Chapter: Cancer In Asian- Pacific region Countries / Lebanon
Shamseddine A, Musallam K.

B. PUBLICATIONS

1. Temraz S, Charafeddine M, Khalifeh MJ, **Shamseddine A.** Pre-Operative Markers of Post-Operative Complications in Pancreatic Cancer Patients: A Single-Center Study. J Epidemiol Glob Health. 2025 Feb 17;15(1):28.
2. George G, Enting D, Garmo H, Stattin P, Franck Lissbrant I, Monroy-Iglesias M, Scailteux L-M, Balusson F, Van Praet C, Lumen N, Marvaso G, Corrao G, Jereczek-Fossa B A, Chehade L, **Shamseddine A,** Charafeddine M, Van Hemelrijck M. Guidelines and variations in patterns of GnRH analogue use in castration-resistant prostate cancer across six countries. ESMO RWD Digital Oncol. 2025 (In press)
3. Abbas N, Chehade L, Tarhini H, Abdul Sater Z, **Shamseddine A.** Trends and Gaps in Colorectal Cancer Screening Research in the Arab World: A 16-Year Bibliometric Analysis (2007-2023). Int. J. Environ. Res. Public Health 2025, 22(2), 264.
4. Abbas N, Chehade L, Abdul Sater Z, **Shamseddine A.** The Silent Burden of De Novo Metastatic Prostate Cancer in the Middle East: A Call for Region-Specific Screening Guidelines. Soc. Int. Urol. J. 2025, 6(1), 4.
5. Abbas N, Zahreddine L, Tawil A, Natout M, **Shamseddine A.** An Atypical Case of Pancreatic Cancer with Mesenchymal Differentiation in a Patient with Primary Lung Adenocarcinoma:

- Insights into Tumor Biology and Novel Therapeutic Pathways. *Diagnostics* (Basel). 2024 Nov 9;14(22):2512.
6. Chehade L, Dagher K, Shamseddine A. Tailoring treatment for locally advanced rectal cancer. *Cancer Treat Res Commun*. 2024;41:100847. doi: 10.1016/j.ctarc.2024.100847. Epub 2024 Oct 2.
 7. Mourad M, Al Mahmasani L, Abbas N, Sainamthip P, Freile B, Zayed A, Alsuwailem R, Khatib O, Sinno S, Sabatin F, Shia J, Kreidieh F, Paroder V, Alam S, **Shamseddine A**, Abou-Alfa GK. Balancing anticancer therapy efficacy and safety in advanced hepatocellular carcinoma: a case report. *J Gastrointest Oncol* 2024. doi: 10.21037/jgo-24-359
 8. Pereira MM, Couto E, **Shamseddine A**, Macedo T. Two Decades of Gastrointestinal Stromal Tumor Management With First-Line Treatment: A Case Report. *Cureus*. 2024 Oct 12;16(10):e71299. doi: 10.7759/cureus.71299.
 9. Abi Ghanem A, El Annan T, El Ghawi N, Omran N, Natout M, Assi H, **Shamseddine A**, Saliba N, Haidar M. Enhanced Pancreatitis Detection: FAPI PET/CT Emerging Utility in Patient with Pancreatic Mass. *Diagnostics*. 2024; 14(15):1622.
 10. Saleh Y, Abu Hejleh T, Abdelrahim M, **Shamseddine A**, Chehade L, Alawabdeh T, Mohamad I, Sammour M, Turfa R. Hepatocellular Carcinoma: The Evolving Role of Systemic Therapies as a Bridging Treatment to Liver Transplantation. *Cancers* 2024, 16, 2081.
 11. Abbas N, Chehade L, **Shamseddine A**. Personalized treatment with PARP inhibitors in advanced urothelial carcinoma: a case report and literature review. *Ther Adv Med Oncol*. 2024 Apr 16;16:17588359241245283.
 12. El-Karak F, **Shamseddine A**, Omar A, Haddad I, Abdelgawad M, Naqqash A, Kaddour MA, Sharaf M, Abdo E. Prostate cancer across four countries in the Middle East: a multi-centre, observational, retrospective and prognostic study. *eCancer* 2024, 18:1695
 13. Kattan J, Temraz S, Nasr F, Tfayli A, Khater C, Mugharbel A, Ghanem H, Kourie HR, Hachem G, Masri S, Debs J, **Shamseddine A**. Management practices of locally advanced and metastatic urothelial carcinoma: A questionnaire-based survey among Lebanese oncologists. *Open J. Urol* (in press).
 14. Sbaity E, Tamim H, El-Hajj Fuleihan G, Abbas J, Zahwe M, El Sayed R, **Shamseddine A**. Effect of young age (below 40 years) on oncologic outcomes in Lebanese patients with breast cancer: a matched cohort study. *BMC Cancer* 2024 (in press).
 15. Mahmoud W, Hassoun L, Kerbage A, Mukherji D, **Shamseddine A**, Tamraz S, Hakim A, Barada K. Esophageal cancer: a twenty-four-year experience at a tertiary care center with an evaluation of the prognostic significance of the neutrophil-lymphocyte ratio. *BMC Gastroenterol*. 2024 Jan 9;24(1):27.
 16. Temraz S, Kreidieh Firas, Nassar F, Mezher M, Mukherji D, **Shamseddine A**. Second-line modified GTX versus Gemcitabine-Nab-Paclitaxel (GmAb) following first-line

FOLFIRINOX in advanced pancreatic cancer: a retrospective analysis at the American University of Beirut Medical Center (AUBMC). *MEJC*. 2023 Oct; 14(4): 550-558.

17. Chehade L, Elias C, Mukherji D, Temraz S, Salem Z, Charafeddine M, Darazi MA, **Shamseddine A**. Maintenance chemotherapy in advanced and metastatic pancreatic cancer, a narrative review and case series. *Asia Pac J Clin Oncol*. 2023 Aug;19(4):419-426
18. Kourie HR, Mahrous M, Naim N, Zouein J, Benbrahim Z, Rasul K, Mokhtar M, Shehri AA, Shakeeb M, Khatib S, Al-Shamsi H, **Shamseddine A**, Smyth E. The first Middle East and North Africa expert consensus recommendations for management of advanced gastric cancer. *Future Oncol*. 2023 Jul;19(21):1451-1459.
19. Haidar M, Al Mahmasani L, Chehade L, Elias C, El Jebai M, Temraz S, Charafeddine M, Al Darazi M, **Shamseddine A**. Well-differentiated gastro-entero-pancreatic neuroendocrine tumors with positive FDG-PET/CT: a retrospective chart review. *Nucl Med Commun*. 2023 Jun 1;44(6):471-479.
20. Abdallah R, Atallah D, Bitar N, Chahine G, Ghanem H, Ghosn M, Kattan J, Nasr F, Makdessi J, **Shamseddine A**. Consensus on the management of platinum-sensitive high-grade serous epithelial ovarian cancer in Lebanon. *Gynecol Oncol Rep*. 2023 Apr 23;47
21. Ghosn M, Kattan J, Karak FE, Ghanem H, Debs J, Ibrahim K, **Shamseddine A**. Renal cell carcinoma management: real-world practice and challenges at a national level. *Future Oncol*. 2023 Apr;19(12):863-872. Doi: 10.2217/fon-2021-1189.
22. Abdallah R, Atallah D, Bitar N, Chahine G, Ghanem H, Ghosn M, Kattan J, Nasr F, Makdessi J, **Shamseddine A**. Consensus on the management of platinum-sensitive high-grade serous epithelial ovarian cancer in Lebanon, *Gynecol Oncol Rep*. 2023 Apr 5;47:101186
23. Hamadeh LN, Farhat L, Hilal L, Assi H, Nasr F, Chahine G, Kattan J, Farhat F, Kourie H, El Hachem G, Ghosn M, El Saghir N, Chamseddine N, Finianos A, Ghanem H, Younes A, Gerges DA, Temraz S, Haidar M, Nabhan T, **Shamseddine A**, Tfayli A, Zaatari G, Mahfouz R. Frequency and mutational spectrum of PIK3CA gene mutations in breast cancer patients: Largest and first report from Lebanon. *Gene*. 2023 Apr 15; 871:147433.
24. Haidar M, Al Mahmasani L, Chehade L, Elias C, El Jebai M, Temraz S, Charafeddine M, Al Darazi M, **Shamseddine A**. Well-differentiated gastro-entero-pancreatic neuroendocrine tumors with positive FDG-PET/CT: a retrospective chart review. *Nucl Med Commun*. 2023 Mar 10.
25. Temraz S, Jabbour J, Nassar F, El Helou R, Hadla R, Mezher M, El Lakkiss A, Charafeddine M, Nasr R, **Shamseddine A**. Can plasma vitamin C predict survival in stage IV colorectal cancer patients? Results of a prospective cohort study. *Front Nutr*. 2023 Mar 6; 10:1110405.
26. Machmouchi A, Chehade L, Temraz S, **Shamseddine A**. Overcoming EGFR Resistance in Metastatic Colorectal Cancer Using Vitamin C: A Review. *Biomedicines*. 2023 Feb 23;11(3):678.

27. El Charif MH, Amro S, Boulos F, Khalife M, **Shamseddine A**, Assi H, Sbaity E. Extra-gastrointestinal stromal tumors (EGISTs): A case report for a mischief entity. *Medicine (Baltimore)*. 2023 Mar 31;102(13):e33394
28. Bouferraa Y, Haibe Y, Hamdan H, Mahfouz R, Chakhachiro Z, **Shamseddine A**. Thrombotic Microangiopathy in the Setting of Colorectal Cancer: A Therapeutic Challenge with a Bad Prognosis. *Hematol Rep*. 2023 Jan 4;15(1):9-16.
29. Chehade L, Elias C, Mukherji D, Temraz S, Salem Z, Charafeddine M, Darazi MA, **Shamseddine A**. Maintenance chemotherapy in advanced and metastatic pancreatic cancer, a narrative review and case series. *Asia Pac J Clin Oncol*. 2022 Dec 20.
30. Elias C, Zeidan YH, Bouferraa Y, Mukherji D, Temraz S, Charafeddine M, Al Darazi M, **Shamseddine A**. A phase II single arm study of Nivolumab with stereotactic Ablative radiation Therapy after induction chemotherapy in CHolangiocarcinoma (NATCHO) *BMC Cancer*. 2022 Dec 12;22(1):1296.
31. Ayoub Z, Khader J, Bulbul M, Khaulil RB, Andraos TY, **Shamseddine A**, Mukherji D, Geara FB. Adjusting the duration of androgen deprivation therapy (ADT) based on nadir PSA for high risk localized prostate cancer patients treated with definitive external beam radiation therapy and ADT. *BMC Urol*. 2022 Dec 12;22(1):204.
32. Temraz S, Nassar F, Hammoud MS, Mukherji D, O'Reilly EM, Dbouk H, Farhat F, Charafeddine M, Faraj W, Khalifeh MJ, Abou-Alfa GK, **Shamseddine A**. Neo-adjuvant FOLFIRINOX in borderline resectable and locally advanced pancreatic adenocarcinoma. *Asia Pac J Clin Oncol*. 2022 Dec;18(6):735-742.
33. Haidar M, Abi-Ghanem AS, Moukaddam H, Jebai ME, Al Zakleet S, Al Rayess S, Akkawi AR, Kassas M, Tamim H, Hajj AE, Estrada-Lobato E, Osman MM, **Shamseddine A**. (68) Ga-PSMA PET/CT in early relapsed prostate cancer patients after radical therapy. *Sci Rep*. 2022 Nov 28;12(1):20500.
34. Abdul-Sater Z, Mukherji D, Adib SM, **Shamseddine A**, Abu-Sitta G, Fadhil I, Sullivan R, Omari AA, Saleh S, Taher A. Cancer registration in the Middle East, North Africa, and Turkey (MENAT) region: A tale of conflict, challenges, and opportunities. *Front Oncol*. 2022 Nov 24; 12:1050168. e-collection 2022.
35. Kakati RT, Faraj W, Qaraq T, El Chaer F, Hussain H, **Shamseddine A**, Khalife MJ. Immunotherapy for metastatic liver disease from colorectal carcinoma: case series from the Middle East *J Surg Case Rep*. 2022 Aug 31;2022(8):142.
36. Kourie HR, Ibn shamsah F, Zouein J, Naim N, Abbasi S, Allahloubi N, Al-Naqqash M, Alolayan A, Alshehri A, Bitar N, Bounedjar A, Farsi AA, Shamsi HE, Ghali R, Jaafar H, Larbaoui B, Mahrous M, Mrabti H, Nweir AR, Oukkal M, Rasul K, Razavi M, Turfa R, Khatib S, **Shamseddine A**. The first Middle East and North Africa expert consensus recommendations for the management of advanced colorectal cancer. *Future Oncol*. 2022 Aug;18(24):2733-2744. Epub 2022 Jul 6.

- 37.** Farge D, Frere C, Connors JM, Khorana AA, Kakkar A, Ay C, Muñoz A, Brenner B, Prata PH, Brilhante D, Antic D, Casais P, Guillermo Esposito MC, Ikezoe T, Abutalib SA, Meillon-García LA, Bounameaux H, Pabinger I, Douketis J; International Initiative on Thrombosis and Cancer (ITAC) advisory panel. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. *Lancet Oncol.* 2022 Jul;23(7): e334-e347.
- 38.** Temraz S, Nasr R, Mukherji D, Kreidieh F, **Shamseddine A.** Liquid biopsy derived circulating tumor cells and circulating tumor DNA as novel biomarkers in hepatocellular carcinoma. *Expert Rev Mol Diagn.* 2022 May;22(5):507-518. Epub 2022 Jun 29.
- 39.** Bouferraa Y, Haibe Y, Jabra E, Charafeddine M, Kreidieh M, Raad R, Temraz S, Mukherji D, Ershaid F, Muallem N, Faraj W, Khalife M, Eid RA, **Shamseddine A.** Comparison Between Liver Stiffness Measurement By Fibro scan And Splenic Volume Index As Noninvasive Tools For The Early Detection Of Oxaliplatin-Induced Hepatotoxicity. *Journal Of Clinical And Experimental Hepatology.* 2022, vol.12, no.2, pp-448-453
- 40.** Yalcin S, Philip PA, Athanasiadis I, Bazarbashi S, **Shamseddine A.** Classification Of Early-Stage Colon Cancer With Immunoscore®: Clinical Evidence And Case Studies. *Future Oncology (London, England).* 2022, vol.18, no.5, pp-613-623
- 41.** Bouferraa Y, Haibe Y, Chedid A, Jabra E, Charafeddine M, Temraz S, Mukherji D, El Saghir N, **Shamseddine A.** The Impact of Young Age (<40 years) On The Outcome Of a Cohort Of Patients With Primary Non-Metastatic Breast Cancer: Analysis Of 10-Year Survival Of a Prospective Study. *BMC Cancer.* 2022, vol.22, no.1, pp-27
- 42.** Temraz S, Nasr F, Kattan J, Abigeres D, Moukadem W, Farhat F, Maatouk L, Chahine G, **Shamseddine A.** A Non-Interventional Multicenter Study Of First-Line Bevacizumab In Combination With Chemotherapy In Patients With Metastatic Colorectal Cancer In Lebanon. *Biologics: Targets & Therapy.* 2022, vol.16, pp-7-15
- 43.** Temraz S, Salim Hamoud M, Zorkot M, Albonji W, Dbouk H, Farhat F, Charafeddine M, Mukherji D, **Shamseddine A.** Neo-Adjuvant Folfirinox in Borderline-Resectable/Locally Advanced Pancreatic Adenocarcinoma: An Updated Analysis. *Annals Of Oncology.* 2022, vol.29, no.5
- 44.** Abdel Sater AH, Bouferraa Y, Amhaz G, Haibe Y, Lakkiss AE, **Shamseddine A.** From Tumor Cells to Endothelium and Gut Microbiome: A Complex Interaction Favoring The Metastasis Cascade. *Frontiers In Oncology.* 2022, vol.12, pp-804983
- 45.** de Castria TB, Tang L, Queiroz MM, Awani BM, Paroder V, **Shamseddine A,** Bariani GM, Mukherji D, Matar CF, Fernandes GDS, El-Olayan A, Sabatin F, Elias R, Gupta R, Janjigian YY, Abou-Alfa GK. Hepatoid Esophagogastric Adenocarcinoma and Tumoral Heterogeneity: A Case Report. *Journal Of Gastrointestinal Oncology.* 2021, vol.12, no.6, pp-3123-3132
- 46.** Husseini ZE, Haibe Y, Bouferraa Y, Kreidieh M, Darazi MA, Mukherji D, Temraz S, Charafeddine M, **Shamseddine A.** Total Neoadjuvant Therapy in Patients with Locally Advanced Rectal Cancer: A Tertiary Medical Center Experience. *Molecular And Clinical*

Oncology. 2021, vol.15, no.4, pp-220

47. Daher M, Televizian T, Dagher C, Abdul-Sater Z, Massih SA, Chediak AE, Charafeddine M, Shahait M, Alameddine R, Temraz S, Geara F, Youssef B, El Hajj A, Nasr R, Wazzan W, Bulbul M, Khauli R, **Shamseddine A**, Mukherji D. High Rates of Advanced Prostate Cancer in the Middle East: Analysis From A Tertiary Care Center. *Urology Annals*. 2021, vol.13, no.4, pp-418-423
48. Abdul-Sater Z, **Shamseddine A**, Taher A, Fouad F, Abu-Sitta G, Fadhil I, Saab R, Sullivan R, Adib SM, Saleh S, Mukherji D, Cancer Registration in The Middle East, North Africa, And Turkey: Scope And Challenges. *JCO Global Oncology*. 2021, vol.7, pp-1101-1109
49. Bouferraa Y, Chedid A, Amhaz G, El Lakkiss A, Mukherji D, Temraz S, **Shamseddine A**. The Role of Gut Microbiota in Overcoming Resistance to Checkpoint Inhibitors in Cancer Patients: Mechanisms and Challenges. *Int J Mol Sci*. 2021 Jul 27;22(15):8036.
50. Temraz S, Nassar F, Kreidieh F, Mukherji D, **Shamseddine A**, Nasr R. Hepatocellular Carcinoma Immunotherapy, and the Potential Influence of Gut Microbiome. *Int J Mol Sci*. 2021 Jul 21;22(15):7800.
51. Jabra E, Al-Omari A, Haddadin F, Alam W, Ammar K, Charafeddine M, Alrawashdeh M, Kasasbeh N, Habis C, Mukherji D, Temraz S, **Shamseddine A**. Waterpipe Smoking among Bladder Cancer Patients: A Cross-Sectional Study of Lebanese and Jordanian Populations. *J Smok Cessat*. 2021 Apr 19; 2021:6615832.
52. Khauli M, Heidar NA, Degheili JA, Hakam N, Al-Moussawy M, Shahait M, El-Asmar J, Bustros G, Merhe A, Nasr R, Bulbul M, Wazzan W, El-Hajj A, **Shamseddine A**, Kfoury H, Mukherji D, Khauli R. Comparative analysis of histopathological subtypes of renal cell carcinoma in the Middle East compared to other world regions. *Urol Ann*. 2021 Apr-Jun;13(2):130-133.
53. Temraz S, Mukherji D, Nassar F, Moukalled N, **Shamseddine A**. Treatment sequencing of metastatic colorectal cancer based on primary tumor location. *Semin Oncol*. 2021 Jun 2: S0093-7754(21)00025-7.
54. Alam W, Bouferraa Y, Haibe Y, **Shamseddine A**. Complete Radiological Response of Recurrent Metastatic Adrenocortical Carcinoma to Pembrolizumab and Mitotane. *Clin Med Insights Oncol*. 2021 Apr 8; 15:11795549211007682.
55. Alam W, Bouferraa Y, Haibe Y, Mukherji D, **Shamseddine A**. Management of colorectal cancer in the era of COVID-19: Challenges and suggestions. *Sci Prog*. 2021 Apr-Jun;104(2):368504211010626.
56. El Sayed R, Haibe Y, Amhaz G, Bouferraa Y, **Shamseddine A**. Metabolic Factors Affecting Tumor Immunogenicity: What Is Happening at the Cellular Level? *Int J Mol Sci*. 2021 Feb 21;22(4):2142.
57. Nassar FJ, Msheik ZS, Itani MM, Helou RE, Hadla R, Kreidieh F, Bejjany R, Mukherji D, **Shamseddine A**, Nasr RR, Temraz SN. Circulating miRNA as Biomarkers for Colorectal Cancer Diagnosis and Liver Metastasis. *Diagnostics (Basel)*. 2021 Feb 19;11(2):341.

58. El Halabi M, Horanieh R, Tamim H, Mukherji D, Jdiaa S, Temraz S, **Shamseddine A**, Barada K. The impact of age on prognosis in patients with gastric cancer: experience in a tertiary care center. *J Gastrointest Oncol*. 2020 Dec;11(6):1233-1241.
59. **Shamseddine A**, Zeidan YH, El Hussein Z, Kreidieh M, Al Darazi M, Turfa R, Kattan J, Khalifeh I, Mukherji D, Temraz S, Alqasem K, Amarin R, Al Awabdeh T, Deeba S, Jamali F, Mohamad I, Elkhaldi M, Daoud F, Al Masri M, Dabous A, Hushki A, Jaber O, Charafeddine M, Geara F. Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma. *Radiat Oncol*. 2020 Oct 7;15(1):233.
60. Halabi IE, Hussein ZE, Haibe Y, Charafeddine M, Mukherji D, Temraz S, Bulbul M, Khauli R, Nasr R, Wazzan W, Hajj AE, Geara F, **Shamseddine A**. Cystectomy vs. bladder preservation after neoadjuvant chemotherapy in muscle-invasive bladder cancer: A tertiary medical center experience. *Cancer Treat Res Commun*. 2020 Oct 10; 25:100222.
61. Nasr R, **Shamseddine A**, Mukherji D, Nassar F, Temraz S. The Crosstalk between Microbiome and Immune Response in Gastric Cancer. *Int J Mol Sci*. 2020 Sep 9;21(18):6586.
62. **Shamseddine A**, Zeidan YH, Kreidieh M, Khalifeh I, Turfa R, Kattan J, Mukherji D, Temraz S, Alqasem K, Amarin R, Al Awabdeh T, Deeba S, Jamali F, Mohamad I, Elkhaldi M, Daoud F, Al Masri M, Dabous A, Hushki A, Jaber O, Khoury C, El Hussein Z, Charafeddine M, Al Darazi M, Geara F. Short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma. *BMC Cancer*. 2020 Sep 1;20(1):831
63. Haibe Y, El Hussein Z, El Sayed R, **Shamseddine A**. Resisting Resistance to Immune Checkpoint Therapy: A Systematic Review. *Int J Mol Sci*. 2020 Aug 27;21(17):6176.
64. Temraz S, Haidar M, Assi R, Hakim R, Jabra E, Charafeddine M, El Halabi I, Mukherji D, **Shamseddine A**. Pancreatic Neuroendocrine Tumors: Experience of a tertiary care center in Lebanon. *Ann Cancer Res Ther*. 2020; 28 (1): 9-15.
65. Abou-Kheir W, Mukherji D, Hadadeh O, Saleh E, Bahmad HF, Kanso M, Khalifeh M, **Shamseddine A**, Tamraz S, Jaafar R, Dagher C, Khalifeh I, Faraj W. CYR61/CCN1 expression in resected pancreatic ductal adenocarcinoma: A retrospective pilot study of the interaction between the tumors and their surrounding microenvironment. *Heliyon*. 2020 May 3;6(5): e03842
66. Haibe Y, Kreidieh M, El Hajj H, Khalifeh I, Mukherji D, Temraz S, **Shamseddine A**. Resistance Mechanisms to Anti-angiogenic Therapies in Cancer. *Front Oncol*. 2020 Feb 27; 10:221
67. Baassiri A, Nassar F, Mukherji D, **Shamseddine A**, Nasr R, Temraz S. Exosomal Non-Coding RNA in LIQUID Biopsies as a Promising Biomarker for Colorectal Cancer. *Int J Mol Sci*. 2020 Feb 19;21(4):1398
68. Skelton M, Alameddine R, Saifi O, Hammoud M, Zorkot M, Daher M, Charafeddine M, Temraz S, **Shamseddine A**, Mula-Hussain L, Saleem M, Namiq KF, Dewachi O, Abu Sitta G, Abdul-Sater Z, Televizian T, Faraj W, Mukherji D. High-Cost Cancer Treatment Across Borders in Conflict Zones: Experience of Iraqi Patients in Lebanon. *JCO Glob Oncol*. 2020 Feb; 6:59-66.

69. Mukherji D, Youssef B, Dagher C, El-Hajj A, Nasr R, Geara F, Rabah D, Al Dousari S, Said R, Ashou R, Wazzan W, Jabbour M, Farha G, Al Hamdani N, Al Hallaq Y, Ghazal H, Dbouk H, Bachir B, El Khoury C, Sakr G, Hussain HK, Sayyid K, Ibrahim K, Haidar M, Zouain N, Bitar N, Alameh W, Abbas F, Faddoul S, Nemer E, Assaf G, Farhat F, Bulbul M, Temraz S, **Shamseddine A**, Gillessen S, Omlin A, Khauli R. Management of patients with high-risk and advanced prostate cancer in the Middle East: resource-stratified consensus recommendations. *World J Urol.* 2020 Mar;38(3):681-693
70. Chahinian R, El-Amine A, , Matar S, Annan M, **Shamseddine A**, Haidar M. 68Ga–Prostate-Specific Membrane Antigen: A Potential Radiopharmaceutical in PET/CT To detect primary Cholangiocarcinoma. *Asia Oceania Journal of Nuclear Medicine and Biology Asia Ocean J Nucl Med Biol.* 2020; 8(2)
71. Kreidieh M, Mukherji D, Temraz S, and **Shamseddine A**. Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions. *BioMed Research International* [In press].
72. Kulhánová I, Znaor A, Shield K, Arnold M, Vignat J, Charafeddine M, Fadhil I, Fouad H, Al-Omari A, Al-Zahrani A, El-Basmy A. **Shamseddine A**, Bray F, Soerjomataram F. Proportion of cancers attributable to major lifestyle and environmental risk factors in the Eastern Mediterranean region. *Int J Cancer.* 2020 Feb 1;146(3):646-656.
73. Farge D, Frere C, Connors JM, Ay C, Khorana AA, Munoz A, Brenner B, Kakkar A, Rafii H, Solymoss S, Brillhante D, Monreal M, Bounameaux H, Pabinger I, Douketis J; International Initiative on Thrombosis and Cancer (ITAC) advisory panel. Collaborators (84) Ageno W, Ajauro F, Al-Aboudi KR, Alcindor T, Andre T, Angchaisuksiri P, Antic D, Arcelus JI, Assenat E, Bauer KA, Bazarbachii A, Benzidia I, Beyer-Westendorf J, Bitsadze V, Blickstein D, Blostein M, Bogalho I, Bournet B, Casais P, Carpentier AF, Cesarman-Maus G, Chakrabarty J, Clemente H, Connault J, Doucet L, Durant C, Emmerich J, Falanga A, Feistritz C, Font C, Francis C, Gallardo E, Gary T, Gris JC, Guillermo C, Hij A, Hull RD, Ikezoe T, Jara-Palomares L, Key NS, Khrizroeva J, Koolian M, Langer F, Le Hello C, Lecumberri R, Lee LH, Liebman H, Lopes Dos Santos L, Machado DH, Madelaine I, Makatsariya A, Mandala M, Marayevs A, Marjanovic Z, Marosi C, Martin E, Meillon L, Messas E, Moreira A, Demir AM, Ndour A, Nguessan M, Otero-Candelera R, Pachon Olmos V, Pais A, Posch F, Preusser M, Riess H, Righini M, Rothschild C, Roussin A, Rueda-Camino JA, Ruiz-Artacho P, Saseedharan S, **Shamseddine A**, Soff G, Stricker H, Tagalakis V, Taher A, Toussaint T, Trujillo-Santos J, Villiers S, Wong R, Yamada N. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. *Lancet Oncol.* 2019 Oct;20(10): e566-e581.
74. Temraz S, Salim Hammoud M, Saleh A, Charafeddine M, Mukherji D, **Shamseddine A**. Perceptions of Cancer Status Disclosure in Lebanon. *J Cancer Educ.* 2019 Oct;34(5):874-881.
75. Temraz S, Nassar F, Nasr R, Charafeddine M, Mukherji D, **Shamseddine A**. Gut Microbiome: A

- Promising Biomarker for Immunotherapy in Colorectal Cancer. *Int J Mol Sci.* 2019 Aug 25;20(17).
76. Salem R, Haibe Y, Dagher C, Salem C, **Shamseddine A**, Bitar N, Makdessi J, Khatib S, Boussen H, Benna F, Al Sukhun S, El Saghir N, Temraz S, Mukherji D. Female oncologists in the Middle East and North Africa: progress towards gender equality. *ESMO Open.* 2019 Jun 14;4(3):e000487.
 77. Kreidieh M, Zeidan YH, **Shamseddine A**. The Combination of Stereotactic Body Radiation Therapy and Immunotherapy in Primary Liver Tumors. *J Oncol.* 2019 Apr 28;2019.
 78. Salem R, Matar C, Assi R, Alameddine R, Temraz S, Shamseddine A, Mukherji D. Perceptions and attitudes of cancer patients and caregivers towards enrollment in clinical trials in Lebanon. *J Cancer Educ.* 2019 Apr;34(2):334-338.
 79. Greally M, Agarwal R, El Dika I, **Shamseddine A**, El-Olayan A, Haibe Y, Paroder V, Shia J, Abou-Alfa GK, Ku GY. Maximizing response: a case report of salvage chemotherapy after immune checkpoint inhibition in a patient with previous chemo-refractory metastatic esophageal carcinoma. *J Gastrointest Oncol.* 2019 Apr;10(2):367-372.
 80. Saade C, Chokr J, Naffaa L, Faraj W, **Shamseddine A**, Mukherji D, Sayegh SE, Assi R, Haydar A. Reduced Contrast Volume and Radiation Dose During Computed Tomography of the Pancreas: Timing-Specific Contrast Media Protocol. *Acad Radiol.* 2019 Apr;26(4):480-488.
 81. Cheaito KA, Bahmad HF, Hadadeh O, Saleh E, Dagher C, Hammoud MS, Shahait M, Mrad ZA, Nassif S, Tawil A, Bulbul M, Khaulil R, Wazzan W, Nasr R, **Shamseddine A**, Temraz S, El-Sabban ME, El-Hajj A, Mukherji D, Abou-Kheir W. EMT Markers in Locally Advanced Prostate Cancer: Predicting Recurrence? *Front Oncol.* 2019 Mar 11; 9:131
 82. Faraj W, Nassar H, Zaghal A, Mukherji D, **Shamseddine A**, Kanso M, Jaafar RF, Khalife M. Pancreaticoduodenectomy in the Middle East: Achieving optimal results through specialization and standardization. *Hepatobiliary Pancreatic Dis Int.* 2019 Oct;18(5):478-483.
 83. Temraz S, Haibe Y, Charafeddine M, Saifi O, Mukherji D, **Shamseddine A**. The unveiling of a new risk factor associated with bladder cancer in Lebanon. *BMC Urol.* 2019 Mar 5;19(1):16.
 84. El Halabi I, Bejjany R, Nasr R, Mukherji D, Temraz S, Nassar FJ, El Darsa H, **Shamseddine A**. Ascorbic Acid in Colon Cancer: From the Basic to the Clinical Applications. *Int J Mol Sci.* 2018 Sep 13;19(9).
 85. Temraz S, **Shamseddine A**, Mukherji D, Charafeddine M, Tfayli A, Assi H, Hammoud MS, Makki I, Nassif S. Ki67 and P53 in Relation to Disease Progression in Metastatic Pancreatic Cancer: A Single Institution Analysis. *Pathol Oncol Res.* 2018 Sep 5.
 86. Mrad RA, El-Majzoub N, **Shamseddine A**, Soweid A. The Elusive Diagnosis of Primary Esophageal Lymphoma. *Turk J Haematol.* 2018 Aug 3;35(3):199.
 87. El Chediak A, Mukherji D, Temraz S, Nassif S, Sinno S, Mahfouz, **Shamseddine A**. Primary Synovial Sarcoma of the Kidney: a Case Report of Complete Pathological Response at a

- Lebanese Tertiary Care Center. *BMC Urol.* 2018 May 11;18(1):40.
88. Fakh R, Rahal M, Hilal L, Hamieh L, Dany M, Karam S, Shehab L, Saghir N, Tfayli A, Salem Z, Assi H, Temraz S, **Shamseddine A**, Mukherji D. Prevalence and Severity of Sleep Disturbances among Patients with Early Breast Cancer. *Indian J Palliat Care* 2018, 24(1):35-38.
 89. Nasr R, Salim Hammoud M, Nassar F, Mukherji D, **Shamseddine A**, Temraz S. Inflammatory Markers and MicroRNAs: The Backstage Actors Influencing Prognosis in Colorectal Cancer Patients. *Int J Mol Sci.* 2018 Jun 26;19(7).
 90. El Chediak A, Haydar AA, Hakim A, Massih SA, Hilal L, Mukherji D, Temraz S, **Shamseddine A**. Increase in spleen volume as a predictor of oxaliplatin toxicity. *Ther Clin Risk Manag.* 2018 Apr 11; 14:653-657.
 91. Shaib WL, Assi R, **Shamseddine A**, Alese OB, Staley C 3rd, Memis B, Adsay V, Bekaii-Saab T, El-Rayes BF. Appendiceal Mucinous Neoplasms: Diagnosis and Management. *Oncologist.* 2018 Jan;23(1):137.
 92. Nasr R, Temraz S, Mukherji D, **Shamseddine A**, Akika R, Abbasi S, Khauli R, Bulbul M, Tamim H, Zgheib N. Distribution and Role of N-acetyltransferase 2 Genetic Polymorphisms in Bladder Cancer Risk in a Lebanese Population. *Asian Pac J Cancer Prev.* 2017 Sep 27;18(9):2561-2568
 93. Geara F, Bulbul M, Khauli R, Andraos T, Abboud M, AlMousa A, Serhan N, Salem A, Ghatasheh H, Alnsour A, Ayoub Z, Abou Gheida I, Charafeddine M, Shahait M, **Shamseddine A**, Abu Gheida R, Khader J. Nadir PSA is a Strong Predictor of Treatment Outcome in Intermediate and High Risk Localized Prostate Cancer Patients Treated by Definitive External Beam Radiotherapy and Androgen Deprivation. *Radiat Oncol.* 2017 Sep 7;12(1):149
 94. Vasan N, Braghiroli MI, Shoushtari AN, Do RKG, Edelweiss M, **Shamseddine A**, FarMukherji D, Haydar A, Olayan A, Sabatin F, Assi R, El Dika I, Saltz LB, Abou-Alfa GK, O'Reilly EM. An elderly man with remote history of metastatic melanoma now with localized pancreas cancer and new liver masses. *J Gastrointest Oncol.* 2017 Jun;8(3):596-602.
 95. El Chediak A, **Shamseddine A**, Bodgi L, Obeid J, Geara F, Zeidan Y. Optimizing Tumor Immune Response through Combination of Radiation and Immunotherapy. *Medical Oncology Med Oncol* (2017) 34:165.
 96. Temraz S, Charafeddine M, Mukherji D, **Shamseddine A**. Trends in lung cancer incidence in Lebanon by gender and histological type over the period 2005-2008. *J Epidemiol Glob Health.* 2017 Sep;7(3):161-167
 97. Charafeddine MA, Olson SH, Mukherji D, Temraz SN, Abou-Alfa GK, **Shamseddine AI**. Proportion of cancer in a Middle eastern country attributable to established risk factors. *BMC Cancer.* 2017 May 18;17(1):337
 98. Shaib WL, Assi R, **Shamseddine A**, Alese OB, Staley C, Memis B, Adsay V, Bekaii-Saab T, El-Rayes BF. Appendiceal Mucinous Neoplasms: Diagnosis and Management. *The Oncologist* 2017; 22:1–10.
 99. El Chediak A, Alameddine R, Hakim A, Hilal L, Abdel Massih S, Hamieh L, Mukherji D, Temraz S, Charafeddine M, **Shamseddine A**. Age less than 40 years is an independent predictor of worse

- prognosis among Lebanese Non-metastatic breast cancer patients: Analysis from a Prospective Cohort. *Breast Cancer* (Dove Med Press). 2017 Jun 10; 9:407-414.
- 100.** Kulhánová I, Bray F, Fadhil I, Saeed Al-Zahrani A, El-Basmy A, Anwar W, Omari A, **Shamseddine A**, Znaor A, Soerjomataram I. Profile of cancer in the Eastern Mediterranean region: the need for action. *Cancer Epidemiol*. 2017 Apr; 47:125-132.
- 101.** Haidar M, Jreige M, Mukherji D, Abou Said R, Ibrahim T, Haddad M, **Shamseddine A**. The Role of 68Ga- DOTA-NOC PET in Evaluating Neuroendocrine Tumors: Real-world experience from single Lebanese institution. *Nuclear Medicine Communication Nucl Med Commun*. 2017 Feb;38(2):170-177.
- 102.** Tfayli A, Rafei H, Mina A, Khalil M, Fakhreddin N, Mahfouz R, Hamouri Sh, Farhat F, Salem Z, Dbouk H, Rabee H, Saghir N, **Shamseddine A**, Makarem J, Bitar N, Mougharbil A, Assi H, Temraz S, Mukherji D, Matalka I, Zaatari G. Prevalence of EGFR and ALK Mutations in Lung Adenocarcinomas in the Levant Area - a Prospective Analysis. *Asian Pac J Cancer Prev*. 2017 Jan 1;18(1):107-114
- 103.** Charara N, Kreidieh F, Farhat R, Al-Feghali K, Khoury K, Haydar A, Nassar L, Berjawi G, **Shamseddine A**, El Saghir S. Practice and Impact of Multidisciplinary Tumor Boards on Patient Management: A Prospective Study. *J Glob Oncol* 2016 (ASCO)
- 104.** Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, Tomasek J, Raderer M, Lahner H, Voi M, Pacaud LB, Rouyrre N, Sachs C, Valle JW, Delle Fave G, Van Cutsem E, Tesselaa M, Shimada Y, Oh DY, Strosberg J, Kulke MH, Pavel ME; RAD001 in Advanced Neuroendocrine Tumors, Fourth Trial (RADIANT-4) Study Group. 7. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomized, placebo-controlled, phase 3 study. *Lancet*. 2016 Mar 5;387(10022):968-77 (**listed as collaborator in the RADIANT-4 study group**).
- 105.** Temraz S, Mukherji D, **Shamseddine A**. Dual Targeting of HER3 and EGFR in colorectal tumors might overcome anti-EGFR resistance. *Crit Rev Oncol Hemat*. 2016.
- 106.** Assi R, Temraz S, **Shamseddine A**, Mukherji D. New compounds targeting the androgen receptor for treatment of advanced prostate cancer. *Curr Drug Targets*. 2016; 17(3): 290-302.
- 107.** Hilal L, Barada K, Mukherji D, Temraz S, **Shamseddine A**. Gastrointestinal (GI) Leiomyosarcoma (LMS) Case Series and Review on Diagnosis, Management, and Prognosis. *J Surgical Oncol* 2016 Feb;33(2):20.
- 108.** Assi R, Mukherji D, Haydar A, Saroufim M, Temraz S, **Shamseddine A**. Metastatic colorectal cancer presenting with bone marrow metastasis: a case series and review of literature *Gastrointest Oncol*. 2016 Apr;7(2):284-97.
- 109.** Mukherji D, Jabbour M, Saroufim M, Temraz S, Nasr R, Charafeddine M, Assi R, **Shamseddine A**, Tawil A. PD-L1 expression in muscle-invasive bladder cancer cystectomy specimens and lymph node metastasis: A reliable treatment selection biomarker. *Clin Genitourin Cancer*. 2016 Apr;14(2):183-7.
- 110.** Faraj W, El-Kehdy J, Nounou GE, Deeba S, Fakh H, Jabbour M, Haydar A, El Naaj AA, Abou-Alfa GK, O'Reilly EM, **Shamseddine A**, Khalife M, Mukherji D. Liver resection for metastatic colorectal leiomyosarcoma: a single center experience. *J Gastrointest Oncol*. 2015 Oct; 6(5): E70-6.

111. Li D, Abou-Alfa G, Viny A, Cammarata M, **Shamseddine A**, Al-Olayan A, Osman H, Haydar A, Kananzi G, Naghy M, O'Reilly E, Epstein A. *J Gastrointest Oncol*. 2015 Oct; 6(5):589-93.
112. Temraz S, Mukherji D, **Shamseddine A**. Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers. *Int J Mol Sci*. 2015 Sep 23;16(9):22976-88.
113. Hilal L, Shahait M, Mukherji D, Charafeddine M, Farhat Z, Temraz S, Khauli R, **Shamseddine A**. Prostate Cancer in the Arab World: A View From the Inside. *Clin Genitourin Cancer*. 2015 Dec;13(6):505-11.
114. Alameddine RS, Yakan AS, Skouri H, Mukherji D, Temraz S, **Shamseddine A**. Cardiac and vascular toxicities of angiogenesis inhibitors: The other side of the coin. *Crit Rev Oncol Hematol*. 2015 Nov;96(2):195-205.
115. Snyder A, Kemeny N, **Shamseddine A**, Al-Olayan A, El-Merhi F, Kelsen DP, Jamali F, Sidani M, Mukherji D, El-Naghy M, O'Reilly EM, Saltz LB, Abou-Alfa GK. Liver-directed conversion therapy in metastatic colon cancer. *J Gastrointest Oncol*. 2015 Jun;6(3):322-8.
116. El Saghir NS, Zgheib NK, Assi HA, Khoury KE, Bidet Y, Jaber SM, Charara RN, Farhat RA, Kreidieh FY, Decousus S, Romero P, Nemer GM, Salem Z, **Shamseddine A**, Tfayli A, Abbas J, Jamali F, Seoud M, Armstrong DK, Bignon YJ, Uhrhammer N. BRCA1 and BRCA2 mutations in ethnic Lebanese Arab women with high hereditary risk breast cancer. *Oncologist*. 2015 Apr;20(4):357-64.
117. Temraz S, Alameddine R, **Shamseddine A**. B-type proto-oncogene-mutated tumors of colon cancer: promising therapeutic approaches. *Curr Opin Oncol*. 2015 May;27(3):276-81.
118. Salem J, Shamseddine A, Khalife M, Nounou GE, El Naaj AA, Mukherji D, Haydar A, Faraj W. Malignant fibrous histiocytoma presenting with complete opacification of the hemithorax: A case report. *Int J Surg Case Rep*. 2014;5(12):1162-3.
119. Chami HA, Faraj W, Yehia ZA, Badour SA, Sawan P, Rebeiz K, Safa R, Saade C, Ghandour B, **Shamseddine A**, Mukherji D, Haydar AA. Predictors of pneumothorax after CT-guided transthoracic needle lung biopsy: the role of quantitative CT. *Clin Radiol*. 2015 Dec; 70(12):1382-7.
120. Assi R, Hamieh L, Mukherji D, Haydar A, Temraz S, El -Dika I, **Shamseddine A**. Leptomeningeal Metastasis as Initial Manifestation of Signet Ring Colorectal Adenocarcinoma: a Case Report with Review of Literature. *J Gastrointest Oncol* . 2015 December 6(6): 1-13.
121. Temraz S, Alameddine R, **Shamseddine A**. Angio prevention in Colon Cancer from Bench to Bedside. *Curr Colorectal Cancer Rep* (2015) 11:422–431.
122. Rebeiz K, **Shamseddine A**, Hachem R, Brown K, Mukherji D, Faraj W, Abou-Alfa G, Nasr L, Haydar A. Pancreatic neuroendocrine tumor with aneurysm of the gastroduodenal artery: a case report. *Clin Imaging*. 2015 December 39(6): 935-1142.
123. Khaled H, Abdel Azim H, Barsoum E, Chahine G, **Shamseddine A**, Abdel Metaal G, Omar A, Jazeih A, Haggag R, Badran A. A multicenter, phase II study of the RAF- kinase inhibitor sorafenib in patients with advanced renal cell carcinoma. *Mol Clin Oncol*. 2015 July 3: 1099-1102.
124. Assi H, Sbaity E, Abdelsalam M, **Shamseddine A**. Controversial Indications for Sentinel Lymph Node Biopsy in Breast Cancer Patients. *Biomed Res Int*. 2015; 2015:405949
125. Haroun F, Al-Shaar L, Habib RH, El-Saghir N, Tfayli A, Bazarbachi A, Salem Z, **Shamseddine A**, Taher A, Cascorbi I, Zgheib NK. Effects of CYP2B6 genetic polymorphisms in patients receiving

- cyclophosphamide combination chemotherapy for breast cancer. *Cancer Chemotherapy Pharmacol.* 2015 Jan; 75(1):207-14
126. Temraz S, Mukherji D, Farhat ZA, Nasr R, Charafeddine M, Shahait M, Wehbe MR, Ghaida RA, Gheida IA, **Shamseddine A.** Preoperative lymphocyte-to-monocyte ratio predicts clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder: a retrospective analysis. *BMC Urol.* 2014 Sep 19; 14:76
 127. Salem J, **Shamseddine A,** Khalife M, Nounou GE, El Naaj AA, Mukherji D, Haydar A, Faraj W. Malignant fibrous histiocytoma presenting with complete opacification of the hemithorax: A case report. *Int J Surg Case Rep.* 2014 Nov 11;5(12):1162-1163
 128. El Dika I, Mukherji D, Temraz S, Assi R, **Shamseddine A.** Sunitinib Induced Thrombotic Thrombocytopenic Purpura in addition to Severe Hypothyroidism: A Case Report and Review of the Literature. *Case Rep Med.* 2014;2014
 129. Haydar AA, Mukherji D, Faraj W, Khalifeh M, Taslakian B, Yehia ZA, Temraz S, Brown KT, Abou- Alfa GK, **Shamseddine A.** Challenges in combining antiangiogenic therapy with transarterial chemoembolization for hepatocellular carcinoma. *Gastrointest Cancer Res.* 2014 May;7(3- 4):98-102.
 130. Alameddine RS, Hamieh L, **Shamseddine A.** From sprouting angiogenesis to erythrocytes generation by cancer stem cells: evolving concepts in tumor microcirculation. *Biomed Res Int.* 2014
 131. Mukherji D, El Dika I, Temraz S, Haidar M, **Shamseddine A.** Evolving treatment approaches for the management of metastatic castration-resistant prostate cancer - role of radium-223. *Ther Clin Risk Manag.* 2014 May 23; 10:373-80
 132. Ajouz H, Mukherji D, **Shamseddine A.** Secondary bile acids: an underrecognized cause of colon cancer. *World J Surg Oncol.* 2014 May 24; 12:164
 133. Dbouk H, Mentha S, Mukherji D, Lee J, Haydar A, **Shamseddine A,** O'Reilly EM, Saltz L, Abou- Alfa GK. A 39-year-old female patient with metastatic rectal cancer develops thrombocytopenia. *Gastrointest Cancer Res.* 2014 Mar;7(2):55-8
 134. Temraz S, Mukherji D, Alameddine R, **Shamseddine A.** Methods of overcoming treatment resistance in colorectal cancer. *Crit Rev Oncol Hematol.* 2014 Feb;89(2):217-30.
 135. Haidar M, Jreige M, **Shamseddine A,** Haddad M, Ghosn J, Chehade F. Metabolic radiotherapy of neuroendocrine tumors using DOTATATE labeled with lutetium 177: Lebanese experience about 6 cases with review of the literature. *Med Nucl.* 2013; 37 (10-11): 490-7
 136. Temraz S, Mukherji D, **Shamseddine A.** Sequencing of treatment in metastatic colorectal cancer: Where to fit the target. *World J Gastroenterol.* 2014; 20(8): 1993-2004.
 137. Mukherji D, Omlin A, Pezaro C, **Shamseddine A,** De Bono JS. Metastatic Castration Resistant Prostate Cancer: Preclinical and clinical evidence for the sequential use of novel therapeutics. *Can Metasta Rev* 2014 Sep;33(2-3):555-66
 138. Ajouz H , Mukherji D , Haydar A, Yakan AS , Saleh A , Elias E , Temraz S, Faraj W , Khalife M, **Shamseddine A.** Modified GTX as Second-line Therapy for Advanced Pancreatic Adenocarcinoma. *J Gastrointest Cancer.* 2014; 45(1): 109-12
 139. **Shamseddine A,** Saleh A, Charafeddine M, Seoud M, Mukherji D, Temraz S, Sibai A. Cancer Trends in the Lebanese population: A review of incidence rates for the period of 1998-2007 and projections until 2017. *Popul Health Metr.* 2014; 12(1):4.

140. Shoushtari A, Covey A, Zaatari G, **Shamseddine A**, Epstein A, Haydar A, Naghy M, Mukherji D, Kelsen D, Abou-alfa G, O'Reilly E. A woman with metastatic pancreatic neuroendocrine tumor. *Gastrointest Cancer Res.* 2014; 7(1): 27-32.
141. Alameddine RS, El Saghir N, Elias E, Saleh A, Geara F, Temraz S, **Shamseddine A**. Effect of nodal status and extent of surgery on survival in triple negative breast cancer. *J Can Res Updates.* 2013; 2(4): 1-8
142. Bazarbachi S, Bachour M, Bulbul M, Al-Otibi M, Jaloudi M, Jaafar H, Farah N, Al-Rubaii T, **Shamseddine A**, Metastatic castrate resistant prostate cancer: current strategies of management in the middle east. *Crit Rev Oncol Hematol.* 2014; 90(1): 36-42
143. Zgheib NK, Shamseddine AA, Geryess E, Tfayli A, Bazarbachi A, Salem Z, **Shamseddine A**, Taher A, El-Saghir NS Genetic polymorphisms of CYP2E1, GST, and NAT2 enzymes are not associated with risk of breast cancer in a sample of Lebanese women. *Mutat Res.* 2013 Jul-Aug; 747-748:40-7.
144. **Shamseddine A**, Farhat FS, Elias E, Khauli RB, Saleh A, Bulbul MA. High-dose calcitriol, docetaxel and zoledronic acid in patients with castration-resistant prostate cancer: a phase II study. *Urol Int.* 2013; 90(1):56-61.
145. Dbouk H, Ajouz H, **Shamseddine A**, Mukherji D, O'Reilly EM, Haydar A, Kelsen D, Naghy M, Eloubeidi M, Geara F, Saltz L, Abou-Alfa GK. Modified GTX as Second-Line Chemotherapy in Advanced Pancreatic Cancer. *Gastrointest Cancer Res.* 2013 Jul; 6(4):115-7.
146. Temraz S, Mukherji D, **Shamseddine A**. Potential targets for colorectal cancer prevention. *Int J Mol Sci.* 2013 Aug 22;14(9):17279-303.
147. Hajj C, Goodman K, Kelsen D, Shia J, **Shamseddine A**, Naghy M, Sidani M, Eloubeidi M, Merhi F, Geara F, Ang C, Saltz L, Abou-Alfa GK. A 40-year-old woman with locally advanced rectal cancer and a solitary liver metastasis. *Gastrointest Cancer Res.* 2013 May; 6(3):87-9.
148. Won E, Yu KH, **Shamseddine A**, Saltz L, Mukherjee D, Haydar A, El-Olayan A, Temraz S, Naghy M, Makanjoula D, O'Reilly EM, Abou-Alfa GK. Management of a patient diagnosed with pancreatic cancer and myelodysplastic syndrome. *Gastrointest Cancer Res.* 2013 Mar; 6(2):56-60.
149. Abbas O, **Shamseddin A**, Temraz S, Haydar A. Posterior reversible encephalopathy syndrome after bevacizumab therapy in a normotensive patient. *BMJ Case Rep.* 2013 Feb 21; 2013.
150. Awada Z, Haidar S, Tfayli A, Bazarbachi A, El Saghir N, Salem Z, **Shamseddine A**, Taher A, and Zgheib NK, Pharmacogenomics Variation in Drug Metabolizing Enzymes and Transporters in Relation to Docetaxel Toxicity in Lebanese Breast Cancer Patients: Paving the Way for Omics in Low and Middle Income Countries. *OMICS Journal of Integrative Biology.* 2013 Jul; 17(7):353-67.
151. Faraj W, Alameddine R, Mukherji D, Musallam K, Haydar A, Eloubiedi M, **Shamseddine A**, Halal A, Abou-Alfa GK, O'Reilly EM, Jamali F, Khalife M. Postoperative outcomes following pancreaticoduodenectomy: how should age affect clinical practice? *World J Surg Oncol.* 2013 Jun 6:11:131

152. Alameddine RS, Otrrock ZK, Awada **A, Shamseddine**. Crosstalk between HER2 signaling and angiogenesis in breast cancer: Molecular basis, clinical applications and challenges. *Curr Opin Oncol*.2013 May;25(3):313-24
153. Ang CS, Do RK, **Shamseddine A**, O`Reilly EM Haydar A, Al-Olayan A, Faraj W, Boulos F, Naghy M, Makanjoula D, Farran H, Wehbe D, Kelsen DP, Abou-Alfa GK. A young Woman with Liver Cancer, *Gastrointest Cancer Res*. 2013 Jan; 6(1): 17-21.
154. Mukherji D, Pezaro CJ, **Shamseddine A**, DE BONO JS. New treatment Developments applied to elderly patients with advanced prostate cancer. *Cancer Treat Rev*. 2013 Oct; 39(6):578-83.
155. Mukherji D, Temraz S, Wehbe D, **Shamseddine A**. Angiogenesis and anti- angiogenic therapy in prostate cancer. *Crit Rev Oncol Hematol*. 2013 Aug; 87(2):122-31.
156. Synder A, Allen P, **Shamseddine A**, Haydar A, Eloubeidi M, Faraj w, Khalife M, Temraz S, El- Olayan A, Kelsen DP, El Merhi F, Naghy M, Saltz LB, Abou-Alfa GK, O`Reilly EM. Neoadjuvant Therapy in Clinical Stage II Pancreatic adenocarcinoma, *Gastrointest Cancer Res*.2012Sep; 5(5):169-73.
157. Alameddine R, Wehbe D, Weiser M, Segal N, Goodman K, **Shamseddine A**, Ang C, Haydar A, Sidani M, Geara F, Naghy M, O`Reilly EM, Abou-Alfa GK. Management Of locally advanced rectal cancer in a patient who declined surgery. *Gastrointest Cancer Res*. 2012 Nov; 5(6):205-9.
158. Epstein AS, Abou-Alfa GK, **Shamseddine A**, Al-Olayan A, Ang C, Naghy M, Lowery MA, O`Reilly EM. Communication and palliative care in a 64- Year-old man with pancreatic adenocarcinoma. *Gastrointest Cancer Res*.2012Jul; 5(4):130-4.
159. Mukherji D, Faraj W, Khalife M, **Shamseddine A**, El Majzoub N, Zaatari G, Shah M, Abou Alfa GK, O`Reilly EM.A 71- year old man with a large cystic pancreatic mass. *Gastrointest cancer Res*. 2012Jul; 5(4):130-4.
160. Elias E, Mukherji D, Faraj W, Khalifeh M, El Oubeidi M, Hatoum H, Dimassi H, Meki C, Abou Alfa GK, **Shamseddine A**. Lymph node ratio is an independent prognostic factor in stage III colorectal cancer patients: a retrospective study from the Middle East. *World J Surgical Oncology*; 2012; April 25; 10:63.
161. **Shamseddine A**, Mukherji D, Melki C, Elias E, El Oubeidi M, Dimassi H, Khalifeh M, Abou Alfa GK, O`Reilly E, Faraj W. Lymph node ratio is an independent prognostic factor after resection of peri ampullary malignancies: Data from a tertiary Referral Center in the Middle East. *American J of Clinical Oncology*; 2012, Oct. 29.
162. Ang C, Janjigian Y, **Shamseddine A**, Tawil A, Lowery M, Intlekofer A, Faraj W, Al-Olayan A, Tang L, O`Reilly E, Geara F, Al-Kutoubi A, Kelsen DP, Abou Alfa GK. A case of advanced gastric cancer. *J. Gastrointest Cancer*; 2012, Mar; 5(2):59-63.
163. Tamraz S, **Shamseddine A**, Shah M, El Oubeidi M, Zaatari G, Geara F, Lowery M, O`Reilly E, El Kutoubi A, Faraj W, Kelsen DP, Abou Alfa GK. A 72 year old man with duodenal carcinoma. *J Gastrointest Cancer*; 2012 May; 5(3):93-6.

- 164.** Farhat F, Tfayli A, Fakhreddine N, Awada A, **Shamseddine A.** Expression, Prognostic and Predictive impact of VEGF and bFGF in non-small cell lung cancer. *Critical reviews in Oncology/Hematology*; 2012. *Crit Rev Oncol Hematol.* 2012 Nov; 84(2):149-60.
- 165.** Zaghal A, Khalifeh M, Mukherji D, El Majzoub N, Shamseddine A, Hoballah J, Marangoni G, Faraj W. Update on Totally Implantable venous access devices. *Surg Oncol* 2012 Mar 17. 21 (3): 307-15
- 166.** Smyth EC, Lee YJ, Abou Alfa G, Seo S, **Shamseddine A.** O'Reilly E, Farran H, Kanj S, Musharrafieh U, Awar G, Sibai H, Strong V, Shah MA. Gastrointestinal cancer educational case series: a 65 year-old female with locally advanced gastric cancer and a supraclavicular lymph node. *J Gastrointest cancer* 2012 Mar; 43(1); 93-6.
- 167.** **Shamseddine A,** Farhat FS. Platinum-based compounds for the treatment of metastatic breast cancer, *Chemotherapy* 2011; 57(6):468-87.
- 168.** Farhat FS, Temraz S, Kattan J, Ibrahim K, Bitar N, Haddad N, Jalloul R, Hatoum HA, Nsouli G, **Shamseddine A.** A Phase II Study of lipoplatin (liposomal cisplatin) vinorelbine combination in HER-2neu-negative metastatic breast cancer. *Clin Breast Cancer.* 2011 Dec; 11(6):384-9.
- 169.** Ang C, Abu-Alfa AK, Abdullah K, Lowery M, Sibai H, El Farran H, Temraz S, Al Olayan A, **Shamseddine A,** Naghy M, Faraj W, O'Reilly EM, Abou-Alfa GK. Hepatocellular carcinoma following renal transplantation. *Gastrointest Cancer Res.* 2011 Sep; 4(5-6):180-3.
- 170.** Faraj W, Sbaity E, Mukherji D, **Shamseddine A,** Khalife M. Successful one stage operation for a synchronous, duodenal carcinoma, colonic carcinoma and renal oncocytoma in an adult patient. *World J Surg Oncol.* 2011 Sep 1; 9:99
- 171.** Hassen WA, Karsan FA, Abbas F, Beduk Y, El-Khodary A, Ghosn M, Khader J, Khauli R, Rabah DM, **Shamseddine A,** Srinivas S; Modification and implementation of NCCN guidelines on prostate cancer in the Middle East and North Africa region. MENA Prostate Cancer Regional Guidelines Committee. *J Natl Compr Canc Netw.* 2010 Jul; 8 Suppl 3:S26-8.
- 172.** Postow M, Shah MA, Lowery M, **Shamseddine A,** El Kutoubi A, Al Olayan A, Naghy M, Ang C, Tamraz S, Jazieh AR, O'Reilly EM, Kelsen DP, Abou-Alfa GK. A Man with Klinefelter's Syndrome and New Abdominal Distension: A Discussion of Evaluation and Management. *J Gastrointest Cancer.* 2012 Jun;43(2):314-8
- 173.** El Saghir N, El-Asmar N, Hajj C, Eid T, Khatib S, Bounedjar A, Ajarim D, **Shamseddine A,** Geara F, Jazieh A, Azim H, Abdel Kader Y, Kattar J, Abdul Khair O. Survey of Utilization of multidisciplinary management tumor boards in Arab Countries. *Breast* 2011 Supple 2: S70-4
- 174.** Soubra A, Faraj W, Saab J, **Shamseddine A.** Periampullary Mixed Acinar-Endocrine carcinoma: Case report and literature review. *Rare Tumors* 2011. 4, 3(2): e 15.
- 175.** Smyth E, Abou-Alfa GK, Lowery M, **Shamseddine A,** Al-Olayan A, Naghy M, Power D, Saliba T, Kelsen D, Shah MA. Gastrointestinal cancer educational case series: The history and management of complex cases in oncology. A 72-year-old man with metastatic gastric cancer. *J Gastrointest cancer.* 2011, 42(1):46-9

176. Abi Saad GS, Hussein M, El Saghir NS, Temraz S, Sharara Al, **Shamseddine A**. Isolated splenic metastasis from colorectal cancer. *Int J Clin Oncol*.2011;16(4):306-13
177. Faraj W, Ajouz H, Mukherji D, Kealy G, **Shamseddine A**. Khalife M. Inflammation pseudo-tumor of the liver a rare pathological entity: *World J Sur Oncol*.2011; 23:9-5.
178. Tfayli A, Temraz S, Abou Mrad R, **Shamseddine A**. Breast cancer in low-and middle-income countries: an emerging and challenging epidemic. *J Oncol* 2010; 1(1):47-50.
179. Epstein AS, O'Reily EM, Lowery M, **Shamseddine A**, Shia J, Temraz S, Al Olayan A, Naghy M, Kelsen D, Shah MA, Abou-Alfa GK. A Woman with Remotely Treated Pancreas Cancer and New Abdominal Pain: A Discussion of Evaluation and Management. *J Gastrointest Cancer*.2011;42(4):236-40
180. Ang C, O'reily EM, Abou-Alfa GK, **Shamseddine A**. Skouri H, Tawil A. Eloubeidi MA, Lowery M, Karealian T, Temraz S, Sibai H, H.Farran H. Shah MA. Educational Case Series. Management of Metastatic Adenocarcinoma of Unknown Primary Origin in a Ph+ALL Survivor. *J Gastrointestinal Cancer* 2011; 42(3):165-70.
181. Hatoum HA, Abi Saad GS, Otrock ZK, Barada KA. **Shamseddine A**. Metastases of colorectal carcinoma to the testes: clinical presentation and possible pathways. *Int J Clin Oncol*; 2011,16(3) 203-9
182. Geara FB, **Shamseddine A**, Khalil A, Abboud M, Charafeddine M, Seoud M. Phase II randomized trial comparing radiotherapy with concurrent weekly cisplatin or weekly paclitaxel in patients with advanced cervical cancer. *Radiat Oncol* 2010; 5:84.
183. Otrock ZK, Hatoum HA, Musallam KM, Awada AH, **Shamseddine A**. Is VEGF a predictive biomarker to anti-angiogenic therapy? *Crit Rev Oncol Hematol*. 2011;79(2):103-11.
184. Faraj W, Mukherji D, El Majzoub N, **Shamseddine A**, Khalife M. Primary undifferentiated embryonal sarcoma of the liver mistaken of hydatid disease *World J Surg Oncol* 2010 Jul 9;8:58.
185. Tfayli A, Temraz S, Abou Mrad R, **Shamseddine A**. Pseudo neutropenia from EDTA leucoagglutination. *Middle East J Can* 2010; 1(4):189-90
186. Shamseddine AA, Faraj W, Mukherji D, El Majzoub N, Khalife M, Soubra A, **Shamseddine A**. Unusually young age distribution of primary hepatic leiomyosarcoma: case series and review of the adult literature. *World J Surg Oncol*. 2010 Jul 1; 8:56. Review
187. Abboud M, **Shamseddine A**. Maxillary Sinus Squamous Cell Carcinoma Presenting with Fatal tumor Lysis Syndrome: A Case Report and Review of the Literature. *Case Reports in Oncology* 2009; 2(3):229-233.
188. **Shamseddine A**, Musallam KM. Cancer Epidemiology in Lebanon. *Middle East Journal of Cancer* 2010; 1(1):47-50.
189. Charafeddine KM, Hatoum HA, Otrock ZK, Mahfouz RA, Salem ZM, **Shamseddine A**, Taher AT, El-Saghir NS, Bazarbachi A. Long-term outcome of adult acute lymphoblastic leukemia in

Lebanon: A single institution experience from the American University of Beirut Haematol oncol stem cell Ther 2009;2(2):333-9.

190. Hatoum HA, Jamali FR, El Saghir NS, Musallam KM, Seoud M, Dimassi H, Abbas J, Khalifeh M, Boulos FI, Tawil AN, Geara FB, Salem Z, Shamseddine AA, Al-Feghali K, **Shamseddine A**, Ratio between positive lymph nodes and total excused axillary lymph nodes as an independent prognostic factor for overall survival in patients with non-metastatic lymph node-positive breast cancer. *Ann Surg Oncol* 2009; 16(12):3388-95.
191. Musallam KM, Jamali FR, Hatoum HA, Seoud M, El Saghir NS, **Shamseddine A**, Axillary lymph node ratio revisited *J Clin Oncol*.2009; 27(24):e67.
192. Musallam K, Hatoum H, Barud K, Taher A, Salem M, **Shamseddine A**. Primary Colorectal Lymphoma *Med Oncol*. 2010 Jun;27(2):249-54.
193. Musallam K, Dahdaleh F, **Shamseddine A**, Taher A. Incidence and Prophylaxis of Venous Thromboembolic Events in Multiple Myeloma Patients receiving immune-modulatory therapy. *Throm Res*. 2009; 123(5):679-86.
194. Otrrock Z, Hatoum H, Awada A, Ishak R, **Shamseddine A**. Hypoxia-Inducible factor and cancer angiogenesis: Structure regulation and clinical significance. *Crit Rev Oncol Hematolo*: 2009; 70(2): 93-102.
195. Farhat M, El-Saghir N, **Shamseddine A** , Modified Resistance to chemotherapy and Trastuzumab by Bevacizumab in locally recurrent breast cancer. *The Breast* 2009; 18(1):66-8
196. Musallem K, Taher A, **Shamseddine A**, Burkitt's lymphoma of the colon and bronchi. Three case reports. *Cases journal, BioMed Central*. 2008; 1(1):15
197. Musallam KM, Taher AT, Chakhachiro ZI, Habbal MZ, **Shamseddine A**. Solitary mediastinal lymph node metastasis in rectosigmoid carcinoma: A case report *cases J*. 2008; 1(1):69.
198. Seoud M, **Shamseddine A**. Cancer Prevention and Control in the Eastern Mediterranean region: The need for a public health approach. *Hematol Oncol Stem Cell Ther*. 2008; 1(2):139.
199. Rashid K, Otrrock Z, Husari A, Ghosn M, Kattan J, El Saghir N, Bitar N, Nosily G, Moukaddem W, Chahine G, Salem Z, **Shamseddine A**. Gefitinib (Iressa) in Non-Small cell lung cancer: A retrospective analysis. *Pan Arab journal of oncology (PAJO)* 2008; (2): 8-11
200. Farhat M, Barada K, Tawil A, Itani D, Hatoum H, **Shamseddine A**. Effect of mucin production in survival in colorectal cancer: A Case –control study. *World Journal of gastroenterology*, 2008; 14(45) : 6981-6985
201. Farhat M, **Shamseddine A**, Barada K. Small Bowel Tumors: Clinical Presentation, Prognosis, and outcome in 33 patients in a tertiary care center. *Journal of Oncology* 2008; 2008:2/2067.
202. Yassin N, Muwakkat S, Ibrahim A, Kayin I, Habbal M, Chamseddine N, Musallam K, **Shamseddine A**. A novel genotype c. 1228C> G/ C. 1448 C (L371V/Rec-Ncil) in a 3-year-old child with type 1 Gaucher disease. *J. Appl Genet* 2008; 49(4):421-424
203. Palmieri B, Saleh F, Bennzi G, Mousa A , **Shamseddine A**, Al Sbeih K. Polydine Thysiloxane:

An effective immune adjuvant and slow-release cytokine medium for local cancer treatment. *J Carcinog* 2008; 7:5

204. Otrrock Z, **Shamseddine A**, Hatoum H, Bazarbachi A. Overview of Angiogenesis: Mechanisms and predictors. *PAJO* 2008; (3): 26-31
205. Otrrock ZK, Hatoum H, Uthman I, Taher A, Saab S, **Shamseddine A**. Non-Hodgkin's lymphoma in a woman with adult-onset still's disease: a case report *J Med Case Reports*. 2008. 6;72: 73
206. Abou Mourad Y, Otrrock Z, Makarem J, Kattan J, Farhat F, Jalloul R, Mokaddem W, Ghosn M, Taher A, Chehal A, **Shamseddine A**, Docetaxel and Irinotecan as first-line chemotherapy in patients with advanced Non-small cell lung cancer: A Pilot Study. *Leb M J* 2008 ; 56(1): 16-21
207. Farhat M, **Shamseddine A**, Tawil A. Berjawi G, Shamseddeen W, Barada K. Prognostic factors in patients with advanced cholangiocarcinoma: Role of Surgery, Chemotherapy and Body Mass Index. *World J of Gastroenterology*. 2008; 14(20): 3224-30
208. Farhat M, El Saghir N, **Shamseddine A** Hand-Foot Syndrome with Docetaxel a five-case series. *Annals of Saudi Medicine* 2008; 28(5):374-7
209. Hatoum H, Habib J, Tawil A, Chakhachiro Z, Otrrock Z, Husari A, **Shamseddine A**. Adenocarcinoma of the lung presenting as a Metastatic Tongue Mass. *Southern Medical Journal* 2008;101(7):1
210. El Kinge A, Mahfouz A, **Shamseddine A** and Taher A. Recombinant activated factor VII for intractable bleeding post splenectomy in a patient with myeloproliferative disorder. *Blood Coagul Fibrinolysis* 2007;18(6): 577-9
211. El Kinge AR, Arabi M, Al-Kutoubi A, Otrrock Z, **Shamseddine A**. Elastofibroma dorsi mimicking metastatic disease on FDG-PET scan in breast cancer patient. *Clinical Oncology* 2007; 19(8): 633-4.
212. El Zahabi L, Makarem J, Habbal Z, Otrrock Z, Taher A, **Shamseddine A**. Gaucher Disease: different phenotypes associated with a rare mutation (R4 & W) in a Lebanese Family. *Molecular Genetics and Metabolism* 2007; 91(4):402-4
213. Otrrock Z, Makarem J, **Shamseddine A**. Understanding the biology of angiogenesis: Review of the most important mechanisms *Blood cells Mol Dis* 2007;39(2):212-20
214. Otrrock Z, Makarem J, **Shamseddine A**. Vascular endothelial growth factor family of ligands and receptors: Review. *Blood cells Mol Dis* 2007; 38(3):258-68
215. Geara F, Nasr E, Tucker SL, Charafeddine M, Dabaja B, Eid T, Abbas J, Salem Z, **Shamseddine A**, Issa P, El Saghir N. Breast Cancer patients with 10 or more involved axillary lymph nodes treated by multimodality therapy: Influence of Clinical Presentation on outcome. *Int. J Rad Oncol, Biol, Phys.* 2007 ;68(2):364-9
216. Hatoum H, Mahfouz R, Otrrock Z, Hudaib A/R, Taher A, **Shamseddine A** Acute myeloid leukemia with T-cell receptor gamma gene rearrangement occurring in a patient with chronic lymphocytic leukemia: A case report. *Am J Hematol* 2007; (1):69-72

- 217.** El Zahabi L, Jamali F, El-Hajj I, Naja M, Salem Z, **Shamseddine A**, El Saghir N, Zaatari G, Geara F, Soweid A. The value of Endoscopic ultrasonography in predicting the Response of Gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication. *Lymphoma to Helicobacter Pylori Eradication. Gastrointestinal Endoscopy* 2007;65(1):89-96
- 218.** Otrock Z, Taher A, Makarem J, Kattar M, Nsouli G, **Shamseddine A**, Thrombotic Thrombocytopenic purpura and bone marrow necrosis associated with disseminated gastric cancer. *Digestive Diseases and Sciences.* 2007 ;52(6):1589-91
- 219.** El Saghir N, Khalil M, Eid T, Charafeddine M, El Kinge A/R, Geara F, Seoud M, **Shamseddine A**. Trends in Epidemiology and Management of Breast Cancer in Developing Arab Countries. *Int J Surg* 2007; 5(4):225-33
- 220.** Saghir N, Seoud M, Khalil M, Charafeddine M, Salem Z, Geara F, **Shamseddine A**. Effects of young age at presentation on survival in breast cancer. *BMC Cancer* 2006,6:194
- 221.** **Shamseddine A**, Otrock Z, Khalifeh M, Yassine H, Charafeddine M, Abdel-Khalek Z, Chehal A, Bitar N, Jalloul R, Dheiny M, Dandashi A, Wehbeh M, El Saghir N. A clinical phase II study of a non-anthracycline sequential combination of Cisplatin-Vinorelbine followed by Docetaxel as first line treatment in metastatic breast cancer. *Oncology* 2006; 70:3330-338.
- 222.** Hatoum H, Yassine H, Otrock ZK, Taher AT, Khalifeh MJ, **Shamseddine AI**. Testicular metastasis from primary rectal carcinoma. *Colorectal disease* 2006;8 (6):529-530
- 223.** Otrock Z, Makarem J, Seoud M. Shamseddine A, Laparoscopic splenectomy for isolated parenchymal splenic metastasis of ovarian cancer. *International Journal of Gynecological cancer* 2006; 6(5): 1933-5.
- 224.** Ahmad MR, Chehal A, Zahed L, Taher A, Haidar J, **Shamseddine A**, Ohea AM, Bienz N, Dgany O, Aridan N, Bechmann JS, Tomary H, Higgs D, Vyas P, Wood W, Wishramasinghe SN. Linkage and mutational analysis of the CDAN1 gene reveals genetic heterogeneity in Congenital Dyserythropoietic Anemia type 1. *Blood* 2006; 107 (12) : 4968-9
- 225.** Seoud MA, **Shamseddine A**, Khalil; AM, Charafeddine M, Geara FB. Randomized trial comparing concurrent radiotherapy with Cisplatin compared with Paclitaxel in Cervical Cancer. *Obstet Gynecol* 2006, 107 (Suppl 4): 438
- 226.** Otrock. ZK, Taher AT, Saliba TR, Zaatari GS, **Shamseddine AI**. Gastrointestinal relapse of multiple myeloma: a mimic of lymphoma leukemia and lymphoma 2006; 47(10): 1-3
- 227.** Otrock ZK, Taher AT, Mahfouz R.AR, .Makarem JA, **Shamseddine A**. Acute Tumor Lysis Syndrome Secondary to Hydroxycarbamide in chronic Myelogenous Leukemia. *Am J Hematol.* 2006 Mar;81(3):220-1
- 228.** Otrock ZK, **Shamseddine A**, Taher A. Non-Hodgkin's Disease in B. Thalassemia Major. *Am J Hematol.* 2006 Jan;81(1):62-4.
- 229.** Abou Mourad Y. Otrock Z.K, Shabb N.S. Taher AT, Khalil I, **Shamseddine A**. Recurrent Arterial Embolization from a metastatic carcinoma of unknown primary site. *Clinical*

Oncology. 2005;17(5):395-6

- 230. Shamseddine A.**, Khalifeh M., Mourad F, Chehal A, Al Kutoubi A, Abbas J, Habbal ZM, Malaeb L, Bikhazi A. Comparative Pharmacokinetics and Metabolic Pathway of Gemcitabine during Intravenous and Intra-arterial Delivery in Unresectable Pancreatic Cancer Patients with Early Clinical data. *J Clinical Pharmacokinetics* 2005, 44(9):957-67.
- 231. Shamseddine A**, Khalifeh M, Chehal A, Saliba T, Abou Mourad Y, Taher A, Jalloul R, Bitar N, Dandashi A, Abbas J and Geara F. A Clinical Phase II Study of Cisplatin and Vinorelbine (PVn) in Advanced Breast Carcinoma (ABC) *Am J Clin Oncol* 2005, 28(4):393-8
- 232. Shamseddine A**, El-Saghir N, Chehal A, Saliba T, Taher A. "Cisplatin and Vinorelbine (PVn) for the treatment of Advanced Breast Cancer: 10 years of experience. *J Med Liban* 2004, 52(3):126-130.
- 233. Makarem J, Abbas J, Otrock Z, Tawil A, Taher A, Shamseddine A.** Primary Pure Squamous Cell Carcinoma of the Breast: A Case Report and Literature Review. *European J of Gyn Oncol* 2005;26(4):443-5
- 234. Fuleihan Gh., Salamoun M, Abou Mourad Y, Chehal A, Salem Z, Mahfoud Z, Shamseddine A.** Pamidronate in the presentation of chemotherapy induced bone loss in premenopausal women with breast cancer: A Randomized controlled trial. *J Clin Endocrinal Metab.*2005 Jun; 90(6): 3209-14.
- 235. El Saghir NS, Shamseddine A, Geara F, Bikhazi K, Rahal B, Salem Z, Tawil A, Khatib Z, Abbas J, Hourani M, Khalil A, Seoud M.** Breast Cancer in Lebanon. Increased age-adjusted incidence rates in younger-aged groups at presentation: implications for screening and for Arab- American ethnic groups. *Ethn Dis.* 2005 winter, 15 (Suppl 1): 31-11-31-12.
- 236. Geara F, Nasr E, Taker LS., Brihi E., Zeytoun G, Hadi U, Salem Z, El Saghir N, Issa Ph., Shamseddine A.** Cancer in the Middle East: Experience of the American University of Beirut Medical Center. *International Journal of Radiation Oncology, biology and physics* 2005; 61(5): 1408-1415.
- 237. Shamseddine A, Otrock ZK, Mahfouz R, Makarem JA, Taher AT.** Budd-chiari Syndrome in a Paroxysmal Nocturnal Hemoglobinuria Patient with CO-existence of Factor II and MTHFR mutations. (*Thrombosis Haemostasias* 2005, 3(5):1111.
- 238. Khalil AM, NS Shabb, MH Hourani, Shamseddine A, MI El Hajj, MA-F Seoud.** Primary squamous cell carcinoma of the pelvic retroperitoneum presenting as an adnexal mass: a case report. *J of Obstetrics and Gynecology* 2005; 25(1): 92-93.
- 239. Uthman I, Shamseddine A, Taher A.** The Role of Therapeutic Plasma Exchange in the Catastrophic Antiphospholipid Syndrome. *Transfusion and Apheresis Science* 2005; 33(1): 7-11.
- 240. Jabbour R, Taher A, Shamseddine A, Atweh S.** Mayomoya Syndrome with intra ventricular hemorrhage in an adult with factor V-Leiden mutation. *Arch Neurol* 2005, 62(7):114-6

- 241.** Jabr F, **Shamseddine A**, Taher A. Hydroxyurea induced anemia in a patient with essential thrombocythemia. *Am J Hematol.* 2004; 77(4):37-46.
- 242.** **Shamseddine A**, Saliba T, Aoun E, Chehal A, El Saghir N, Salem Z, Bazarbachi A, Khalil M, Taher A. Thrombotic Thrombocytopenic Purpura: 24 years of experience at the American University of Beirut Medical Center. *J Clin Apheresis* 2004; 19(3):119-24.
- 243.** A.Chehal, A.Taher, M.Khalil, **Shamseddine A**, Cisplatin Plus Vinorelbine (PVn) as Salvage Regimen for Refractory Breast Cancer. *Breast* 2004; 13(5):421-4.
- 244.** **Shamseddine A**, Sibai A, Gehchan N, Rahal B, El Saghir N, Ghosn M, Aftimos G, Shamseddine N, Seoud M. Cancer Incidence in Post War Lebanon: Findings from the first national population-based registry, 1998. *Ann Epidemiol* 2004; 14(9):663-668.
- 245.** Abou Mourad Y, **Shamseddine A**, Hamdan A, Koussa S, Taher A. Report of a rare co-incidence of congenital factor V deficiency and thalassemia intermedia in a family. *Ann Saudi Med* 2004, 24 (3): 217-219.
- 246.** Dakdouki Gh. Kanafani Z, Mourad F, **Shamseddine A**, Kanj S. Streptococcus Pyogenes Bactnaemia in the setting of cholangitis *Int. J of infect Dis.*2004, 8 (3): 194-5.
- 247.** El Saghir N, Otrock Z, Mufarrij A, Abou Mourad Y, Salem Z, **Shamseddine A**, Abbas J. Dextrazoxane for anthracycline extravasation and GM-CSF for skin ulceration and wound healing. *Lancet Oncol* 2004; 5:320-21.
- 248.** **Shamseddine A**, Chehal A, Usta I, Salem Z, El Saghir N, Taher A. Thrombotic Thrombocytopenic Purpura in Pregnancy: Report of four cases and literature review. *Journal of clinical Apheressis* 2004; 19(1): 5-10.
- 249.** El Hajj I, Chehal A, **Shamseddine A**, Abu Mrad Y, Taher A. Hb H Disease and Multiple Myeloma. *Hemoglobin:* 2004; 28(1): 79-82 J.
- 250.** Abou Mourad Y, Khalifeh M, Taher A, Tawil A, **Shamseddine A**. Hepatocellular carcinoma with Isolated left adrenal metastasis following liver Transplantation. *Ann Saudi Med* 2004; 24(1):65-67.
- 251.** Abu Murad Y, Taher A, Chehal A and **Shamseddine A**. Successful Treatment of B-Cell Prolymphocytic Leukemia with Monoclonal Anti CD-20 Antibody. *Ann Hematol.*2004; 83(5):319-21.
- 252.** **Shamseddine A**, Taher A, Fakhani S, Zhang M, Scott CR, Habbal MZ, A Novel Mutation, L 371 V, causing multigenerational Gaucher disease in a Lebanese Family. *Am J Med Genetics*, 2004; 15; 125 A (3):257-60.
- 253.** Aoun E, **Shamseddine A**. Chehal A, Obeid M, Taher A. Transfusion in Associated graft-versus host disease: 10 years experience at the American University of Beirut-Medical Center. *Transfusion* 2003.Dec; 43(12):1672-6.
- 254.** Abou Mourad Y, Mattar-Muallem M, **Shamseddine A**. Nail toxicity related to Taxane. *Dermatol on line* 2003, 9(3):15.

255. Chehal A, Taher A, **Shamseddine A**. Idiopathic Thrombocytopenic Purpura and Ovarian Cancer. *Eur. J GYN Oncol* 2003, XXIV, n.6:539-540.
256. Abou Mourad Y, **Shamseddine A**, Taher A. Thalidomide-associated gynecomastia in a patient with multiple Myeloma. *Hematol J* 2003; 4(5):372.
257. El Saghir NS, **Shamseddine A**, Geara F, Bikhazi K, Rahal B, Salem ZM, Taher A, Tawil A, El Khatib Z, Abbas J, Hourani M, Seoud M. Age distribution of breast cancer in Lebanon: increased percentages and age adjusted incidence rates of younger-aged groups at presentation. *Leb M.J* 2002;50(1-2):3-9
258. Abou Murad Y, Taher A , **Shamseddine A**, Acute tumor lysis syndrome in large B-Cell Non-Hodgkin's Lymphoma induced by steroid and anti CD20 *Hematology Journal* 2003; 4(3) 222-224.
259. Taher A, Khalil I, Abou Merhi R, **Shamseddine A**, Bazarbachi A. High Prevalence of Prothrombin G 20210 A mutation among patients with deep venous thrombosis in Lebanon *Thromb Haemat* 2003 May, 89(5): 945-6.
260. Chehal A, Taher A, **Shamseddine A**, IgM Myeloma and Waldenstrom's macroglobulinemia: a distinct clinical feature, histology, immunophenotype and chromosomal abnormality, *Clin Lab Haem.* 2003; 25; 187-190.
261. Haidar J, **Shamseddine A**, Salem Z, Abu Murad Y, Nasr M, Zaatari G, Bazarbachi A. Loss of CD20 expression in relapsed lymphoma after rituximab therapy. *Eu J Haematol.* 2003; 70(5):330-2.
262. Jabr F, **Shamseddine A**, Uthman I, Chehal A, Taher A. Thrombotic Thrombocytopenic purpura in a patient with Bechet's disease. *Arthritis and Rheumatism* 2003 May; 48(5): 1468-1469.
263. **Shamseddine A**, Taher A, Abou –Mourad Y, Seoud M, Khalil A. Cure of Metastatic Uterine Carcinosarcoma to lungs. *Int. J Gynecol Cancer* 2003; 13: 1-2.
264. Seoud M, Geara F, **Shamseddine A**, Salem Z, Khalil A. Short duration neoadjuvant chemotherapy followed by Radiotherapy for advanced carcinoma of the cervix: Results and Prognostic variables. *Eur J Gyn Oncol*, 2003; 24(2):163-168.
265. Chehal A , Seoud M, Taher A, Salem N, Khalil A, **Shamseddine A**, Endometrial Metastasis from Signet Ring Breast Carcinoma. *Eur J Gynaecol Oncol* 2002; 23(6): 563-4.
266. Chahal A, Taher A, **Shamseddine A**, Sicklemia with multiorgan failure Syndrome and Thrombotic Thrombocytopenic Purpura. *Hemoglobin* 2002; 26(4): 345-351.
267. Taher A, Abou –Murad Y, Abchee A, Zalouaa P, **Shamseddine A**. Pulmonary Thromboembolism in better-thalassemia intermedia: are we aware of this complication? *Hemoglobin*, 2002; 26(2):107-12.
268. Seoud M, El Saghir NS, Salem Z, **Shamseddine A**, Awwad J, Medawar W, Khalil A, Tamoxifen and ovarian cysts: A prospective study. *European Journal of Obst and Gyn and reproductive Biology* 2001, 100: 77-80.

- 269.** Taher A, Khalil I, **Shamseddine A**, El Ahdab F, Bazarbachi A. High prevalence of factor V Leiden mutation among healthy individuals and patients with deep venous thrombosis in Lebanon. *Thromb. Haemost.* 2001; 86(2):723-4.
- 270.** Mansour A, **Shamseddine A**, Yamout B, Solitary Metastasis to Oculomotor Nuclear Complex. *Ann Ophthalmol* 2000; 32(3): 201-203.
- 271.** Khoury NJ, Hanna Al-Kass FM, Jaafar HN, Taher AT, **Shamseddine A**, Bilateral breast involvement in acute myelogenous leukemia. *Eur Radiol* 2000; 10(6): 1031.
- 272.** **Shamseddine A**, Taher A, Jaafar H, Haidar JH, Nasr R, Arzoumanian V, Salem Z, Bazarbachi A. Interferon alpha is an effective therapy for congenital dyserythropoietic anemia type 1. *Eur J Haematol* 2000; 64:1-3.
- 273.** Kanj N, **Shamseddine A**, Gharzeddine W, Kanj M, Abi Nasr T, Koussa S, Jibrail J, Taher A, Relation of ferritin levels to pulmonary function tests in patients with thalassemia Major and Acute Effects of Transfusion *Eur J Haematol* 2000;64:1-5.
- 274.** Nouredine BN, Seoud M, Bashshur Z, Salem Z, **Shamseddine A**, Khalil A. Ocular Toxicity in low dose Tamoxifen. A Prospective study. *Eye* 1999; 13 (pt 6), 729-733 2000; 10(6): 1031.
- 275.** Seoud M, **Shamseddine A**, Khalil A, Salem Z, El Saghir N, Bikhazi K, Bitar N, Azar Fg, Kaspar H. Tamoxifen and Endometrial Pathologies. A Prospective Study. *Gyn Oncol J* 1999; 75(1): 15-9.
- 276.** Taher A, **Shamseddine A**, El Saghir N, Seoud M, Mourad F, Dabajah B, Khalil A. Acquired Protein C-deficiency following Cisplatinum-Navelbine administration for locally advanced breast cancer: case report *Eur J Gynec Oncol* 1999 20(4);323-324.
- 277.** Seoud M, Salem Z, **Shamseddine A**, Khabbaz A, Zaatari GH, Khalil A. Papillary Serous carcinoma of the ovary following prolonged Tamoxifen Treatment. *Eur J Gynea Oncol* 1999; 20 (3):237-239.
- 278.** **Shamseddine A**, Taher A, Dabaja B, Dandashi A, Salem Z, El Saghir NS, Combination Cisplatinum-Vinorelbine (Pvn) for Relapsed and Chemotherapy pretreated Metastatic Breast Cancer. A Clinical study. *Am J Clin Oncol* 1999; 22(3):298-302.
- 279.** **Shamseddine A**, Medawar W, Seoud M, Ibrahim K, Habbal L, Kahwagi S, Khalil A. The relation between serum levels of erythropoietin (EPO) and insulin-like growth factor-1 (ILGF-1) in breast cancer patients receiving non-nephrotoxic chemotherapy. *Eur J Gyneac Oncol* 1998 19(6):591-593.
- 280.** **Shamseddine A**. Khalil A, Seoud M, Kahwaji S, Taher A., Bizri AR, Medawar W. The Relation between Erythropoietin and hematocrit in breast Cancer patients in non-nephrotoxic chemotherapy. *Eur J Gynaec Oncol* 1998; 19(6):577-579.
- 281.** **Shamseddine A**, Khalil AM, Kibbi AG, Abu Nasr T, Seoud MA-F, El Saghir NS Granulocyte-macrophage colony stimulating factor for treatment of chemotherapy extravasation *Eur J Gyneac Oncol* 1998 ;(5):474-481.
- 282.** Khalil A, Chammas M, **Shamseddine A.**, Seoud M. Fatal acute tumor lysis syndrome following

- treatment of vulvar carcinoma: Case Report Eur J Gynacec Oncol 1998 19(4): 415-416.
- 283.** Khalil A, Shammam M, Kaspar H, **Shamseddine A.**, Seoud M. Endometrial Cancer implanting in the laparotomy scar. Eur J Gynaec Oncol 1998; 19 (4):408-409.
- 284.** El Saghir N, Adib S, Mufarrij A, Taher A, Kahwaji S, Issa Ph, **Shamseddine A.** Cancer in Lebanon: analysis of 10,220 cases from the American University of Beirut Medical Center. Leb Med J 1998; 46(1):4-11.
- 285.** Adib SM, Mufarrij AA, **Shamseddine A.**, Spiridon KG, Issa Ph, El Saghir N. Cancer in Lebanon: An Epidemiological Review of the American University of Beirut Medical Center Tumor Registry (1983-1994) Ann Epidemiol 1998;8:46-51.
- 286.** Bulbul M, Wazzan W, Farhat W, Kaouk J, Hemady K and **Shamseddine A.** Feasibility of Radiation and Chemotherapy following cystectomy and orthotopic Neobladder for Invasive Bladder Cancer. Canad J of Urol 1998; 5(1): 469-471.
- 287.** Khalil A, Seoud M, Tannous R, Usta I, **Shamseddine A.**, Bernard-Soulier Syndrome in pregnancy: case report and review of Literature. Clin Lab Haematol 1998; 20:125-129.
- 288.** El Saghir NS, Bizri A-RN, Shabb NS, Husami TW, Salem ZM, **Shamseddine A.** Pressure ulcer accelerated healing with local injection of granulocyte macrophage-colony stimulating factor. J Infect 1997 Sep ;35: 179-182.
- 289.** Deeb LS, Yamout BI, **Shamseddine A.**, Shabb NS, Uthman S. Meningeal Carcinomatosis as the Presenting Manifestation Gastric Adenocarcinoma. Am J Gastro 1997; 92(2): 329-331.
- 290.** Khalil AM, Seoud MA-F, Jamal JH, **Shamseddine A.** Non simultaneous breast and cervical cancer. Eur J Gynaec Oncol 1997; 18(5): 434.
- 291.** Khalil AM, Khatib AR, **Shamseddine A.** Sharara NH, Seoud MA-F. Prolonged intake of chlorambucil for ovarian cancer. EUR J of Obst and Gynaec Reprod Biol 1995; 60(1):85-6.
- 292.** Awwad JT, Khalil AM, Mufarrij A, **Shamseddine A.** Shammam FG. Primary Malignant Lymphoma of the uterine cervix: Is radiotherapy the best therapeutic choice for stage IE. Gyn Oncol 1994; 52:91-93.
- 293.** **Shamseddine A.** Khalil AM, and Wehbeh M. Acute Tumor lysis syndrome with squamous cell carcinoma of the vulva: A case report Gyn Oncol 1993; 51-258-260.
- 294.** Khatib RA, Khalil AM, Tawil AN, **Shamseddine A.**, Kaspar HG, Suidan FJ. Non-Hodgkin`s lymphoma presenting as a urethral caruncle. Gynecol Oncol. 1993Sep; 50(3):389-93.
- 295.** **Shamseddine A.** Habbal Z. Prolonged Chlorpromazine infusion as antiemetic in patients on daily Cisplatin infusion; a pilot study. Am J Clin Oncol 1988; 11 (4):470-473

C. ABSTRACTS

- 1.** Abbas N, Chehade L, Abdul Sater Z, **Shamseddine A.** The Silent Burden of De Novo Metastatic Prostate Cancer in the Middle East: A Call for Region-Specific Screening Guidelines. Eighth Annual Urology Research Forum, December 7th, 2024– Best oral presentation award.
- 2.** **Shamseddine A.**, Abbas N, Chehade L, Temraz S, Charafeddine M, Al Darazi M, Nasr R, Khauli R, El Hajj A, Bulbul M. Clinical and Survival Outcomes in Muscle-Invasive Bladder Cancer Patients Undergoing Bladder Preservation versus Radical Cystectomy. 21st Annual Arab Association Of Urology Congress, Qatar, 21- 24 November 2024.

3. Chehade L, Turfa R, Kattan J, Temraz S, Zeidan Y, Amarin R, Alawabdeh T, Deebea S, Doughan S, Mohamad I, Elkhaldi M, Daoud F, Almasri M, Dabous A, Hushki A, Aldarazi M, Charafeddine M, Geara F, **Shamseddine A**. Short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma: Final analysis of the phase II Averectal trial. reference #250F Poster Presentation ESMO Gastrointestinal Cancers Congress Munich, Germany, 26-29 June, 2024.
4. **Shamseddine A**, Abbas N, Chatila W, Walch H, Eichholz J, Schultz N, Solit D, Charafeddine M, Al Darazi M, Abou-Alfa G, Al-Ahmadie H. Genomic profiling of bladder cancer in waterpipe and cigarette smokers: Implications for carcinogenicity and genetic landscape. Abstract #657 Gastrointestinal ASCO, Jan 25-27, 2024.
5. George G, Bill-Axelsson A, Enting D, Garmo H, Stattin P, IFranck Lissbrant I, Monroy-Iglesias M, Scailteux L, Balusson F, Van Praet C, Lumen N, Marvaso G, Corrao G, Jereczek-Fossa B, Chehade L, **Shamseddine A**, Charafeddine M, Hemelrijck M. CRUK Data-Driven Conference Manchester 27-28 February 2024.
6. Alessandro A, Velenik V, Meillat H, Ruíz-Garcia E, Riesco M, J Dekervel J, Carvalho C, Alecha J, Kirac I, Capdevila J, Artaç M, O'Connor J, Braam P, **Shamseddine A**, Moretto R, Paez D, Dulskas A, De Felice F, Vanden Bulcke A, Sclafani F. International real-world study of total neoadjuvant therapy (tnt) for locally advanced rectal cancer (LARC). Gastrointestinal ASCO, Jan 18-20, 2024.
7. Machmouchi A, Zahreddine L, Aoun J, Charafeddine M, Chehade L, Temraz S, **Shamseddine A**. Epithelial-to-mesenchymal transition: An emerging prognostic tool in resectable pancreatic cancer, a retrospective study, reference #269 Poster Presentation at the 25th World Congress on Gastrointestinal Cancer 28 June - 1 July 2023 in Barcelona, Spain.
8. Chehade L, Turfa R, Machmouchi A, Kattan J, Temraz S, Alqasem K, Amarin R, Al Awabdeh T, Mohamad I, Daoud F, Al Masri M, Dabous A, Hushki A, Jaber O, Charafeddine M, Al Darazi M, **Shamseddine A**. The neoadjuvant rectal (NAR) score application in the context of total neoadjuvant treatment with chemo-immuno-radiation for locally advanced rectal cancer: Data from the phase II Averectal study", reference #319 Poster Presentation at the 25th World Congress on Gastrointestinal Cancer 28 June - 1 July 2023 in Barcelona, Spain.
9. **Shamseddine A**, Machmouchi A, Natout M, Turfa R, Kattan J, Temraz S, Tawil A, Elkhaldi M, Jaber O, Amarin R, Awabdeh T, Charafeddine M, Al Darazi M, Hussain H. Assessment of Immunoscore and MRI tumor regression grade to predict complete pathologic response in patients with Locally Advanced Rectal Cancer: Data from Phase II Averectal Study. Abstract #212 Gastrointestinal ASCO, Jan 19-21, 2023
10. **Shamseddine A**, Chehade L, Elias C, Turfa R, Kattan J, Mukherji D, Temraz S, Alqasem K, Amarin R, Al Awabdeh T, Deebea S, Mohamad I, Daoud F, Al Masri M, Dabous A, Hushki A, Jaber O, Charafeddine M, Al Darazi M, Zeidan Y and Geara F. Quality-of-life outcomes after total neoadjuvant short course radiotherapy and chemo-immunotherapy for locally advanced rectal cancer in the Averectal study. Abstract #63 Gastrointestinal ASCO, Jan 19-21, 2023
11. **Shamseddine A**, Elias C, Turfa R, Kattan J, Mukherji D, Temraz S, Alqasem K, Amarin R, Al

Awabdeh T, Deeba S, Mohamad I, Daoud F, Al Masri M, Dabous A, Hushki A, Jaber O, Charafeddine M, Al Darazi M, Zeidan Y and Geara F. Chemo immunotherapy in the context of total neoadjuvant therapy in patients with locally advanced rectal cancer (AVERECTAL). Oncodistinct Study#5 ESMO June-July 2022

12. **Shamseddine A**, Khalifeh I, Elias C, Turfa R, Kattan J, Mukherji D, Temraz S, Alqasem K, Amarin R, Alawabdeh T, Deeba S, Mohamad I, Daoud F, Al Masri M, Dabous A, Hushki A, Jaber O, Charafeddine M, Farhat L, Tawil A. High Immunoscore as a Predictor of Outcome in Patients who underwent Chemoimmuno-Therapy in Locally Advanced Rectal Cancer: A Post-hoc Analysis of the Correlation Between Immunoscore and pCR in The Averectal Study. ASCO Gastrointestinal Symposium 2022. Abstract #353871
13. **Shamseddine A**, Al Mahmasani L , Elias C, Chehade L, Temraz S, Charafeddine M, Al Darazi M, El Jebai M, Haidar M. A Rare Subset of Well-Differentiated Gastro-Enteropancreatic Neuroendocrine Tumors with Positive FDG PET/CT: Is It a Sign of an Aggressive Disease? ESMO June-July 2022.
14. **Shamseddine A**, Chehade L, Elias C, Charafeddine M, Al Darazi M, Temraz S. Maintenance Chemotherapy in Advanced and Metastatic Pancreatic Cancer, a Case Series. ESMO June-July 2022.
15. **Shamseddine A**, Elias C, Aoun J, Temraz S, Charafeddine M, Darazi M and Tawil A. The Prognostic Significance of Epithelial-to-Mesenchymal Transition Expression in Resectable Pancreatic Cancer Patients. ESMO June-July 2022.
16. **Shamseddine A**, Zeidan Y, Bouferraa Y, Turfa R, Kattan J, Mukherji D, Temraz S, Alqasem K, Amarin R, Al Awabdeh T, Deeba S, Doughan S, Mohamad I, Elkhaldi M, Daoud F, Al Masri M, Dabous A, Hushki A, Jaber O, Charafeddine M, Al Darazi M and Geara F. Oncodistinct study #5: Efficacy and Safety of Neoadjuvant Short-Course Radiation Followed by mFOLFOX-6 plus Avelumab for Locally-Advanced Rectal Adenocarcinoma: Averectal Study. ESMO GI 30 June- 3 July 2021.
17. Khalifeh I, El Hussein Z, Zeidan Y, Turfa Z, Kattan J, Mukherji D, Temraz S, Alqasem K, Amarin R, Deeba S, Jamali F, Mohamad I, Elkhaldi I, Daoud F, Masri M, Dabous A, Hushki A, Jaber O, Darazi M, Charafeddine M, Geara F, **Shamseddine A**. Immunoscore in Rectal Cancer Patients Receiving Radiation Followed by mFOLFOX-6 with Avelumab. ESMO GI 1-4 July 2020.
18. Hussein Z, Kreidieh M, Haibe Y, Mukherji D, Temraz S, Charafeddine M, Shamseddine A. Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer Patients: A Tertiary Medical Center Experience. ESMO GI 1-4 July 2020.
19. **Shamseddine A**, Zeidan Y, Khalifeh I, Kattan J, Turfa R, Mukherji D, Temraz S, Jamali F, Shaib Y, Soweid A, Deeba S, Kreidieh M, El Hussein Z, Charafeddine M, Al Darazi M and Geara F. Short-course Radiation Followed by mFOLFOX-6 Plus Avelumab for Locally-

advanced Rectal Adenocarcinoma. Abstract #139. American Society of Clinical Oncology, Gastrointestinal cancer symposium, January 23-25, 2020, San Francisco.

20. Kreidieh M, Chami A, Haddadin F, Al Darazi M, Haydar A, Muallem N, Ershaid F, Faraj W, Khalifeh M, Mukherji D, Temraz S, Dbouk H, **Shamseddine A**. Predictors of Oxaliplatin-Induced Hepatotoxicity: Increase in Spleen Volume or Liver Fibrosis and Steatosis? Connecting through research the joint KHCC-AUBMC-MD Anderson conference- Amman March 22nd 2019
21. **Shamseddine A**, Abdel Massih S, Salim Hammoud M, Charafeddine M, Boulos F, Temraz S, Mukherji D. Discrepancy in Evaluating Her2 Overexpression in Signet Ring Gastric Cancer. 19th World Congress on Gastrointestinal Cancer, Barcelona, 28 June- 1 July 2017.
22. Dagher C, Malak D, Salim Hammoud M, Hdaideh O, Bahmad H, Bulbul M, Khauli R, El Hajj A, Nasr R, Sabban M, Temraz S, **Shamseddine A**, Abu Al Kheir A, Mukherji D. Second multidisciplinary urology research day, September 22nd, 2018.
23. Temraz S, Haibe Y, Charafeddine M, Saifi O, Mukherji D, **Shamseddine A**. The Unveiling of A New Risk Factor Associated with Bladder Cancer in Lebanon. Second multidisciplinary urology research day, September 22nd, 2018.
24. Halabi I, Mukherji D, Geara F, Matar C, Temraz S, Bulbul M, Khauli R, Nasr R, El Darsa H, Eid T, Zeidan Y, **Shamseddine A**. Surgery vs. Bladder preservation in muscle invasive bladder cancer: A single institutional experience. Second multidisciplinary urology research day, September 22nd, 2018.
25. Temraz S, Salim Hammoud M, Zorkot M, Al Bonji W, Dbouk H, Farhat F, Charafeddine M, Mukherji D, Shamseddine A. Neo-adjuvant FOLFIRINOX in borderline-resectable/locally advanced pancreatic adenocarcinoma: An Updated Analysis. ESMO 20th World Congress on Gastrointestinal Cancer Barcelona, Spain 20 - 23 June, 2018.
26. Temraz S, Salim Hammoud M, Makki I, Nassif S, Charafeddine M, Mukherji D, Shamseddine A. High Proliferation is Independently Associated with Disease Progression in Metastatic Pancreatic Adenocarcinoma ESMO 20th World Congress on Gastrointestinal Cancer Barcelona, Spain 20 - 23 June, 2018.
27. Salim Hammoud M, Charafeddine M, Temraz S, **Shamseddine A**, Mukherji D. Evaluation of morphology, HER2 status and its clinical and prognostic correlation in advanced gastric cancer: a prospective study at a tertiary referral center in Lebanon. 19th World Congress on Gastrointestinal Cancer, Barcelona, 28 June- 1 July 2017.
28. **Shamseddine A**, Abdel Massih S, Chahine G, Nasr F, Kattan J, Farhat F, Kobrossy B, Abi Gerges D, Moukadem W, SabaC. LLIVE: A Non-interventional Multicenter Study of First-line Avastin® (Bevacizumab) in Combination with Chemotherapy in Patients with Metastatic Colorectal Cancer in Lebanon. 19th World Congress on Gastrointestinal Cancer, Barcelona, 28 June- 1 July 2017.
29. El Chediak A, Haydar A, Hakim A, Abdel Massih S, Hilal L, Mukherji D, Temraz S,

- Shamseddine A.** Increase in Spleen Volume as a Predictor of Oxaliplatin Toxicity. 19th World Congress on Gastrointestinal Cancer, Barcelona, 28 June- 1 July 2017.
- 30.** Temraz S, Albonji W, Charafeddine M, Farhat Z, Mukherji D, **Shamseddine A.** Modified GTX second-line therapy in pancreatic adenocarcinoma. 18th World Congress on Gastrointestinal Cancer, Barcelona, 29 June- 2 July 2016.
- 31.** Temraz S, Albonji W, Charafeddine M, Farhat Z, Mukherji D, **Shamseddine A.** Neo-adjuvant FOLFIRINOX in borderline-resectable /locally advanced pancreatic adenocarcinoma. 18th World Congress on Gastrointestinal Cancer, Barcelona, 29 June- 2 July 2016.
- 32.** Hakim A, Hilal L, Mukherji D, Temraz S, **Shamseddine A.** Rectal cancer in patients younger than 40 at AUBMC: Tumor characteristics and comparative survival and disease free survival. 18th World Congress on Gastrointestinal Cancer, Barcelona, 29 June- 2 July 2016.
- 33.** Assi R, Hakim A, Mukherji D, Abdel-Massih S, Charafeddine M, Temraz S, **Shamseddine A.** Pancreatic Neuroendocrine Tumors: Experience of a Tertiary Care Center. 13th Annual ENETS Conference, Barcelona, 09-11 March 2016.
- 34.** Haidar M, Jreige M, Mukherji D, Abou Said R, Ibrahim T, Haddad M, **Shamseddine** The Role of 68Ga- DOTA-NOC PET in Evaluating Neuroendocrine Tumors: Real-world experience from single Lebanese institution. 13th Annual ENETS Conference, Barcelona, 09-11 March 2016.
- 35.** Alameddine R, Hakim A, Hilal L, Charafeddine M, Boulos F, Mukherji D, Saghir N , Temraz S, Tfayli A, Mahfouz R, Majzoub N, Elias E, Saleh A, Hamieh L, Nemer G, **Shamseddine A.** Prevalence and clinical characteristics of BRCA mutation in an unselected cohort of newly diagnosed Lebanese breast cancer patients. 4th Annual Breast Cancer Conference, Beirut-Lebanon, February 11-13, 2016.
- 36.** Alameddine R, Hakim A, Hilal L, Charafeddine M, Boulos F, Mukherji D, Saghir N, Temraz S, Tfayli A, Mahfouz A, Majzoub N, Elias E, Saleh A, Hamieh L, Nemer G, **Shamseddine A.** Age less than 40 years is an independent predictor of worse prognosis among Lebanese breast cancer patients: Analysis from a prospective cohort. . 4th Annual Breast Cancer Conference, Beirut- Lebanon, February 11-13, 2016.
- 37.** Jamali F, Seoud M, **Shamseddine A.** Khalifeh M. The management of peritoneal surface malignancies at the American University of Beirut Medical Center (AUBMC): Initial experience. Amman, Jordan, AUBMC- KHCC- MDAnderson, 22-24 October 2015.
- 38.** Charafeddine M, Olson S, Mukherji D, Temraz S, Abou-Alfa G, **Shamseddine A.** Proportion of Attributable and Preventable Cancer to Major Risk Factors in Lebanon. Amman, Jordan, AUBMC- KHCC- MDAnderson, 22-24 October 2015.
- 39.** Temraz S, Charafeddine M, Mukherji D, **Shamseddine A.** Lung cancer epidemiology in Lebanon: Emphasis on histology type and gender differences compared to the Arab region. Amman, Jordan, AUBMC- KHCC- MDAnderson, 22-24 October 2015.
- 40.** Hilal L, Charafeddine M, El Dika I, Eid M, Sabbah P, **Shamseddine A** Temraz S, Mukherji.

Estimation of Creatinine Clearance for Carboplatin Dosing at Naef K. Bassile Cancer Institute (NKBCI). Amman, Jordan, AUBMC- KHCC- MDAnderson, 22-24 October 2015. Poster presentation

41. Fakhri R, Rahal M, Hilal L, Hamieh L, Dany M, Karam S, Shehab L, Saghir N, **Shamseddine A**, Tfayli A, Temraz S, Salem Z, Mukherji D. Insomnia incidence among breast cancer patients during chemotherapy management. Amman, Jordan, AUBMC- KHCC- MDAnderson, 22-24 October 2015.
42. Mukherji D, Jabbour M, Saroufim M, Temraz S, Nasr R, Charafeddine M, **Shamseddine A**, Tawil A. PD-L1 expression in bladder cancer. Amman, Jordan, AUBMC- KHCC- MDAnderson, 22-24 October 2015.
43. El Saghir N, **Shamseddine A**, Hilal L, Mukherji D, Charafeddine M, Hamieh L, Alameddine R, Boulos F. Clinicopathological Breast Cancer Characteristics among Lebanese Women: A Prospective Study. Amman, Jordan, AUBMC- KHCC- MDAnderson, 22-24 October 2015.
44. Hilal L, Garrett C, Mukherji D, Temraz S, **Shamseddine A**. Survival advantage of metformin in patients with colorectal cancer and type II diabetes mellitus: The Middle Eastern perspective. Amman, Jordan, AUBMC- KHCC- MDAnderson, 22-24 October 2015.
45. El Saghir N, Uhrhammer N, Assi H, Khoury K, Decoucouc S, Bidet Y, Jaber S, Charara R, Farhat R, Salem Z, **Shamseddine A**, Tfayli A, Abbas J, Jamali F, Seoud M, Armstrong D, Bignon Y, Zgheib N. BRCA1 and BRCA2 mutations in ethnic Lebanese Arab high risk women for hereditary breast cancer. San Antonio, Breast Cancer Symposium, 9-13 December 2014, poster presentation.
46. Shahait M, Mukherji D, Yacoubian A, **Shamseddine A**, Khauli R. Inter-regional variability of prostate cancer incidence and mortality rates in the MENA region. EAU 10th South Eastern European Meeting in Belgrade, Serbia, 24-26 October 2014, poster presentation.
47. Jamali F, Seoud M, **Shamseddine A**, Khalifeh M. The management of peritoneal surface malignancies at the American University of Beirut Medical Center: initial experience. 9th International Congress on Peritoneal Surface Malignancies, 9-11 October 2014. Amsterdam, Netherlands, poster presentation.
48. Mukherji D, Jabbour M, Saroufim M, Temraz S, Nasr R, **Shamseddine A**, Tawil A. PD-L1 expression in muscle-invasive bladder cancer cystectomy specimens and lymph node metastasis. European Society for Medical Oncology, Barcelona 2014.
49. **Shamseddine A**, Hamieh L, Mukherji D, Temraz S, Garrett C. Survival advantage of metformin in patients with colorectal cancer and type II diabetes mellitus: The middle eastern perspective. 16th World Congress of Gastrointestinal Cancer, June 2014.
50. Assi R, Khalifeh M, Temraz S, Mukherji D, Zaatari G, **Shamseddine A**. Primary hepatic neuroendocrine tumors: 4 familial case series with review of literature. 11th European neuroendocrine tumor society meeting. March 5-7, Barcelona, Spain, poster presentation.
51. Assi R, Haydar A, Haydar M, Mukherji D, Temraz S, **Shamseddine A**. Pancreatic neuroendocrine tumors presenting in pregnancy with severe hypercalcemia. 11th European

- neuroendocrine tumor society meeting. March 5-7, Barcelona, Spain , poster presentation.
52. Abou Yehia Z, Haydar A, Haydar M, Mukherji D, Temraz S, **Shamseddine A**. The pitfall of nuclear imaging in intermediate grade neuroendocrine tumors. 11th European neuroendocrine tumor society meeting. March 5-7, Barcelona, Spain , poster presentation.
 53. Faraj W, El-Kehdy J, Fakh H, Mukherji D, Haydar A, Abou El Naaj A, Abou-Alfa G, O'Reilly E, **Shamseddine A**, Khalife M. Liver Resection for Metastatic Colorectal Leiomyosarcoma: A Single Center Experience. Global Academic Program 2014, Seoul-Korea, poster presentation.
 54. Faraj W, Khoury G, Jabbour S, Haydar A, **Shamseddin A**, Abu Nijaj A, Khalife M. Liver transplantation in Lebanon: A hard lesson to Learn (Updates). International Liver Transplant Society (ILTS) 20th Annual International Congress, June 4 – 7, 2014, London-UK, poster presentation.
 55. **Shamseddine A** ; Abou Kerr S, Alameddine R, Temraz S, El Saghir N. Clinicopathologic characteristics of Lebanese patients under and over the age of 40 presenting with breast cancer at a single institution. Abstract e 12525, ASCO, Chicago May 31-June 4, 2013.
 56. Khaled H, A/Azim H, Barsoum M, Chahine G, **Shamseddine A**, A/Metaal G, Omar A, Jageih A, Badran A. A Multicenter, Middle East, Phase II Study of the Raf-Kinase Inhibitor Sarafenid in Patients with Advanced Renal Cell Carcinoma, ESMO 2012, Vienna, Austria.
 57. Alameddine RS, Elias E, Mukherji D, Faraj W, Saleh A, El Saghir N, **Shamseddine A**. Controversial Role of Nodal Status and Extent of Surgery in Triple Negative Breast Cancer ; Analysis from a Cohort Study. European Breast Cancer Conference -8, Vienna March 21-24, 2012. poster Presentation-Poster Session “ Breast Cancer in Young and Elderly”
 58. Alameddine RS, Mukherji, Elias E, Saleh A, **Shamseddine A**. Triple Negative Breast Cancer – Experience of a single Tertiary Center. European Breast Cancer Conference-8, Vienna March 21-24, 2012. Poster presentation – poster session “ Breast Cancer in Young and Elderly”
 59. Melki C, Mukherji D, Faraj W, Elias E, El Oubeidi M, Dimassi H, Khalifeh M, **Shamseddine A**. Lymph node ratio is an independent Prognostic factor after resection of periampullary malignancies: Data from tertiary referral center in The Middle East. 13th World Congress on Gastrointestinal Cancer. June 22-25, 2011, Barcelona , Spain. (Poster Presentation).
 60. Elias E, Mukherji D, Faraj W, Khalifeh M, El Oubeidy M, Hatoum H, Dimassi H, Melki C, Abou-Alfa GK, **Shamseddine A**. lymph node ratio is an independent prognostic factor in Stage III colorectal Cancer patients, a retrospective study from the Middle East, 13th World Congress on Gastrointestinal Cancer, June 22-25, 2011 Barcelona, Spain (poster presentation).
 61. Geryess E, Haroun F, Issa S, Bazarbachi A, **Shamseddine A**, Salem Z, Taher A, El Saghir N, Tfayli A, Zgheib N. The role of CYP2d, gst genetic polymorphisms in breast cancer risk in Lebanon. Oral presentation at AUB research day, April 2010.
 62. Haroun F, Hatoum H, Bazarbachi A, **Shamseddine A**, Salem Z, Taher A, El Saghir N, Tfayli A, Zgheib NK. The role of CYP2B6 polymorphisms in predicting toxicity from cyclophosphamide based therapy in Lebanese patients with breast cancer on Non-Hodgkin’s lymphoma. Oral

presentation at the 16th World Congress of Basic and clinical pharmacology. July 2011, Copenhagen, Denmark.

63. Holail Y, Tfayli A, Habbal M, Halawi R, Saghir N, Salem Z, **Shamseddine A**, Bazarbachi A, Zgheib N. The influence of CYP2D6 genetic polymorphisms on variability of tamoxifen metabolism in the Lebanese breast cancer population poster presentation at student research day. April 2011.
64. Farhat F, Ibrahim K, Kattan J, Bitar N, Jalloul R, Nsouly G, Ghosn M, Haddad N, Bou Karroum M, Temraz S, **Shamseddine A**. Preliminary results of a phase II study of lipoplatin (liposomal Cisplatin)- Vinorelbine combination first line treatment in HER 2/ neu negative metastatic breast cancer (MBC) ASCO 2009, Orlando FL May 29-June 3 (accepted as Poster Presentation).
65. Hatoum H, Jamali F, El Saghir N, Musallam K, Seoud M, Dimassi H, Abbas J, Khalifeh M, Salem Z, Geara F, Shamseddine A, Al Feghali K, **Shamseddine A**. ASCO 2009, Orlando FL, May 29-June 3.
66. El Saghir N, Hatoum H, Shamseddeen W, Sbaity E, **Shamseddine A**. Prediction of Prognosis by lymph node ratio of involved axillary lymph nodes to the total number of removed lymph nodes in early stage breast cancer. 6th European Breast Cancer Conference April 15-10, 2008 Berlin, Germany (Poster Presentation) and Alco San Francisco 2007. Breast Cancer Symposium, Sept. 2007 (Poster Presentation) European Breast Conference Berlin, Germany, March 2008 (Poster Presentation).
67. El-Kinge A, Makarem J, Bulbul M, Taher A, El Saghir N, Khauli R, Hemadeh K, **Shamseddine A**. A Phase II Clinical Study of high-dose Calcitriol plus Docetaxel and Zoledronic acid in hormone – refractory Prostate Cancer. 1st European Multidisciplinary Meeting on Urological Cancers. Nov. 1-3 2007 Barcelona, Spain (Poster Presentation).
68. Farhat M, **Shamseddine A**, Barada K. Prognostic Factors in Patients with Advanced Cholangiocarcinoma: Role of surgery, chemotherapy, and Body Mass Index. The American College of Gastroenterology Annual Scientific Meeting. Philadelphia Oct. 11-14, 2007. (Poster Presentation).
69. Farhat M, Barada K, **Shamseddine A**. High body mass index and cholangiocarcinoma ASCO 2007, June 1-5 Chicago.
70. Farhat M, Tawil A, Barada K, Itani D, **Shamseddine A**. Effect of high mucin production on survival in colorectal cancer: A case control study. 9th World Congress on Gastrointestinal Cancer. June 27-30, 2007, Barcelona, Spain (Poster, P-0164).
71. **Shamseddine A**, Hatoum H, Salem Z, Abdel Khalek Z, El Saghir N, Taher N; The prognostic value of nodal ratios in node-positive breast cancer: AUBMC experience. Journal of Clinical Oncology, vol 25, No 18S part I of II, June 20, 2007.
72. Ibrahim A, Otrouk Z, Mougharbel A, Mahfouz R, Salem Z, Shebbo W, Hatoum H, Nsouly G, **Shamseddine A**, Jalloul R, Taher A, El Saghir N, Makarem J, El Kinge A, Droubi N, Kreidieh N, Yassine N, Jisr T, Bazarbachi A. Antologus hematopoietic stem cell transplantation as an up-front therapy in stage III multiple myeloma: The Lebanese experience . 33rd Annual meeting of

- the European Group for blood and marrow transplantation, Lyon France, March 24-28, 2007 Bone marrow transplantation 2007; 39 (supplement 1): P 690.
73. **Shamseddine Ali**, Farhat M, Abdel Khalik Z, Barada K. High body mass index and cholangiocarcinoma. 2007 Gastrointestinal Cancer Symposium Orlando, FL, Jan 19-21, 2007.
 74. El-Saghir N, Otrock Z, Abdel Khalik Z, Yassine H, Khalifeh M. Bitar N, Charafeddine M, Jalloul R, Dandashi A, **Shamseddine A**. A Clinical phase II study of combination Cisplatin and Vinorelbine followed by Docetaxel as first line chemotherapy in metastatic breast cancer. J Clin Oncology 2006; 24(189): 582 (Abs # 10683).
 75. **Shamseddine A**, Makarem J, Abdel Khalik Z, Bulbul M, Taher A, Khauli R, Hemadeh K, El Saghir N. Safety and efficacy of the combination of high-dose calcitriol, docetaxel and Zoledronic acid in hormone refractory prostate cancer (HRPC): Interim report of a phase II trial. J Clin Oncology 2006; 24(185): 6445 (Abs # 14600).
 76. El Zahabi L, Hatoum H, Rashid K, Yassine H. Shamseddine A. Th Impact of the ratio of metastatic to examined lymph node on survival in colorectal cancer. Poster presentation: 40th MEMA LSMO-6 meeting May 11-13, Beirut. Ann of Oncology 2006, 17(6): VI 70Abst p-158 (Poster Presentation at the 8th world congress on gastrointestinal cancer June 28-July 2, 2006 Barcelona, Spain.
 77. Hatoum H, El-Zahabi L, Abdel Khalik Z, Yassine H. **Shamseddine A**. The Prognostic implications of Mucinous type colorectal adenocarcinoma. Poster Presentation 40th MEMA LSMO-6 meeting May 11-13 Beirut. Ann of Oncology 2006, 17(6): VI 72 (Abst p-167) poster presented at the 8th world congress on gastrointestinal cancer June 28-July 2, 2006 Barcelona –Spain.
 78. **Shamseddine A**. Makarem J, Bulbul M, Abdel Khalik Z, Taher A, El-Saghir N, A Phase II Clinical Study of High Dose Calcitriol plus Docetaxel and Zoledronic acid in Hormone-Refractory Prostate cancer (HRPC). Poster presentation and poster discussion. 16th International Congress on anti-cancer treatment ICACT Jan. 30-Feb. 2, 2006, Paris.
 79. Geara F, Khalil A, **Shamseddine A**, Charafeddine M, Seoud M. A Phase II Randomized Trial comparing Radiotherapy (RT) with Concurrent Weekly Cisplatin to RT-Paclitaxel in Patients with Advanced Cervical Cancer (oral presentation) 91st Scientific Assembly and Annual Meeting of Radiological Society of North America. December 2, 2005, Chicago Illinois.
 80. Shamseddine A, Abu Mourad Y., Makarem J, Kattan J, Farhat F, Jalloul R, Mukaddem W, Taher A, Chehal A, Ghosn M. Docetaxel-irinotecan doublet chemotherapy as first-line therapy for advanced non-small-cell lung cancer: A Phase II study. Lung cancer 2005, 49 (Suppl 2): S 269 (P-573).
 81. Yassine H, Khalifeh M, Bitar N, Charafeddine M, Dheiny M, Chehal A, Jalloul R, Dandashi A, Wehbeh M, **Shamseddine A**. A Clinical Phase II study of Cisplatin and Vinorelbine followed by docetaxel as first-line treatment in metastatic breast cancer (MBC). J Clin Oncology, 2005, 23 (No.165): 83s (Abst # 822).
 82. Khalil A, **Shamseddine A**, Geara F, Charafeddine M, Seoud M. Concurrent chemo-radiotherapy for locally advanced cervical cancer-radiotherapy for locally advanced

cervical cancer: A Prospective randomized trial comparing Cisplatinum vs Paclitaxel. J Clin Oncology 2005; 23 (No. 16s): 4945 (Abst # 5163).

83. **Shamseddine A**, Rashid K, Ghosn M, Kattan J, Saghir N, Bitar N, Nsouli G, Mukkadem W, Chahine G, Salem Z. A retrospective review of the efficiency of gefitinib in the treatment of NSCLC in Lebanon. J Clin Oncology 2005; 23 (No.16s): 2455(Abst # 3217).
84. Seoud M, Khalil M, El Saghir N, Salem Z, Charafeddine M, Abbas J, Sidani M, **Shamseddine A**. Young age is not always and adverse prognostic factor in breast cancer. J Clin Oncology. 2005; 23(No.16s): 845 (Abst# 825).
85. Taher A, **Shamseddine A**, Saliba T, Aoun E, Chehal A, El Saghir N, Salem Z, Bazarbachi A, Khalil M. Thrombotic Thrombocytopenic Purpura: 24 years of experience at the American University of Beirut Medical Center. The Hemato.Journal. Volume 5.Supplement 2 (2004).
86. **Shamseddine A**, Seoud M, Abbas J, Charafeddine M, Salem Z, Geara F, Bikhazi K, Khalifeh M, Sidani M, El-Saghir N. Clinical characteristics and long-term survival of early breast cancer cases in the American University of Beirut Medical Center, Beirut, Lebanon. Proceedings American Society of Clinical Oncology (Abst 833), New Orleans, LA.(2004).
87. Saghir N., Seoud M., Charafeddine M., Abbas J., Salem Z., Geara F., Bikhazi K., Khalifeh M., Sidani M., **Shamseddine A**. Clinical characteristics and long-term survival of advanced breast cancer cases in the American University of Beirut Medical Center, Beirut, Lebanon. Proceedings American Society of Clinical Oncology (Abst 852), New Orleans, LA.(2004).
88. **Shamseddine A**, Bitar N, Dheiny M, Chehal A, Abu Mourad Y, Jalloul R, Dandashi A, Wehbeh M, Abou Nasr T, El Saghir N. A Clinical Phase II Study of Cisplatin and Vinorelbine followed by Docetaxel as first line treatment in metastatic breast cancer. Poster Presentation, 4th European Breast Conference March 16-20, 2004. Hamburg; Germany (Abst 259) EJC 2004; 2(3):131.
89. **Shamseddine A**. Kattan J, Farhat F, Jalloul R, Mukaddem W, Ghosn M, Taher A, Chehal A, Abu Mrad Y, Phase II Trial of Docetaxel and Irinotecan in patients with advanced Non-small cell lung cancer. Post presentation ICACT, Paris, Feb. 2004.
90. Ahmed M, Sternberg A, Zahed L, Taher A, Haidar J, **Shamseddine A**. Mutational Analysis of the CDAN1 Gene in Familial and Sporadic Congenital Dyserythropoietic Anaemia Type 1.American Society of Hematology 45th Annual Meeting, Dec.6-9,2003, San Diego, CA Blood 2003; 102: Abstract # 552(Oral Presentation).
91. El Saghir N, **Shamseddine A**, Geara F, Bikhazi K, Rahal B, Salem Z, Taher A, Tawil A, Khatib Z, Abbas J, Hourani M, Khalil A, Seoud M. Breast Cancer in Lebanon: Increased percentages and age-adjusted incidence rates in Younger-aged groups at presentation. The 3rd Biennial National Conference of the Arab-American Community, Oct. 24-25, 2002, Dearborn, Michigan,USA (Oral Presentation).
92. Salamoun M, **Shamseddine A**. Chehal A, Abou Mourad Y, Salem Z, Arslanian Y, Basbous S, El Hajj Fuleihan G. Pamidronate in the prevention of chemotherapy induced bone loss in

- premenopausal women with breast cancer. ASBMR Annual Meeting. Minneapolis Sept. 19-23, 2003 (Poster).
93. **Shamseddine A.** El Koutubi A, Chehal A, Taher A, Bikhazi A, Mourad F, Abbas J, Khalifeh M, A phase I/II Clinical and Pharmacokinetics Study of intra-arterial Gemcitabine (dfdc) with selective embolization in locally advanced and regionally metastatic pancreatic carcinoma. Proceedings of the American Society of Clinical Oncology (ASCO). 2003; 22: Abstract 1320.
 94. Seoud M, Abbas J, Khalil M, Charafeddine M, Salem Z, El Saghir N, Geara F, **Shamseddine A.** Clinical characteristics of breast cancer patients diagnosed and treated at the American University of Beirut Medical Center (AUBMC) from 1990 to 2001. Proceedings of the American Society of Clinical Oncology (ASCO) 2003; 22: Abstract 341.
 95. El Saghir N, Abu Mrad Y, Abbas J, Mufarrij A, **Shamseddine A**, Salem Z. Dexrazoxane is an effective immediate therapy in doxorubicin extravasation. Proceedings of American Society of Clinical Oncology (ASCO) 2003; 22: Abstract 580.
 96. Sibai A, **Shamseddine A.** Gehchan N, Rahal B, El Saghir N, Ghosn M, Aftimos G, Chamseddine N, Seoud M. Cancer Incidence in Post war Lebanon: The first population- based estimates, 1993-1998. Proceeding of American Society of Clinical Oncology (ASCO) 2003; 22: Abstract: 2239.
 97. **Shamseddine A.** El Kutoubi A, Chehal A, Taher A, Bikhazi A, Mourad F, Abbas J, Khalifeh M. Pharmacokinetics differences between intravenous and intra-arterial delivery of Gemcitabine in unresectable Pancreatic Cancer patients with initial clinical data. Oral Presentation, session on Regional Tumor Treatment of ISRCT on the 14th International Congress on Anti-Cancer Treatment ICACT, Paris, Feb. 2003.
 98. Bikhazi A, Al Kutoubi A, Abbas J, Khalifeh M, Abou Murad Y, Chehal A, Habbal Z. **Shamseddine A.** Comparative pharmacokinetics between intravenous and Intra-arterial delivery of Gemcitabine in Unresectable Pancreatic Cancer Patients. The IVth Annual Meeting of the Lebanese Society of Medical Oncology. Beirut –Lebanon Sept. 26 to 28, 2002 (Oral). (2002) AAPS (American Association of Pharmaceutical Scientists) annual meeting. Nov. 10-14, 2002 Toronto, Canada (poster). AA PSP Pharm Sci J 2002; 4 (No.4): Abstract W 5224.
 99. **Shamseddine A.** Sibai A, Gehchan N, Rahal B, El Saghir N, Ghosn M. Aftimos G, Chamseddine N, Seoud M. Cancer Incidence in post war Lebanon: The first Population –based estimates 1993 and 1998. The IVth Annual Meeting of the Lebanese Society of Medical Oncology (LSMO4). Beirut, Lebanon, Sept. 26th to 28th, 2002 (oral).
 100. **Shamseddine A.** Taher A, El Saghir N, Salem Z, Chehal A, Jalloul R, Bitar N, Dandashi A, Abbas J, Khalifeh M. A Clinical Phase II Study of Cisplatin and Vinorelbine (PVn) in Advanced Breast Carcinoma (ABC). XII International Congress on Anti-Cancer Treatment. Feb 2002, Paris (Oral).
 101. Bashshur Z, Taher A, Najjar D, Arayssi T, **Shamseddine A**, Noureddine A. Retinol vein occlusion and anticardiolipin antibodies: A prospective study in patients without factors. XVI

- Meeting of the international Society of Haematology, Jan 2002, Cairo (Poster-PF 9/6).
- 102.** Taher A, Mourad F, **Shamseddine A**, Sheikh Taha, Koussa A, Inati A, El Khatib Z, Hoffbrand A. Comparison between desferrioxamine, deferiprone and a combination therapy in iron overloaded thalassemia patients. XVI Meeting of the International Society of Haematology, Jan 2002, Cairo (Oral – OF 13/3).
- 103.** Taher A, Khalil I, **Shamseddine A**, El Ahdab F, El Khatib Z, Bazarbachi A. High Prevalence of Factor V Leiden Mutation among healthy individuals and patients with deep venous thrombosis in Lebanon: Is Eastern Mediterranean region the primary focus of the Mutation? XVI Meeting of the International Society of Hematology, Jan 2002, Cairo (Oral – OF 9/7).
- 104.** **Shamseddine A**. Taher A, Fakhani S, Zhang M, Scott C, Habbal Z. Gaucher Disease Type 1, A Novel Mutation in a Lebanese Family. XVI Meeting of the International Society of Haematology, Jan. 2002, Cairo (Poster-PF 35/9).
- 105.** El Saghir N, **Shamseddine A**, Geara F, Tawil A, Taher A, Salem Z, Khalil A, Seoud M. Age Distribution of Breast Cancer in Lebanon: Analysis of 2282 cases from the American University of Beirut. Pro Am Soc clinical Oncol. April 2002 (Abstract 3045)
- 106.** Geara F, Nasr E, Tucker S, Zaytoun G, Brihi E, Salem Z, Saghir N, **Shamseddine A**. Issa P. Nasopharyngeal Cancer (NPC) in the Middle East : Experience of the American University of Beirut Medical Center. Radiotherapy & Oncology Sept:2000;56 (Suppl 1): S 150 (Abstract 567 poster) 19th Annual Estro Meeting.
- 107.** **Shamseddine A**. Taher A, El Saghir N, Salem Z, Jalloul R, Ibrahim K, Abi Nasr T, Dandashi A, Abbas J, Khalifeh M. A clinical phase II study of Cisplatin and Navelbine (Pva) in advanced breast carcinoma (ABC). Annals of Oncology 2000; 11, Suppl 4:36 (Abstract 151) 25th European Society for Medical Oncology Congress (ESMO).
- 108.** El Saghir N, Shamseddine A. Tawil A, Taher A, Salem Z, Khalil A, Seoud. Breast Cancer in Lebanon: Epidemiological data from the American University of Beirut. M. Poster presentation, 2nd European Breast Cancer Conference, Brussels, Belgium Sept. 2000. (Poster).
- 109.** Geara F, Nasr E, Tucker S, Bikhazi K, Abbas J, Salem Z, El Saghir N, Shamseddine A, Bazarbachi A, Issa P. Results of adjuvant Radiotherapy alone and combined Modality therapy for high risk Breast Cancer patients with 10 or more positive axillary lymph nodes. Radiotherapy Oncology Jan 2001; 58 (suppl 1):565 (Abstract 227 oral) 6th International Congress
- 110.** Saghir N, Tawil A, Salem-Shabb N, Salem Z, Taher A, Bazarbachi A, Jaafar H, Abbas M, Geara F, **Shamseddine A**. Non-Hodgkin's Lymphoma in Lebanon: Review of 758 cases of the American University of Beirut Medical Center (AUB-MC) Tumor Registry 1983-1998. ASCO – PANARAB Lymphoma Conference, Cairo, Nov. 1999 (oral). Proc Am Soc Clin Oncol 2000; 19: A 144.
- 111.** El Saghir N, Jaafar H, Tawil A, Haidar J, Salem Z, Geara F, Taher A, Bazarbachi A, Abbas M, **Shamseddine A**. Hodgkin's Disease in Lebanon: Review of 357 cases of the American

University of Beirut Medical Center (AUBMC) Tumor Registry .ASCO – PANARAB Lymphoma Conference; Cairo, Nov. 1999 (Poster).

112. **Shamseddine A.** Nabulsi M, Seoud M, El Saghir N. The most frequent cancer cases in Pediatrics at AUB-MC (1983-1999). 2nd Annual Cancer Conference of the Lebanese Society of Medical Oncology, Beirut Sept.1999 (oral).
113. Seoud M, Saghir N.Salem Z. **Shamseddine A.** Awwad J, Medawar W, Khalil A. Tamoxifen and Ovarian Cysts: A Prospective Study. Proceedings ASCO Annual Meeting 1999; J Clin Oncol. 18:606a (Abstract#2341).
114. Saghir N, **Shamseddine A.** Tawil A, Taher A., Salem Z., Khalil A and Seoud, M. Breast Cancer at the American University of Beirut Medical Center (P34) Spring Pan-Arab Oncology Meeting. April 14-18, 1999, Cairo, Egypt. First National Conference on Health Issues in the Arab American Community.
115. **Shamseddine A.** Taher A, Haidar JH, Nasr R, Salem Z, Saghir N, Shaib F, Bazarbachi A. Interferon-Alpha Is an Effective Therapy for Congenital Dyserythropoietic Anemia Type I Proceeding of American Society of Hematology, 40th Annual Meeting, Dec. 4-8, 1998, Miami, Florida. Abstract # 3076.
116. Geara F, Nasr E, Stucker S, Zeytoun G, Brihi E, Salem Z, El Saghir N, **Shamseddine A.** Issa P. Nasopharyngeal Cancer in the Middle East: Experience of the American University of Beirut Medical Center 2nd Annual Conference of the Lebanese Society of Medical Oncology. Beirut Sept. 1999 (oral).
117. Seoud M , Khalil A, Kanj N , **Shamseddine A.** Issa P .Short-Term Response of Squamous Cell CA of the Cervix to Neoadjuvant Chemotherapy. Centennial Congress of Wherthein, Vienna, Sept 15-20, 1998 (Oral Presentation).
118. Nouredin BN , Seoud M, Bashshur Z, Salem Z, **Shamseddine A.**, Khalil A, “Ocular Toxicity in Low Dose Tamoxifen A Prospective Study”. Am Acad Ophthalmol, Oct.97, and San Francisco, USA.
119. Khalil A, Seoud M, Matter F, **Shamseddine A.** Kaspar H, Bitar K Nagalakshmi K, Issa P. Cervical Cancer treated with External Radiation Alone. Autumn Pan Arab Oncology Meeting Cairo November, 1997.
120. **Shamseddine A.** Taher A, Dabaja BS, Dandashi A, Salem Z, El Saghir N. Cisplatinum-Vinorelbine (PVN) for Relapsed and Pretreated Metastatic Breast Cancer. Autumn Pan-Arab Oncology Meeting Cairo, November1997.
121. **Shamseddine A.** Medawar W, Habbal Z, Khalil A. The Relationship Between serum levels of Erythropoietin (EPO) and Insulin Like Growth factor-(ILGF1)and Hematocrit (HCT) in Breast Cancer Patients Receiving Non-nephrotoxic chemotherapy. XIVth Meeting of the International Society of Haematology August 1997 (P-100), Stockholm, Sweden.
122. Kanj N, Taher A., **Shamseddine A.** Abi Nasr T, Jibrail J. Relation of serum ferritin levels to pulmonary function in patients with thalassemia major and the acute effects of transfusion.6th International Conference on Thalassemia and the Hemoglobinopathies. Malta, April

1997.

- 123.** Seoud M, **Shamseddine A.** Khalil A, Salem Z, Saghir N, Bikhazi K, Bitar N., Azar G, Kaspar H. Tamoxifen and Gynecologic Pathologies: A prospective study. The Third Middle East Oncology Congress May 1-3 1997, Beirut. *Acta obstetricia et Gynecologica Scandinavica* 76: 167, 1997 (P 51.27).
- 124.** **Shamseddine A,** Khouri F.P, Habbal MZ, Abu Nasr TA., Medawar. WA. The Relation Between Erythropoietin (EPO) Level and Hematocrit (Hct) in the serum of patients with Breast cancer on Non-nephrotic chemotherapeutic Agents. The 1st Pan Arab Cancer Conference, 1996, Cairo.
- 125.** Seoud M, Khalil A, **Shamseddine A,** Issa Ph. Short term response of squamous cell carcinoma of the cervix to neoadjuvant chemotherapy. The 1st Pan Arab Cancer Conference, Cairo, 1996. District IV meeting of the American College of Gynecologists Oct. 19-22, 1996, Florida.
- 126.** Dabaja BS, **Shamseddine A,** Salem ZM-K, ANasr T, Taher A, El Saghir S, Dandashi A. Treatment of Metastatic Breast Cancer with Vinorelbine (VNB) and Cisplatin (DDP): A Clinical Phase II Trial. Proceeding of the 5th International Congress on Anti-Cancer chemotherapy 241 (abst. P444) 1995, Paris.
- 127.** Dabaja BS, **Shamseddine A,** Salem ZM-K, A Nasr T, Taher A. Cisplatin and Vinorelbine : A Novel regimen for the treatment of Metastatic Breast Carcinoma. *Ann Oncol* 1994; 38, (8): Abstract # 189.
- 128.** **Shamseddine A.** Granulocyte Macrophage-Colony Stimulating Factor (GM- CSF) for treatment of chemotherapy Extravasation, Proceedings of ASCO Annual Meeting, March 1994. Abstract # 1588.

D. RESEARCH PROPOSAL AND GRANTS

- 1. Shamseddine A,** Temraz S, Youssef B, Nasr R, Khauli R, El Hajj A, Bulbul M, Abbas N, Al Darazi M, Charafeddine M, Dagher K. A phase II, randomized, non-comparative double arm, open-label, 2-stage, multicenter trial to evaluate the efficacy and safety of 2 Tetra-modality bladder preservation strategies in muscle-invasive bladder cancer with maximum TURBT followed by induction platinum-based Chemotherapy/Avelumab followed by radiation therapy then maintenance Avelumab or watch and wait approach (Budget 2.7 million USD), November 2024
- 2. Shamseddine A,** Temraz S, Chehade L, Abbas N, Smaily H, Al Darazi M, Charafeddine M, Dagher K. Maintenance chemotherapy with 5-Fluorouracil in metastatic pancreatic cancer: safety, efficacy, and quality of life. October 2024
- 3. Shamseddine A,** Abbas N, Smaily H, El Darazi M, Charafeddine M. Digestive Tumors in Young Adults in Lebanon: A 10-Year Retrospective Study Evaluating Incidence Trends, Characteristics, and Outcomes Compared to Older Patients. October 2024
- 4. Shamseddine A,** Murad M, Abbas N, Smaily H. Uncharted Territory: Lower Doses, Longer Intervals: Analyzing Immunotherapy Responses in Mismatch-Repair Deficient and Microsatellite

5. **Shamseddine A**, Chehade L, Abbas N, Smaily H, Charafeddine M. Utilizing artificial intelligence to predict risk scores based on temporal and geospatial data of patients with colorectal cancer. June 2024
6. **Shamseddine A**, Zeidan Y, Geara F, Mukherji D, Temraz S, Khalifeh I, Khalifeh M, Faraj W, Haibe Y, Kreidieh M, Hussein Z. A pilot study of Nivolumab with stereotactic ablative radiation therapy after induction chemotherapy in cholangiocarcinoma (Budget 1.6 million USD)
7. **Shamseddine A**, Jamali F, Khalifeh I, Geara F, Temraz S, Mukherji D, Khalifeh I. Short-course radiation followed by mfolfox-6 plus Avelumab for locally-advanced rectal adenocarcinoma. Supported by Merck (Budget 710,000 € EUR).
8. **Shamseddine A**, Zeidan Y, Geara F, Temraz S, Mukherji D. A Pilot Study of Avelumab with Ablative Radiation Therapy after Induction Chemotherapy in Biliary Tract Cancer
9. **Shamseddine A**, Temraz S, Mukherji D. An open Label, Single Arm, Multicentre, Safety Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-urothelial Carcinoma of the Urinary Tract.
10. **Shamseddine A**, Temraz S, Mukherji D, Charafeddine M, Khaulil R, Bulbul M, Hajj A, Nasr R. Waterpipe smoking and the Bladder: A cross-sectional study in a Lebanese population.
11. Temraz S, Mukherji D, **Shamseddine A**. Observational Prospective Study In Management of 1st line KRAS Wildtype mCRC with Erbitux™ (Cetuximab) – OPTIM1SE.
12. Temraz S, Mukherji D, **Shamseddine A**. Colorectal cancer outcome study.
13. **Shamseddine A**, Temraz S, Mukherji D, Haydar A. Oxaliplatin-induced increase in spleen volume; accurate detection and correlation with other Oxaliplatin adverse events.
14. **Shamseddine A**, Temraz S, Mukherji D, Eid T, Geara F. Rectal cancer in patients younger than 45 at AUBMC: Epidemiology, tumor, characteristics and survival.
15. **Shamseddine A**, Temraz S, Hassoun L, Hilal L, Hamieh L, Charafeddine M, Barada K. Esophageal cancer in Lebanon: epidemiology, risk factors and survival
16. Abou Najm M, Sukkarieh I, **Shamseddine A**. Water-health Coupling: Is the State of the Environment Impacting the Health.
17. Mukherji D, Temraz S, Saghir, N, Tfayli A, **Shamseddine A**. Insomnia incidence among breast cancer patients during chemotherapy
18. Mukherji D, Temraz S, **Shamseddine A**. Estimation of creatinine clearance for Carboplatin dosing at NKBCI.
19. **Shamseddine A**, Zaatari G, Abou Yehia Z, Assi R, Haydar A, Mahfouz R, Mukherji D, Temraz S, Abou Alfa G. Familial Hepatic neuroendocrine tumor: ahistopathological, biochemical; and molecular study. March 2014. (IRB ID: IM.AS.23)
20. Mukerji D, **Shamseddine A** (Co-investigator), Mukadem H, Temraz S. Evaluation of morphology, Her2neu status and its clinical and prognostic correlation in advanced gastric cancer.
21. Haydar A, Bahouth S, Mukherji D, Abou Yehia Z, **Shamseddine A** (Co-Investigator). Radio-pathological discrepancies in diagnosis of malignancies between referral centers in Iraq and AUBMC, a tertiary care center in Lebanon.

22. Mukherji D, Abou-kheir W, Sabban M, Khauli R, **Shamseddine A** (Co-investigator). Collaborative prostate cancer translational research project: Development of pre-clinical models of disease and non-invasive biomarkers of treatment response.
23. Mukherji D, Haydar A, **Shamseddine A** (Co-inverstigator), Temraz S, Farhat Z, Faraj W, Khalifeh M. Changes in body composition in patients with pancreatic adenocarcinomas treated with FOLFIRINOX (IRB approval, April 7th 2014, IRB ID: IM.DM.06)
24. Mukherji D, Mukaddem H, Temraz S, **Shamseddine A** (Co-PI). Prospective data collection of signet ring gastric carcinomas. (IRB approval Jan 7th 2014)
25. **Shamseddine A**. Ajouz H, A randomized, Double blind, multicenter, Phase III study of Everolimus (RAD 001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of GI or lung origin. IRB ID: CRAD001T2302 Approved march 11, 2013, supported by Novartis (Budget \$ 25,000)
26. Mukherji D, Saroufim M, Jabbour M, Nasr R, Tawil A, Temraz S, **Shamseddine A**. PD-L1 expression in muscle invasive bladder cancer.
27. Temraz S, Nasr R, Mukherji D, **Shamseddine A**. A retrospective review of bladder cancer cases at AUBMC.
28. Husari A, El Sabban M, Eid A, Zaatari G, **Shamseddine A**. The effect of Pomegranate Juice in the incidence of lung cancer secondary to chronic cigarette smoke exposure in a mouse lung model. IRB approved 2013.
29. **Shamseddine A**., Alameddine R, Temraz S, Perifosine in Metastatic refractory Colorectal Cancer. A compassionate use of Perifosine. Perifosine 343. A Phase III Randomized Study to Assess The Efficacy and Safety of Perifosine Plus Capecitabine versus Placebo Plus Capecitabine in Patient with Refractory Advanced Colorectal Cancer. (Supported by Aeterna Zantaris and Hikara).
30. **Shamseddine A**. Alameddine RS, Temraz S. A non-interventional multicenter Study of first-line Avastin bevacizumab in combination with chemotherapy in patients with metastatic colorectal cancer. IRB ID: ML 25198 funded by Hoffman La Roche Ltd. (Budget \$ 25,000).
31. **Shamseddine A**, Saleh A, Seoud M. Cancer Trends in Lebanon: Ten year trend analysis of cancer incidence in Lebanon. IRB ID: IM.AS.18 funded by Tumor Registry AUBMC Approved Oct. 2011.
32. **Shamseddine A**. Elias E, Yakan A. A Phase III randomized double-blind Placebo-controlled study of Tasquinimod in men with metastatic castrate-resistant prostate cancer. IRB ID: 10TASQ10 funded by: Active Biotech AB C # 12,000, Approved: August, 2011.
33. **Shamseddine A**. Cabazitaxel Cohort Compassionate Use Program in Patients with Metastatic Hormone Refractory Prostate Cancer Previously treated with Docetaxel-containing Regimen. (CABAZ C 05505) approved , 2011 (funded by Sanofi-Aventis Liban SAL)
34. **Shamseddine A**, Tfayli A, Boulos F. Prognostic determinants of outcome at presentation in young Lebanese female patients (< 40y) compared to those > 40yers with newly diagnosed breast carcinoma: A prospective clinico pathologic and molecular study. Approved Feb 2011 (Budget \$ 92,000-GSK Grant \$ 68,000)
35. Tfayli A, **Shamseddine A**, Bazabachi A, Abbas J. Assessing the sensitivity of P53 mutant breast cancers to close dense Adriamycin-Cyclophosphamide followed by Docetaxel in the neoadjuvant setting. Approved Feb 2010 (Budget \$ 27,000).

36. **Shamseddine A**, Hatoum H, Saliba T, Shahine G, Khaled H. An open-label, multi-center, expanded access study of RAD 001 in patients with metastatic carcinoma of the kidney that are intolerant of or have progressed despite any available vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy. CRAD001 L2401 Approved April 20, 2009
37. **Shamseddine A**, Saliba T. The Global Observational Registry, collecting Longitudinal Data on Advanced Gastrointestinal Stromal Tumors patients Gold Registry. Protocol GIST 571B2404 approved by IRB Nov. 4, 2008. (Funded by Novartis A/C 114110525166)
38. **Shamseddine A**. Saliba T. Metastatic and Adjuvant Colorectal Cancer Observational Study (Macro-Study) Protocol OXALI L 03917 approved by IRB Nov. 4, 2008 (Funded by Sanofi / Aventis A/C #
39. **Shamseddine A**, Saliba T. A multi-center, single arm, Phase II study of adjuvant imatinib mesylate (Glivec) in patients following the resection of primary Gastrointestinal Stromal tumor (GIST), Protocol CSTI 571 BIC 08 approved by IRB Nov. 4, 2008 (funded by Novartis A/C #
40. **Shamseddine A**, Harmoush I, Masroujeh R, Musallem K, Taher A. Retrospective review of clinical, pathological and molecular characteristics of colorectal lymphoma patients at AUBMC. IRB approval Feb. 2008 (funded by Tumor Registry Fund A/C # 11411024304).
41. **Shamseddine A**, El-Kinge A, Saliba T. Open-Label Study of Bevacizumab (AVASTIN) plus Taxane monotherapy or in combination for the first-line treatment of patients with locally recurrent or metastatic breast cancer, IRB approval August 2007 (funded by Roche for budget \$ 9,600).
42. **Shamseddine A**, Hatoum H, Salem Z, Saghir N, Jalloul R, Nsouli G, Farhat F, Ibrahim K, Bitar N, Kattan J. Phase II study for Clinical Evaluation of Lipoplatin (Liposomal Cisplatin) in Combination with Vinorelbine for Treatment of Metastatic Breast Cancer. IRB approval May 8, 2007 (Funded by Pharmamed: \$ 10,000, Pierre Fabre : \$ 14,500 and Tumor Registry Fund: 3000 A/C 11411024304 , Total Cost \$ 27,300
43. **Shamseddine A**, El Kinge A, Bulbul M, Khauli R. 18 months, multicenter, Middle East, Phase II study, Non comparative of the Raf-Kinase Inhibitor Sorafenib in patients with advanced renal cell carcinoma to evaluate the efficiency and tolerability of the drug (MERITS Study) IRB approval May 8, 2007. (Funded by Bayer –Schering Pharma \$ 3000). Reactivated and approved Nov. 2008 DCR A/C 114110526101.
44. **Shamseddine A**, Makarem J, Adjuvant colon Cancer with Eloxatin/5-Fu based regimen (ACCELOX Registry (Observational study). IRB approval Dec. 5, 2006. (Funded by Sanofi-Aventis \$ 4500)
45. Barada K, Farhat M, **Shamseddine A**. A Review of Small bowel tumors: Presentation, Prognosis and outcome AUB experience (1986-2006) Oct. 2006-Tumor Registry Fund A/C # 11411024304)
46. Khalifeh M, Farhat M, Gabriel G, **Shamseddine A**. A Review of Pancreatic Surgeries performed in the American University of Beirut-Medical Center 1998-2006 (Sept 2006-Tumor Registry Fund A/C # 11411024304).
47. Barada K, Farhat M, **Shamseddine A**, A Review of cholangiocarcinoma at AUBMC (1986-2006) (July 2006-Tumor Registry Fund A/C # 11411024304).
48. **Shamseddine A**, Al Kinge A. A Phase III, Parallel group, Randomized open-Label, Multi-Center Clinical Trial of Zoledronic Acid (Zometa) in Males Receiving Androgen Deprivation therapy for Advanced Prostate Cancer. (Approved by IRB Dec. 2005-funded by Novartis Pharma A/C # 114110025075 - \$ 67,448).

49. **Shamseddine A**, El-Zahabi L, Al Kinge A. A Review of Clinical Characteristics of Pancreatic Cancer cases seen and/or treated at The American Univesity of Beirut –Medical Center (1990-2004) Approved by IRB Nov. 2005).
50. **Shamseddine A**, First-line Bavacizumab and chemotherapy in metastatic cancer of the colon or rectum. First BEAT (Bevacizumab Expanded Access Trial) study ID (M018024). Open-Label, non-comparative, multi-center study (Phase IIIb) Sponsored by F.Hoffmann-La Roche Ltd. Approved by IRB March 09, 2005 (10,600).
51. **Shamseddine A**, Saliba T, Jamali F. A Review of Clinical Characteristics of Colorectal Cancer Cases Seen and /or treated at the American University of Beirut Medical Center from 1983 till 2003 (accepted by IRB March 2003) Tumor Registry Fund A/C 11411024304.
52. **Shamseddine A**, Taher A, Salem Z, Bazarbachi A, Saghir N, Abu Mourad Y, Yassine H, Khalifeh M, Abbas J, Geara F. A Clinical Phase II Study of Vinorelbine and Oxaliplatin (Vinox) with or without Transtugumab (Herceptin®) in Advanced Breast Cancer (Approved Feb. 2004, funded by Sanofi, Roche and Pierre Fabre companies \$ 24,000)
53. **Shamseddine A**, Seoud M, Zalloua P, Bulbul M, Khawli R. Bladder Cancer in Lebanon, Raja Khawli. Bladder Cancer in Lebanon: Epidemiology and Incidence of HPV infection (Approved by IRB May 2003, not funded yet).
54. **Shamseddine A**, Abou Mourad Y, Tawil A, Seoud M, Zallouaa P, Sharara A. A Clinical and pathological Study of Prognostic Significance of Guanylyl Cyclase C Messenger RNA Reverse Transcriptase Polymerase Chain Reaction in lymph nodes of Node-Negative Colorectal Cancer Patients (Grant US \$ 5000).
55. **Shamseddine A**, Taher A, Abu Murad Y, Khauli R, Bulbul M, Wazzan W, Hemadeh K. A Phase II Clinical Study of high dose Calcitriol plus Docetaxel and Zoledronic acid in hormone refractory prostate cancer (HRPC). (Approved by IRB May 8, 2003. Grant US \$ 20,000 covered by Novartis and Aventis.
56. **Shamseddine A**, A randomized phase III study comparing docetaxel plus gemcitabine to sequential therapy of docetaxel followed by gemcitabine in anthracycline pretreated metastatic or locally recurrent breast cancer patients. (Approved by IRB Oct. 25, 2002). Grant 1000 Eu/patient from ECOG (Central European Cooperative Oncology Group).
57. **Shamseddine A**, Chehal A, Taher A, Bazarbachi A, Salem Z, Khalifeh M, Abbas J. A Clinical Phase II Study of Cisplatin and Vinorelbine followed by Docetaxel as first line treatment in metastatic breast cancer. (Approved by IRB July 30, 2002. Grant (URB) US \$ 10,000.
58. **Shamseddine A**, Taher A, Salem Z, El Saghir N, Bazarbachi A, Jamaledine G. A phase II clinical study of Docetaxel and Irinotecan in advanced non-small cell lung cancer. July 31, 2001 grant (URB) DCU 14886074100 amount US \$ 10,000 plus grant from Aventis Company US \$ 7000.
59. **Shamseddine A**, Murad F, Taher A, Abbas J, Khalifeh M, Bikhazi A. A phase I/II Clinical and Pharmacokinetic Study of Intra-arterial chemotherapy in locally advanced and regionally metastatic pancreatic carcinoma with selective embolization. March 2001, Terry Fox Grant # 1141102633 amount US \$ 15,000.
60. **Shamseddine A**, Gemcitabine and Doxorubicin in first line metastatic breast cancer (approved : Dec. 29, 1999 ongoing funded by Eli Lilly Suisse in support of PAMECOG Group amount US \$ 800/patient, March 2000).Terminated.
61. **Shamseddine A**, Salem Z, El Saghir N, Taher A, Seoud M, Jaafar H. A Review of Clinical

Characteristics of Breast Cancer Cases seen /or treated at the American University of Beirut Medical Center (AUB-MC approved Oct. 99 (on going – funded May 2000 US \$ 3,450 MPP grant # DCU 27110-686019).

62. **Shamseddine A,** Salem Z, Taher A, El Saghir N, Bazarbachi A, Khalifeh M. A Pilot study of Cisplatin and Vinorelbine in advanced Breast Carcinoma. May 12, 99. (Tumor Registry fund 11411024304)
63. **Shamseddine A,** Mudawwar W, El Saghir S, Kaspar H, Nasr H. Cardiotoxic Effect of Vinorelbine. (Approved in Jan. 14, 1999) amount USD 2000. Massabki # 11411024308.
64. **Shamseddine A,** Seoud M, Taher A, Kahwaji S, El Saghir N. The 1993 Cancer Incidence Rates in Lebanon (on going- Terry Fox Account # 11411024304 Sept. 1998. Amount USD 1500). Activated August 1999 (grant from Aventis account #11411024304, July 14, 2000. Amount US \$ 9000)
Shamseddine A, A Multicenter, Randomized, Double-Blind Study of Idoxifen 40mg/day vs Tamoxifen 20mg/day as first-line Hormonal therapy in postmenopausal woman with mets.breast cancer. (closed-sponsored by Smithkline Beecham International). # 32411025102, June 98. Amount: (USD \$ 2000).
65. **Shamseddine A,** Seoud M, Khalil A. An Open-Label, Multicentre Study of Second-Line Intravenous Topotecan in advanced Epithelial Ovarian Cancer. International Study (closed-sponsored by Smithkline Beecham International) #1411025306, June 97. Amount : (USD \$ 4500)
66. **Shamseddine A,** Medawar W, Habbal Z, Khalil A. The relationship between serum levels of erythropoietin (EPO) and insulin-like growth factor-1 (ILGF-1) and hematocrit (HCT) in breast cancer patients receiving non-nephrotoxic chemotherapy. (published) MPP # 686019, March 1994. Amount: (USD \$ 2700).

III. TEACHING

A. COURSES & TEACHING

1. Liver, biliary tree and pancreatic cancers Hematology-Oncology fellowship program at American University of Beirut Medical Center, AUBMC, December 3rd, 2024.
2. Gastroesophageal cancer, Hematology-Oncology fellowship program at American University of Beirut Medical Center AUBMC November 26th, 2024.
3. Colon cancer, Hematology-Oncology fellowship program at American University of Beirut Medical Center AUBMC November 19th, 2024.
4. Management of rectal cancer. Hematology-Oncology fellowship program at American University of Beirut Medical Center AUBMC, October 22nd 2024.
5. Oligometastatic colon cancer. Hematology-Oncology fellowship program AUBMC, September 22, 2020.
6. Updates in the management of neuroendocrine tumors. Hematology-Oncology fellowship program AUBMC, September 17, 2020.
7. Management of advanced prostatic cancer. Urology division resident training program, Jan. 2019.
8. Sequence of treatment in Neuroendocrine Tumors, Hematology- Oncology fellowship training program, Nov. 2018.
9. Epidemiology of prostatic cancer in Lebanon and Arab countries, core curriculum lecture for urology team April 2015.
10. Fellowship educational program: Debates in the management of advanced prostate cancer: St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. August 2015.
11. Hepatocellular carcinoma: current updates. August 2014. Hem-Onc fellowship program
12. Core curriculum lecture for urology team. Recent advances in the treatment of advanced renal cell carcinomas, April 4th , 2014.
13. Epidemiology of communicable and non-communicable diseases course, faculty of health sciences, lectures on:
 - a. History of cancer registry, its functionality and issues
 - b. The most current realities of cancer incidence/ prevalence / burden in the country and region
 - c. Challenges and opportunities to estimating the size and burden of cancer in Lebanon (and the region)
14. Other important information for students. March 10th , 2014 for 3 hrs. Van Dyck, 2nd floor Fellowship educational program: Epidemiology of lung cancer: Causes and protective factors. December 8th 2013, Naef K. Basile Cancer Center, AUBMC.
15. Core Curriculum lectures: Prostatic Carcinoma from early stage to advanced stage: update in 2012. Feb 2012
16. EPHD 323 Courses, Master of Public Health Students, Faculty of Health Sciences. Statistics of

- Cancer in Lebanon, the past, Present and the future. March 20, 2010, Van Dyke Bldg., AUBMC
17. Fellowship educational program. Prostate Cancer from early stage to Hormone refractory disease. March 18, 2010, Basile Cancer Center AUBMC.
 18. Fellowship educational program
 - a. Treatment of early colon cancer
 - b. Treatment of Advanced Colon Cancer
 - c. Updates in the management of rectal cancer
 - d. Management of hepatic metastasis in colorectal cancer July – August 2010, Basile Cancer Center AUBMC.
 19. Core Curriculum lecture. State of the art in the treatment of Prostatic cancer; Lecture for house staff-AUBMC, March 2009
 20. Core Curriculum lecture. Update in Colorectal Cancer Lecture for housestaff-AUBMC, Feb 21, 2009.
 21. Fellowship (Hematology- Oncology) research program 2001- Present.
 22. Fellowship (Hematology-Oncology) review program 2001-Present.
 23. Teaching Activities-Internal Medicine in Outpatient Clinic, Emergency, Private and Ward Floors for Residents, MED III and IV students. (1989 – Present).
 24. Fellowship Teaching Program in Hematology–Oncology, Outpatient Clinic and Ward Round 1989- Present.
 25. Hematology Course, MED II student, 1995-Present.
 26. Physical Diagnosis Course, MED II student, 1989 – Present.
 27. Hematology Course, Family Medicine Residency Program, Bahrain-January 1993.
 28. Coordinator, Physical Diagnosis Course, MED II student 1989 - 1990.

B. GRAND ROUNDS

1. Cancer Trends in Lebanon (1998-2007) and Projected Cancer Incidence Rates 2012 Oct. 2012.
2. New perspectives in colorectal cancer April 2004.
3. Epidemiology of cancer in Lebanon May 2002.
4. Sicklemia Feb. 2000, American University of Beirut.
5. Tamoxifen: Why? Risks and Benefits. April 1998. American University of Beirut.
6. Cancer Related Anemia. April 1997 American University Hospital
7. Thrombotic thrombocytopenic purpura. March 1996. American University Hospital.
8. Hematopoietic Growth factors.1992 American University of Beirut.
9. Angio immunoblastic lymphadenopathy April 10, 1990. American University of Beirut.

C. LECTURES AND COMMUNICATIONS

- 1. Erleada: A new milestone in mHSPC multidisciplinary advanced course in Hematology-Oncology “MATCHO”- Men’s health module.** December 7th, 2024, Saint Joseph Hospital, Beirut – Lebanon (**invited speaker**).
- 2. From the medical oncologist perspective, what is the current standard? Is TNT universal? Consolidation vs. induction.** The 14th International Gastrointestinal Cancer conference. November 28- December 1st, 2024, Istanbul, Turkey (**invited speaker**).
- 3. First line standard of care as maintenance in the management of metastatic urothelial cancer.** Merck- PURSUE Meeting November 8-9, Istanbul, Turkey (**invited speaker**).
- 4. What the future holds: Tailoring treatment for locally advanced rectal cancer.** Merck- PURSUE Meeting November 8-9, Istanbul, Turkey (**invited speaker**).
- 5. Lebanon urothelial cancer burden.** Merck- PURSUE Meeting November 8-9, Istanbul, Turkey (**invited speaker**).
- 6. Powerful start: Fortitude at 40.** Merck- PURSUE Meeting November 8-9, Istanbul, Turkey (**Panelist**).
- 7. EEMEA Group Input meeting in RCC for MSD.** October 29, 2024 Virtual meeting (**Panelist**).
- 8. A glance at advanced gastric cancer in the region.** EEMEA GU- GI Meeting for MSD October 18- 19, 2024, Cairo – Egypt (**invited speaker**).
- 9. Advanced RCC and evolving treatment options.** EEMEA GU- GI Meeting for MSD October 18- 19, 2024, Cairo – Egypt (**invited speaker**).
- 10. Bladder preservation strategy: A non-comparative phase II clinical trial.** Oncodistinct Biannual meeting. October 18th 2024, Marseille- France (**speaker**).
- 11. Improving access to immunotherapy increasing access to IO: A Global webinar series society for immunotherapy of cancer.** August 15th 2024, Virtual meeting (**Invited speaker**).
- 12. Perioperative chemotherapy (FLOT) versus neoadjuvant chemoradiation (CROSS) for resectable esophageal adenocarcinomas (The ESOPEC trial).** Best of ASCO meeting. July 12-13, Beirut- Lebanon (**invited speaker**).
- 13. Xtandi in metastatic hormone sensitive prostate cancer.** The 7th south multidisciplinary oncology congress (SMOHC-7). June 15th 2024, Rotana- Beirut – Lebanon (**invited speaker**).
- 14. MSD EEMEA Genito-urinary cancers, virtual group input meeting.** June 13th 2024 (**invited speaker**).
- 15. Immunotherapy in GU malignancy.** 3rd Biotech forum 2024 by Hikma May 23-25, Dead sea- Jordan (**Moderator**).
- 16. Updates in the management of MSS rectal cancer: Risk stratifications and shedding light on the future.** 3rd Biotech forum 2024 by Hikma May 23-25, Dead sea- Jordan (**invited speaker**).
- 17. Doublets vs triplets therapy in mHSPC.** Emerging markets oncology summit III

- OncoTalk. May 17-18, 2024 Istanbul, Turkey **(invited speaker)**.
18. **Evidence and insights in innovative treatment for advanced / metastatic bladder cancer.** Hikma cancer forum. April 25-26, 2024, Lisbon- Portugal **(invited speaker)**.
 19. **State of the art in the neoadjuvant treatment of muscle-invasive bladder cancer** Hikma cancer forum. April 25-26, 2024, Lisbon- Portugal **(invited speaker)**.
 20. **Biliary tract cancer advisory board epidemiology and risk factors for biliary tract cancer.** April 17th 2024, Beirut – Lebanon **(invited speaker)**.
 21. **Reach beyond in advanced BTC with Durvalumab plus GEM-CIS, MOIF V Congress,** March 8th 2024 Beirut – Lebanon **(invited speaker)**.
 22. **Recent updates in the management of RCC, Role of Pembrolizumab.** Genitourinary-Oncology Group. February 27th 2024, Rotana- Beirut – Lebanon **(invited speaker)**.
 23. **Immunoscore: The prognostic value of the Immunoscore in rectal cancer patients.** Oncodistinct Network Scientific meeting. January 25th 2024, Brussels- Belgium. **(invited speaker)**.
 24. **Definitive systemic therapy with chemotherapy and immunotherapy as bladder-sparing strategy for non-metastatic muscle invasive bladder cancer patients.** Oncodistinct Network Scientific meeting. January 25th 2024, Brussels- Belgium. **(invited speaker)**.
 25. **IO/TKI regimens are the recommended standard of care for favorable risk patients with advanced RCC.** Oncodebates scientific meeting by Ipsen. December 9th 2023, Istanbul- Turkey **(invited speaker)**.
 26. **Considering the risk profile of RCC patients is important before using adjuvant Pembrolizumab and optimal sequencing of progression.** Oncodebates scientific meeting by Ipsen. December 9th 2023, Istanbul- Turkey **(invited speaker)**.
 27. **Paradigm change in early and locally advanced gastric and GEJ cancers management.** Bridging gaps in Oncology. National cancer institute, Cairo university. November 30th 2023, Cairo, Egypt **(invited speaker)**.
 28. **Risk stratifications and patient’s decision in the management of locally advanced rectal cancer.** Bridging gaps in Oncology. National cancer institute, Cairo university. November 30th 2023, Cairo, Egypt **(invited speaker)**.
 29. **Prostatic cancer epidemiology and screening for the month of November.** November 28th 2023 **(invited speaker)**.
 30. **Putting new data into regional context, regional guidelines discussion.** 4th Genitourinary cancer working group educational workshop series. November 21st 2023 **(invited speaker)**.
 31. **Third- line treatment of colorectal cancer.** The 13th International gastrointestinal cancers conference (IGCC). November 30- December 3rd , 2023. Antalya- Turkey **(invited speaker)**.
 32. **GI teaching course for fellows:**
 - a. Dec. 12, 2023: Gastroesophageal, gastric and esophageal cancer updates
 - b. Nov. 14,2023: Hepatobiliary / Pancreatic cancer updates
 - c. Oct. 24, 2023: Updates in colon cancer
 - d. Sep. 12, 2023: Algorithm for the treatment of locally advanced rectal cancer
 33. **A rapidly changing landscape with management of mHSPC.** November 3rd 2023,

- Algeria (**invited speaker**).
34. **Locally advanced rectal cancer, risk stratification and patients decision.** 22nd Pan Arab cancer congress. November 2nd 2023, Algeria (**invited speaker**).
 35. **HCC forum angiogenesis to immunotherapy.** 6th course of angiogenesis and immunotherapy. November 1st 2023, Algeria (**invited speaker**).
 36. **Safety of angiogenesis therapy.** 6th course of angiogenesis and immunotherapy. November 1st 2023, Algeria (**invited speaker**).
 37. **Management of early stage muscle invasive bladder cancer.** Optimal strategies for management of MIBC. October 20th 2023, Madrid- Spain (**invited speaker**).
 38. **Maintenance or watch and wait: Javelin 100 study in bladder cancer.** ABC Oncology education course 2023. September 21-22, 2023. Beirut- Lebanon (**invited speaker**).
 39. **Optimizing the management of ovarian cancer: a Lebanese consensus.** 6th South multidisciplinary oncology congress. September 21-22, 2023. Beirut- Lebanon (**invited speaker**).
 40. **Shaping research futures: Challenges and gaps in genitourinary research in MENA.** 6th South multidisciplinary oncology congress. September 21-22, 2023. Beirut- Lebanon (**invited speaker**).
 41. **Metastatic Hormone Sensitive Prostate Cancer: Willing from the Beginning with Apalutamide.** United for prostate cancer forum. July 11th 2023. Gefinor Rotana Hotel, Beirut (**invited speaker**).
 42. **Role of Pembrolizumab in metastatic gastric and esophageal cancer.** GI Oncology MENA region summit. July 8th, 2023, Citea Hotel, Beirut- Lebanon.
 43. **GI session, chair, the 18th Best of ASCO 2023.** July 7th, 2023 (**Chair and invited speaker**).
 44. **Colorectal cancer: screening in the Middle East.** A special lecture for internal medicine at AUBMC by: Dr. Laudy Chehade and Loyal el Mahmassani. March 23rd, 2023 AUBMC, Beirut. (**Moderator**).
 45. **First- line immunotherapy in upper GI cancer: recent updates.** GI Oncology congress, Zahraa Hospital, March 11th, 2023. Beirut- Lebanon (**invited speaker**).
 46. **1) 3rd- line treatment in metastatic colorectal cancer**
2) Updates on rectal preservation
Updates in GI cancers, March 9th, 2023, Virtual meeting (**invited speaker**).
 47. **Colorectal cancer screening in the Middle East.** American Society of Clinical Oncology (ASCO meeting). June 9th, 2023, Chicago- USA (**invited speaker**).
 48. **Checkpoint inhibitors for all patients with gastric cancer: A debate.** The 11th International Gastrointestinal, liver and uro-oncology conference. July 21-22, 2022. Mena-house hotel, Cairo- Egypt (**invited speaker**).
 49. **Watch and wait approach in rectal cancer: Controversies and new directions.** July 21-22, 2022. Mena-house hotel, Cairo- Egypt (**invited speaker**).
 50. **Prostatic cancer landscape in Lebanon: Management of mCRPC in Lebanon virtual advisory board (sponsored by AstraZeneca),** August 9, 2022. (**invited speaker**).
 51. **Case discussion: Metastatic colon and gastric cancer.** Scope GI cancer meeting organized by Servier. Rotana, Hamra, Beirut- Lebanon. August 16, 2022. (**invited speaker**).
 52. **The role of Pemrolizumab in metastatic gastric and esophageal cancer.** GI Oncology

- MENA Region Summit, September 3rd, 2022, Beirut- Lebanon. (**invited speaker**).
53. **Biomarkers in advanced gastric cancer: consensus of recommendation for gastric cancer in the MENA region.** 2nd GI MENA summit, Beirut- Lebanon, September 1st, 2022. (**invited speaker**).
 54. **Pembrolizumab in the management of advanced gastric and esophageal cancer.** 2nd GI MENA summit, Beirut- Lebanon, September 3rd, 2022. (**invited speaker**).
 55. **Changing face in the management of prostatic cancer.** Annual urology society conference. Beirut- Lebanon, September 3rd, 2022 (**invited speaker**).
 56. **Clinical perspective of Immunotherapy in the first-line treatment of advanced squamous esophageal carcinomas.** IO Academy meeting, organized and sponsored by MSD. Dubai, UAE, September 30th-October 1st 2022. (**invited speaker**).
 57. **Immune checkpoint inhibitors: potential benefits in early urothelial carcinoma setting. Management of advanced urothelial carcinoma.** Meeting sponsored by Merck, October 11th 2022, Beirut- Lebanon. (**Chair and invited speaker**).
 58. **Epidemiology of bladder cancer and clinical treatment protocols in MIBC. Immunotherapy in urothelial carcinoma series, muscle-invasive bladder cancer..** Sponsored by NKBasile Cancer center and the Oncodistinct clinical trial Network and the genitourinary cancer working group. Virtual meeting October 13th, 2022 (**invited speaker**).
 59. **First-line ovarian cancer maintenance treatment: Monotherapy or combination?** Breast and Gynecology cancers updates organized by LSMO. October 28th, 2022 (virtual) (**invited speaker**).
 60. **2nd AfME Oncology Precision Medicine** expert committee meeting sponsored by Pfizer, October 29th, 2022 (Virtual) (**Expert invitee**).
 61. **Emerging treatment for advanced gastric cancer: should all patients receive immunotherapy: No.** The fourth Middle East and North Africa Immuno-Oncology forum: MIOF-4. November 5th 2022, Beirut-Lebanon (**invited speaker**).
 62. **Locally advanced rectal cancer: Total Neoadjuvant therapy vs. chemoradiation.** 1st Almoosa Hospital International conference. Daman, Saudi Arabia. November 10-12, 2022. (**invited speaker**).
 63. **Updates in the management of hormone sensitive metastatic prostate cancer.** 7th MEA Oncology and Hematology summit. Dubai-UAE, November 18-19, 2022. (**invited speaker**).
 64. **MDT forum meeting to optimize patient care in mCRPC.** International Diagnostic excellence academy MEA, November 24th, 2022. (**Moderator and speaker**).
 65. **Discussion/presentation of a clinical case with mCRPC.** 11th HOPES meeting 2022. Istanbul – Turkey, November 25th 2022. (**invited speaker**).
 66. **Watchful- waiting. Strategy and rectal preservation in locally advanced rectal cancer.** The 12th international gastrointestinal cancers conference. December 1-4, 2022, Istanbul- Turkey. (**invited speaker**).
 67. **Updates in the management of metastatic hormone sensitive prostate cancer KHCC scientific nights.** Management of locally advanced organ confined (Metastatic prostate cancer) November 29th 2022. (**invited speaker**).
 68. **Colon cancer: Epidemiology, risk factors, genetic background and updated standards**

- for management fellowship teaching programe. December 14th 2022, AUBMC, Lebanon (**speaker**).
69. **Gastric cancer: Localized and metastatic disease fellowship teaching program.** December 20, 2022, AUBMC- Lebanon. (**speaker**).
 70. **Management of metastatic Hormone sensitive prostate cancer (invited speaker) 2022**
 71. **Immunotherapy is the first-line management of HCC.** MIOF III conference. Lebanon 2022 (**invited speaker**)
 72. **Overview of Cancer Incidence with MENAT region ICRIM workshop - Global Health Institute AUB.** AUB- GHI (**invited speaker**)
 73. **Efficacy and Safety of Neoadjuvant Short-course Radiation Followed by FOLFOX-6 plus Avelumab for Locally-Advanced Rectal Adenocarcinoma: Averectal Study.** ESMO GI: the world conference of Gastro-intestinal Cancer. Spain 2021 (**invited speaker**)
 74. **Maintenance Therapy in Metastatic Colorectal Cancer. Maintenance Therapy in Metastatic Colorectal Cancer.** 11th IGICC. Jordan 2021 (**invited speaker**)
 75. **Ovarian Cancer in the ERA of Precision Medicine: the Role of PARPi.** Astrazeneca online educational conference (**invited speaker**)
 76. **Sequencing of therapy in mCRC.** Amgen Online Educational Conference (**invited speaker**)
 77. **Moving from adjuvant to neoadjuvant in rectal cancer.** 20th International Jordanian conference society, 9-11 September 2021. Amman, Jordan. (**invited speaker**).
 78. **Guidelines for metastatic colorectal cancer.** GI oncology MENA region summit. mCRC consensus. September 3, 2021 (virtual) (**session moderator**).
 79. **Moving from adjuvant to neoadjuvant in rectal cancer.** 10th International Gastrointestinal liver and Uro-Oncology conference. July 15-16, 2021 Cairo, Egypt. (**invited speaker**).
 80. **OncoBoard bladder Faculty Expert Meeting (virtual).** Feb. 4-7, 2021. Management of Advanced Bladder Cancer and The Role of Maintenance Therapy (**invited speaker**).
 81. **Management of Metastatic Colorectal Cancer during covid Pandemic.** A Forum for Young Lebanese OncologiSTR. Dec. 15, 2020. Sponsored by MERCK. (**invited speaker**).
 82. **Maintenance Therapy in Metastatic Colorectal Cancer.** The 10th Intenrational Gstrointestinal Cancer Conference (virtual). Dec. 2-6, Istanbul, Turkey (**invited speaker**).
 83. **Non-Metastatic Hormone Sensitive Prostate Cancer.** 2020 Middle East Oncoilogy Summit (virtual). Dec. 2020 (**invited speaker**).
 84. **Role of Pembrolizumab in Non-Muscle invasive Bladder Cancer and Metastatic Urothelial Carcinoma.** The 2nd Middle East and North Africa Immuno-Oncology Forum. Novmeber 6, 2020, Beirut, Lebanon. (**invited speaker**).
 85. **2020 Treatment Approach for MCRC: Moving Away from a one-size-fits-all approach.** The 2nd Middle East and North Africa Immuno-Oncology Forum. Novmeber 6, 2020, Beirut, Lebanon. (**invited speaker**).
 86. **Prostate Cancer in theMiddle East: Epidemiology and Overview.** Third Satellite Meting of the Advanced Prostate Cancer Consensus Conference (CAPCCC) and the Middle East Prostate Cancer Consortium (MEPCC). Nov. 20, 2020, Beirut, Lebanon (**invited speaker**).
 87. **Biomarkers in metastatic colorectal cancer.** 19th International Jordanian Oncology conference, Amman, Jordan, Sept 10, 2020 (**invited speaker**).

- 88. Check point inhibitors in non-muscle invasive bladder cancer.** Urothelial carcinomas: shifting the management paradigm in first and second line immune-oncology in bladder cancer virtual meeting hosted by MSD, September 8, 2020 **(invited speaker)**.
- 89. Personalized medicine in mCRC: How to select earlier lines?** Webinar, September 4, 2020. In collaboration with LSMO, ECS, EOS **(invited speaker)**.
- 90. Management of metastatic colorectal cancer during COVID-19 Pandemic** hosted virtually by AMGEN, September 1st, 2020 **(invited speaker)**.
- 91. Treatment landscape in the management of mCRC**
- a. First line treatment in mCRC
 - b. Molecular biomarkers in mCRC
- Hosted virtually by Merck, July 21st, 2020 **(Invited speaker)**.
- 92. The Role of Immunotherapy in Metastatic Colorectal Cancer.** The 17th LSMO Meeting Live Webinar, Beirut- Lebanon, 4 June, 2020 **(invited speaker)**.
- 93. Re-Thinking in HSPC: What Do We Need to Debate?** The 17th LSMO Meeting Live Webinar, Beirut- Lebanon, 4 June, 2020 **(invited speaker)**.
- 94. Current Treatment Landscape with First Line m CRC hand on molecular profiling.** Group Workshop Network Meeting Beirut- Lebanon, 4- 6 February, 2020 **(invited speaker)**.
- 95. Newer Immunotherapy, Non-Muscle Invasive, Bladder Cancer.** ASCO Genitourinary Malignancies Summit, San Francisco, 27-29 February, 2020 **(invited speaker)**.
- 96. The 15th Best of ASCO 20 Virtual Trastuzumab with Trimodality Treatment for Esophageal Adenocarcinoma with HER 2 overexpression: NRG Oncology /RTOG 1010.** LSMO 2020, July 10-11, 2020, Beirut- Lebanon. **(invited speaker)**.
- 97. First-Line Management of Metastatic Colorectal Cancer.** Cancer Research Group & AMAAC. ABC Oncology Educational Course: Gastro-Intestinal Module - Online Webinar June 19, 2020. **(invited speaker)**.
- 98. How Do I Treat Non-Metastatic Cartrate-Resistant Prostate Cancer.** Cancer Research Group & AMAAC. ABC Oncology Educational Course: Gastro-Intestinal Module - Online Webinar June 19, 2020 **(invited speaker)**.
- 99. Updates with Treatment of Hormone sensitive Prostate Cancer.** Urology resident. February 5, 2020 **(invited speaker)**.
- 100. Biomarkers in m CRC and complications in daily practice.** Group Workshop Network Meeting. **(invited speaker)**.
- 101. MIOF 1: First Annual Middle East & North Africa Immuno-Oncology Forum (speaker and scientific committee).** December 20-21, 2019, Le Bristol Hotel- Beirut- Lebanon.
- 102. Role of maintenance therapy in advanced colorectal cancer (speaker)**
Global cancer control: Focus on Gastrointestinal cancers (Chair session)
How to increase international scientific collaboration in the region (speaker). 9th
 International Gastrointestinal cancer conference. December 6-8, 2019. Istanbul- Turkey.
- 103. Short course radiation followed by m FOLFOX-6 plus Avelumab for locally –advanced rectal adenocarcinoma (speaker)**
A Pilot study of Nivolumab with stereostatic ablative radiation therapy after induction chemotherapy in cholangiocarcinoma (speaker), 9th Oncodistinct meeting, November 21-22, 2019, Brussels, Belgium.
- 104. Rectal cancer: current and emerging approaches to treatment (invited speaker),** 1st

regional EMEA Colorectal cancer masterclass, November 8-9, 2019, Oncology center Nicosia, Cyprus.

- 105. Management of oligometastatic prostate cancer.** Arab African International Cancer conference AAICC, Cairo, Egypt Oct 10-11, 2019 **(Invited speaker)**.
- 106. The choice of first line treatment of metastatic renal cell carcinoma.** Immunotherapy vs. Targeted therapy Arab African International cancer conference AAICC. Cairo, Egypt Oct 10-11, 2019 **(Invited speaker)**.
- 107. Prostatic cancer epidemiology and recent updates 2nd Near East Prostate cancer Master class.** Habtoor Hotel, Beirut- Lebanon. October 5th, 2019, **(Chair session and invited speaker)**.
- 108. Recent management of advanced gastric cancer and the role of nutritional support.** Mena oncology scientific exchange meeting (Breast and GI Cancer). September 6-7, 2019, Dubai-UAE **(Invited speaker)**
- 109. Gastric cancer workshop.** July 25, 2019, Rotana Hotel, Beirut- Lebanon, Organized by Lilly **(Chair and invited speaker)**
- 110. First-line endocrine therapy in prostate cancer. Baltic and Eurasia masterclass in clinical Oncology.** July 11-14, 2019, Minsk, Belarus **(Chair of Genito-urinary cancer session and invited speaker)**
- 111. Total Neoadjuvant therapy in rectal cancer discussant of oral abstracts (2 abstracts)**
Abstract #62 Voltage study
Abstract #556 CAO/ARO/ AIO-12 Study
World congress on Gastrointestinal Cancer. 3-6 July, 2019, Barcelona, Spain **(Invited speaker)**
- 112. Synchronous liver metastases in patients with rectal cancer.** World Congress on Gastrointestinal cancer. 3-6 July, 2019, Barcelona, Spain **(Invited Speaker)**.
- 113. Debate Session: Future prospects with total neoadjuvant treatment in rectal cancer: the optimal sequencing of multimodality treatment in rectal cancer.** World congress on Gastrointestinal Cancer. 3-6 July, 2019, Barcelona, Spain **(Chair of session)**
- 114. Sequences of treatment of advanced Colon cancer.** Middle East Solid Tumors meeting June 29, 2019, Hilton Beirut Metropolitan Beirut- Lebanon. Supported by LSMO **(Invited speaker)**.
- 115. Total Neo-adjuvant therapy in rectal cancer.** 16th LSMO Meeting April 11-13, 2019, Phoenicia Hotel, Beirut- Lebanon **(Invited speaker)**.
- 116. Sequence of treatment in advanced neuroendocrine tumors.** 16th LSMO Meeting April 11-13 April, 2019, Phoenicia Hotel, Beirut- Lebanon **(Invited speaker)**.
- 117. Management of neuroendocrine tumor: Experience and challenges.** 19th Pan-Arab Cancer congress, Amman- Jordan, 25-27 April, 2019 **(Invited speaker)**.
- 118. Safety of Antiangiogenesis therapy.** 5th course of Angiogenesis with recent advanced in immunotherapy, February 15-16, Algiers- Algeria. Organized by Arab collaborative Hematology and Oncology Group (ACHOG)
-Algerian Society of training and research in oncology (SAFRO)
-Memorial Sloan Kettering Cancer Center (MSKCC) NYC- USA
(Invited speaker and course director).
- 119. Precision Medicine in countries with limited resources: practical utility.** ASCO Direct

- Genitourinary malignancy summit, Feb 22-23, 2019, Beirut- Lebanon.
- 120. Maximizing treatment benefits in advanced renal cell carcinoma.** 16th LSMO meeting, April 11-13, 2019. Beirut- Lebanon (**Invited speaker**).
 - 121. Implementing treatment strategy in managing gastric and GEJ cancer.** 16th LSMO meeting, April 11-13, 2019. Beirut- Lebanon (**Invited speaker**).
 - 122. Management of relapsed testicular cancer.** 7th ESO Masterclass in clinical oncology Arab and southern European countries 14-17 December, 2018, Limassol- Cyprus (**Invited speaker**).
 - 123. Total Neoadjuvant therapy in rectal cancer.** The 16th International Jordanian Oncology Society conference, 27-29, Sept 2018, Amman- Jordan (**Invited speaker**).
 - 124. Total Neoadjuvant therapy in rectal cancer.** Global Summit on Gastrointestinal malignancies Sep 21-22, 2018, Dubai- UAE (**Invited speaker**).
 - 125. Neuroendocrine tumors updates.** Lebanese gastrointestinal society meeting August 31- Sept 1. 2018, Tyre, Lebanon (**Invited speaker**).
 - 126. First-line endocrine therapy in prostate cancer**
Endocrine resistant/ refractory prostate cancer. Baltic and Eurasia Masterclass in clinical Oncology, 12-15 July, 2018, Riga, Latvia. (**Invited speaker and chair genitourinary session**).
 - 127. Total Neoadjuvant therapy in rectal cancer.** Lebanese Society of general surgery conference, June 28-30, 2018, Beirut- Lebanon (**Invited speaker**).
 - 128. Moving forward in castrate-resistant prostate cancer.** 1st South Multi-disciplinary oncology Hematology conference, April 27-28, 2018, Saida- Lebanon (**Invited speaker**).
 - 129. What do the evolution in GI cancer mean for my practice: Data from Middle East ESMO**
World congress on Gastrointestinal cancer, June 20-23, 2018, Barcelona, Spain (Invited speaker).
 - 130. Optimal systemic treatment strategy for advanced RAS mutant colorectal cancer.** 8th International gastrointestinal cancer conference 7-9 December, 2018, Istanbul- Turkey (**Invited speaker**).
 - 131. BRAF mutation in metastatic colorectal cancer, how we can select the patient accordingly.** The 7th International gastrointestinal- liver and Uro-Oncology, 10-11 May 2018, Cairo Egypt (**Invited speaker**).
 - 132. Tumor sidedness: A Surrogate marker of the molecular profile.** International gastrointestinal cancer conference, April 15, 2018, Madrid- Spain (**Invited speaker**).
 - 133. Optimizing treatment outcome in gastric cancer.** Gastric cancer and soft tissue sarcoma meeting, April 10, 2018, Beirut- Lebanon (**Invited speaker**).
 - 134. Updates in pancreatic cancer**
Management of mCRPC: The role of second generation anti-Androgen
Important of treatment sequencing in optimizing advanced gastric cancer outcome
Total Neoadjuvant therapy in rectal cancer
15th Lebanese Society of Medical Oncology (LSMO) National Forum, March 22-24, 2018, Beirut- Lebanon (**Invited speaker**).
 - 135. First-line treatment in mRCC: Optimizing patients' oncology.** Excellence forum journey, 4-5 May, 2019, Amman- Jordan (**Invited speaker**).
 - 136. Clinical development in urothelial cancers.** Immuno- oncology preceptorship meeting

from bench to Bedside, March 2-3, 2018, Beirut- Lebanon (**Chair of the meeting and speaker**).

- 137. Advanced renal cell carcinoma: Epidemiology, presentation and overview of treatment landscape.** Therapeutic considerations in the management of advanced renal cell carcinoma, February 16, 2018, Beirut- Lebanon (**Invited speaker**).
- 138. Immunotherapy in colorectal cancer,** prIME Oncology Masterclass in colorectal cancer, February 23, 2018, Dubai- UAE (**Invited speaker**).
- 139. Major debates in immunotherapy.** Breast-gynecology and immune-Oncology International cancer conference, January 19, 2018, Cairo, Egypt (**Invited Panclist**).
- 140. Moving from adjuvant to total Neoadjuvant therapy in rectal cancer.** 11th Belgian Symposium on the integration of molecular biology advances into Oncology clinical practice. November 24-25, Brussels- Belgium (**Invited speaker**).
- 141. First-line treatment in hormone sensitive advanced prostate cancer Endocrine resistant/ refractory prostate cancer.** 4th ESO Masterclass in clinical Oncology, 18-20 October 2017, Tbilisi- Georgia (**Invited speaker and chair of session**).
- 142. Optimizing management in 1st line-line m CRC
Which targeted agents and appropriate treatment sequence
The gray side of the colon cancer**
Spotlighting in Oncology: Leading survival in colorectal cancer, May 5-6, 2017, Beirut- Lebanon (**Invited speaker and chair of the meeting**).
- 143. Safety of Angiogenesis therapy.** The 4th course of Angiogenesis and recent advances in Immunotherapy, February 17-18, 2017, Beirut- Lebanon (**Course co-directors and speakers**).
- 144. Moving from adjuvant to total neoadjuvant therapy in rectal cancer.** 11th Belgian symposium on the integration of molecular biology advances into oncology clinical practice. November 24-25, 2017, Parker Hotel Brussels, Belgium (**invited speaker**).
- 145. Cancer immunotherapy in MSI- H colorectal cancer.** Oncology Medical Summit 2017. November 3-4, 2017; Beirut- Lebanon (**invited speaker**).
- 146. Treatment sequences in castrated- resistant prostatic cancer.** The advanced prostate cancer consensus conference (APCCC) satellite meeting and the middle east prostate cancer consortium (MEPCC) meeting. November 2-4, 2017. Gefinor Rotana Hotel, Beirut- Lebanon (**Invited speaker**).
- 147. Plenary presentation; first-line management of metastatic renal cell carcinomas.** AFME Renal cell carcinomas care league workshop. October 27-28, 2017, Movempick Hotel, Beirut- Lebanon (**Invited speaker**).
- 148. A) First-line treatment in hormone sensitive advanced prostate cancer
B) Endocrine resistant / refractor prostate cancer**
4th Master class in Clinical Oncology organized by the European Society of Oncology. October 18-20, 2017, Tbilisi- Georgia (**Chair GU session and invited speaker**)
- 149. A) The gray side of colorectal cancer
B) New landscape in the management of advanced prostate cancer: The role of chemotherapy.** Middle East solid tumor meeting. September 22-23, 2017. Le Royal Hotel, Beirut- Lebanon (**Chair session and invited speaker**)

- 150. Management of Pancreatic Neuroendocrine Tumors.** Endo live Beirut 2017 meeting, September 15-16, 2017, Monroe Hotel- Beirut (**Invited speaker**).
- 151. A) Optimizing survival in metastatic colorectal cancer**
B) The gray side of colorectal cancer
C) Total neoadjuvant therapy (TNT) in rectal cancer
 2nd Near East Anti-EGFR Masterclass. July 28-29, 2017, Beirut- Lebanon (**Chair of scientific program and session, Invited speaker**)
- 152. Best of ASCO in Lebanon.** July 14-15, 2017, Phoenicia Hotel, Beirut- Lebanon (**Invited speaker**).
- 153. Second-line treatment in metastatic gastric cancer.** Exploring new directions in gastric cancer through multidisciplinary management and treatment selection strategies. May 9th 2017, Gefinor, Rotana, Beirut- Lebanon (**Invited speaker**).
- 154. A) Optimizing management in first-line metastatic colorectal cancer and sequence of treatments**
B) New trends in the management of rectal cancer
 Spotlight in Oncology: Leading survival in colorectal carcinomas, May 5-6, 2017, Gefinor Rotana Hotel Beirut- Lebanon (**Invited speaker**).
- 155. Personalized treatment in metastatic colorectal cancer beyond K-ras.** 17th Pan-Arab Cancer conference, April 19-21, 2017, Algeria (**Invited speaker**).
- 156. A) Bladder Cancer in Lebanon**
B) Total Neoadjuvant Therapy (TNT) in rectal cancer.
 14th Lebanese Society of Medical Oncology (LSMO) National Forum. March 30th- April 1, 2017. Phoenicia Hotel, Beirut- Lebanon (**Invited speaker**).
- 157. A) Chain Gastrointestinal Oncology. 4 Abstracts presented**
B) Chair session: Perspective in clinical trials/ research collaboration
 Connecting through research meeting, March 24-25, 2017, Monroe Hotel, Beirut- Lebanon (**Invited faculty**).
- 158. Bladder cancer epidemiology and first line treatment of advanced bladder carcinomas.** MSD advisory board meeting in Beirut, February 22, 2017. Intercontinental Hotel, Beirut- Lebanon (**Invited speaker**).
- 159. Cancer Incidence in Lebanon compared to Arab and Western countries and the associated risk factors.** For undergraduate and graduate students at FHS, American University of Science and Technology (AUST). February 21, 2017, Beirut- Lebanon (**Invited speaker**).
- 160. Safety of Angiogenic therapy.** The 4th course of Angiogenesis with recent advances in immunotherapy. February 17, 2017, Beirut- Lebanon (**Invited speaker**).
- 161. Advancing cancer research in Arab countries.** The 5th Annual Beirut Breast cancer conference (BBCC-5). February 9, 2017, Beirut- Lebanon (**Invited speaker and moderator of the session**)
- 162. Epidemiology of breast cancer.** Arab Health Conference, Dubai, January 30-31st, 2017 (**Invited speaker**).
- 163. Chemotherapy in hormone sensitive prostate cancer.** The 1st Lebanese Oncology Forum. Mount Lebanon Hospital, Beirut, January 27-28, Lebanon (**Invited speaker**).
- 164. Treatment of metastatic colorectal cancer.** Oncology virtual tumor board organized by

- Bayer. Beirut. December 13th 2016, Beirut, Lebanon (**moderator and invited speaker**).
- 165. Total neoadjuvant therapy in rectal cancer.** OncoDISTinCT Network 3rd meeting, Brussels, Belgium, November 25th 2016 (**Active participant**).
- 166. Updates in the management of rectal cancer.** Emirates oncology conference. November 17-19th 2016, Abu Dhabi, UAE (**Invited speaker**).
- 167. Latest updates in metastatic colorectal cancer, challenges in your treatment decisions.** Organized by Merck. November 11th 2016, Beirut, Lebanon (**moderator and session chair**).
- 168. Systemic treatment in castration resistant prostate cancer, 5th ESO Arab Countries.** Masterclass in clinical oncology organized by European school of oncology (ESO): October 28-30, 2016, Cairo, Egypt. (**Invited speaker and chair of session**).
- 169. A) Neuroendocrine overview, background, incidence and prevalence.** Neuroendocrine tumors forum for gastroenterologists organized by Novartis. October 25th 2016, Beirut, Lebanon (**Invited speaker**).
- B) The disease management algorithm.**
- 170. Bladder cancer incidence in Lebanon.** Immunotherapy for bladder cancer forum organized by Roche. October 17th 2016, Beirut- Lebanon (**Invited speaker**).
- 171. First-line therapy in metastatic renal cell carcinoma.** GLM Oncology forum. Dubai October 14-15, 2016 (**Invited speaker**).
- 172. A) Optimizing management in 1st line metastatic colorectal cancer**
B) Which targeted agents and appropriate treatment sequence
C) The gray side of the colon cancer
D) When is neoadjuvant chemotherapy, without radiotherapy, an option in rectal cancer?
E) Total Neoadjuvant therapy in rectal cancer
 All presented in the 2nd spotlight in Oncology (Optimizing survival in colorectal cancer) Organized by Merck for Iraqi Oncologists. Gefinor Rotana, September 30th – October 1st 2016, Beirut, Lebanon. (**Director of the course and invited speaker**)
- 173. Checkpoint blockade in genitourinary malignancies.** Immuno-oncology academy, outsmarting cancer: the dawn of a new era organized by MSD Oncology. Dubai, September 23-24, 2016 (**Invited speaker**).
- 174. History of Immunotherapy.** Immunotherapy: New era in cancer treatment organized by MSD Oncology, Gefinor Rotana, September 20th , 2016 (**Invited speaker and chair of session**)
- 175. A multiinstitutional ETCTN phase 2 study of Novolumab in refractory metastatic squamous cell carcinoma of anal canal.** Presented during the 11th Best of ASCO, September 2-3, 2016, Phoenicia Hotel, Beirut, Lebanon (**Invited speaker**).
- 176. Update in chemotherapy in castrated-resistant prostate cancer.** The first north Uro-oncology meeting organized by LSMO and the Lebanese urology society, Ehden country club, Lebanon August 27th 2016 (**Invited speaker**).
- 177. The gray side of colon cancer.** Presented during the world gastrointestinal cancer conference as special lecture organized by Merck. Barcelona July 29th 2016 (**Invited Speaker**).
- 178. Gastric cancer disease landscape and epidemiology in Lebanon.** Cyramza launch event

- organized by Lilly Oncology, May 30th 2016, Beirut, Lebanon (**Invited speaker**).
- 179. From clinical trial to doing practice: gastric cancer case presentation.** Cyramza launch event, May 24th 2016, Beirut, Lebanon (**Invited speaker**).
- 180. BRAF mutations in metastatic colorectal cancer.** Talk of the town meeting organized by Roche, May 20-21, 2016, Conard Hotel, Dubai- UAE (**Invited speaker**).
- 181. Multidisciplinary perspectives and collaborative care in the management of colorectal cancer.** Organized by virtual center of excellence, Lilly /Oncology. May 10th 2016, Beirut, Lebanon (**Moderator**).
- 182. A) Optimising management in 1st line metastatic colorectal cancer**
B) Which targeted agents and appropriate treatment sequence
C) Moving from adjuvant to neoadjuvant chemotherapy in rectal cancer: a matter of debate
Presented during the 1st spotlights in oncology meeting (leading survival in head and neck and colorectal carcinoma) organized by Merck, May 5-7, 2016, Gefinor Rotana, Beirut, Lebanon (**Course chair and invited speaker**).
- 183. Current management of castrate resistant prostate cancer.** The 16th Pan Arab Cancer Congress (PACC) organized by the Arab Association against Cancer (AMMAC), Cairo, Egypt, April 28-30, 2016 (**Invited speaker**).
- 184. Impact of cancer registries on research in Arab countries.** 4th Annual Beirut Breast Cancer Conference (BBCC4) organized by CME office at AUBMC. Gefinor Rotana, February 11-13, 2016, Beirut, Lebanon (**Invited speaker**).
- 185. Should Docetaxel be standard of care for patients with metastatic-sensitive prostate cancer: Pros.** The 13th meeting of the Lebanese Society of Medical Oncology (LSMO). April 9th, 2016, Beirut- Lebanon (**invited speaker**).
- 186. Therapeutic considerations in the management of renal cell carcinoma- The role of Votrient in the first line treatment of mRCC.** The 13th meeting of the Lebanese Society of Medical Oncology (LSMO). April 9th, 2016, Beirut- Lebanon (**invited speaker**).
- 187. Changing face of metastatic renal cell carcinoma.** The 13th meeting of the Lebanese Society of Medical Oncology (LSMO). April 8th, 2016, Beirut- Lebanon (**invited speaker**).
- 188. Advances in the treatment of hepatocellular carcinomas.** Iraqi oncology forum, April 7th 2016, Beirut- Lebanon, (**invited speaker**).
- 189. Chemotherapy in the treatment of prostatic cancer.** GI-GU oncology meeting organized by the Jordanian Society of Medical Oncology, April 1st 2016, Amman- Jordan, (**invited speaker**).
- 190. The role of immunotherapy.** MSD Expert Input Forum on solid tumors. February 26th 2016, Zurich- Switzerland (**active participant**).
- 191. The impact of cancer registries on research in the Arab countries.** The 4th AUBMC Breast Cancer Conference (BBC4). February 11-13, 2016, Beirut, Lebanon (**invited speaker**).
- 192. Metastatic Gastric Cancer.** Middle East Gastric Educational consultant meeting. January 24th , 2016, Dubai, UAE (**active participant**).
- 193. Colorectal Cancer Overview. Gastric Cancer/Cyramza trials.** Lilly Oncology team, educational forum. January 19th 2016. Byblos, Lebanon (**invited speaker**).
- 194. Immunotherapy in bladder cancer.** Breast Gynecological international cancer

- conference (BGICC). January 14-15th 2016, Cairo, Egypt (**invited speaker**)
- 195. Updates on Regorafenib in metastatic colorectal cancer and gastrointestinal stromal cell tumors.** Organized by Bayer. December 14, 2015, Beirut, Lebanon (**active participant**).
- 196. Neuroendocrine Tumors:**
Epidemiology- presentation and role of multidisciplinary approach
Individualizing the therapeutic management of pancreatic neuroendocrine tumors
Thoracic neuroendocrine tumors
 The NET Alliance meeting, organized by Novartis, December 5, 2015, Beirut, Lebanon (**Invited speaker and organizer**).
- 197. Interactive case discussion: prostate cancer ambassadors meeting.** Organized by Astellas November 13-14, 2015, Beirut, Lebanon (**Invited speaker**).
- 198. Epidemiology of breast cancer in Lebanon.** The second consultation meeting on the regional comparative breast cancer research programme organized by World Health Organization, 9-10 November, 2015, Amman , Jordan, (**invited speaker and advisor to WHO**).
- 199. 6th Masterclass in neuroendocrine tumors** November 7-8, 2015, Brussels , Belgium (**active participants**).
- 200. Metastatic Renal cell carcinoma: optimal strategies to Maximize patients' treatment outcomes for first –line therapy.** 1st Kurdistan oncology forum. October 30-31, Beirut- Lebanon (**Invited speaker**).
- 201. The choice of first line treatment in metastatic colorectal cancer: an issue for debate:** 3rd cancer care forum of CMC Hospital October 30, 2015, Beirut, Lebanon (**Invited speaker**).
- 202. Tumor Profiling: Transforming the promise of precision medicine into reality.** Toward precision in optimizing cancer treatment meeting. October 20, 2015, Beirut, Lebanon (**Invited speaker**).
- 203. Impact of aspirin as secondary prevention in an unselected cohort of 25,644 patients with colorectal cancer: A population- based study (Abstract # 3504).**
Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E+B) in patients with locally advanced or metastatic pancreatic neuroendocrine tumors (PNET), CALGB 80701 (Alliance) (Abstract # 4005). 10th Best of ASCO, 2015 Annual meeting September 11-12, 2015, Beirut, Lebanon (**Invited speaker**).
- 204. Updates in the treatment of castrate resistant prostatic cancer, the oncologist opinion.** Astellas Middle East prostate meeting, June 13, 2015, Beirut, Lebanon (**Invited speaker**).
- 205. Clinical updates in the management of neuroendocrine tumors.** The Lebanese Society of endocrinology annual meeting, June 12, 2015, Beirut, Lebanon (**Invited speaker**).
- 206. Gastric cancer treatment paradigm and unmet needs.** Ranucirumab in Gastro–intestinal cancers. May 12, 2015. Istanbul, Turkey (**Invited speaker**).
- 207. Regional Oncology status in the middle East.** 47th Middle East medical assembly (MEMA), May 7-9, 2015. Beirut – Lebanon (**Chair of the session**).
- 208. Colorectal cancer session: sphincter preservation and robotic surgery in rectal cancer.** 47th Middle East medical assembly (MEMA), May 7-9, 2015. Beirut – Lebanon (**Chair of the session**).

- 209. Cancer Incidence in Lebanon: Projections in 2020:** Session: Cancer in Lebanon: present situation and future challenges. 47th Middle East medical assembly (MEMA), May 7-9, 2015. Beirut – Lebanon **(Invited speaker)**.
- 210. Updates in the treatment of neuroendocrine tumors (core presentation).** 47th Middle East medical assembly (MEMA), May 7-9, 2015. Beirut – Lebanon **(Invited speaker)**.
- 211. A case of advanced gastric cancer.** Virtual center of excellence meeting on gastric cancer for multidisciplinary approaches in the management of gastric cancer. May 5, 2015. Crown plaza Hotel, Beirut. **(Invited speaker)**.
- 212. Recent advances in the treatment of metastatic castrated resistant prostatic carcinoma.** Lecture to COOP physicians. April 30, 2015, Movenpick Hotel, Beirut **(Invited speaker)**.
- 213. Sumit and difficult to treat patients with urothelial carcinoma.** April 11, 2015. Geneva. **(Active participant)**.
- 214. The management of colorectal cancer.** The 15th Pan Arab Cancer Congress and 12th Lebanese society of Medical Oncology National Forum (LSMO), March 26-28th, 2015, Beirut- Lebanon **(invited speaker)**.
- 215. Advanced pancreatic cancer.** The 15th Pan Arab Cancer Congress (PACC) and 12th Lebanese society of Medical Oncology National Forum (LSMO), March 26-28th, 2015, Beirut- Lebanon **(invited speaker)**.
- 216. Treatment sequencing in CRPC: What do we know?** MENA /SSA oncology and hematology summit. March 6-7 Dubai, UAE by Astellas **(Invited speaker)**.
- 217. Safety aspects of Anti-Angiogenic therapy.** The 3rd ACHOG course on Angiogenesis, Amman, Jordan. February 20-21, 2015 **(Invited speaker)**.
- 218. The 3rd ACHOG course in Angiogenesis.** February 20-21, 2015, Amman, Jordan. A joint meeting between Memorial Solan- Kettering Cancer Center, American University of Beirut Medical center and ACHOG. CME accredited from MSKCC **(Co-Director of the course)**.
- 219. Metastatic colorectal cancer guidelines workshop, expert meeting.** Invited by Bayer, Amman, Jordan, January 2015 **(Active participant)**.
- 220. Cross-multidisciplinary approach for diagnosis and treatment of Neuroendocrine tumors with updates of Medical treatment.** The 13th Annual Congress of the Lebanese Society of Gastroenterology. November 27th, 2014, Beirut- Lebanon **(invited speaker)**.
- 221. Case presentation: Neuroendocrine Tumor of pancreas,** 5th Masterclass in Neuroendocrine tumors. November 14-15th 2014, London, UK. **(Active participation in the interactive session)**
- 222. Antiangiogenic therapy in Gastric cancer Near East & Gulf Gastric summit,** November 7th 2014, The Ritz Carlton, Dubai, UAE, **(invited speaker)**.
- 223. Updates in the treatment of advanced pancreatic cancer.** 17th Annual International Scientific Conference of Alexandria Clinical Oncology Department and the Egyptian Cancer society, October 29-31, 2014. Alexandria, Egypt **(invited speaker)**.
- 224. Optimum treatment sequencing in hormone refractory prostate cancer,** 2nd cancer care forum, October 18th 2014, Clemenceau Medical Center. Beirut- Lebanon **(invited speaker)**.
- 225. Perceptorship program for colorectal cancer. Treatment of elderly with colorectal**

- cancer, conversion therapy in unresected metastatic liver disease and AUBMC experience with HIPEC in peritoneal carcinomatosis.** October 13-15, 2014. Antwerp University Hospital, Belgium **(invited speaker).**
- 226. Epidemiology of cancer in Lebanon and the region with discussion and focus on breast cancer.** SHARP Masters of Science students course (Advances in non-communicable disease research – SHARP 340) AUB- Faculty of Health sciences October 1st 2014, Beirut- Lebanon **(invited speaker).**
- 227. Cancer Epidemiology in Lebanon, public health and clinical importance of breast cancer** SHARP course 340 for SHARP Masters of sciences student. October 1st 2014, Beirut- Lebanon **(invited speaker).**
- 228. Epidemiology of Prostatic Cancer in the Middle East** for urology resident training program. September 19th 2014, Beirut- Lebanon **(invited speaker).**
- 229. Management of CRPC.** Astellas Pharma Global Advisory board. September 13th 2014. Dubai, UAE **(invited speaker).**
- 230. The evolving landscape in the management of advanced NSCLC.** September 16th 2014. Live webcast joining AUBMC with Salmaniya Medical complex (Bahrain) and NCCR (Qatar) **(invited speaker).**
- 231. Cancer registry Training Courses.** Temporal Advisor to WHO Cairo. August 31- September 4, 2014, Cairo, Egypt **(invited speaker).**
- 232. Metastatic castration resistant prostate cancer (mCRPC): Optimum sequencing strategy.** EASO Master class, June 19-22nd, 2014. Casablanca, Morocco. **(invited speaker and chair session).**
- 233. Multidisciplinary management of locally advanced and metastatic pancreatic cancer:** Input of Medical Oncologist 11th Lebanese Society of Medical Oncology National forum. April 25-26, 2014, Hilton Habtour, Beirut- Lebanon **(Invited speaker).**
- 234. Road map for consensus on management of metastatic castrated resistance prostate carcinomas** 6th Middle East Prostate cancer meeting March 14, 2014, Dubai, UAE **(Invited speaker).**
- 235. Castration resistant prostatic cancer: when to start chemotherapy.** The 3rd Joint Uro-Oncology winter symposium February 22, 2014, Movenpick Hotel, Beirut, Lebanon **(Invited speaker).**
- 236. Bronchial neuroendocrine tumors: presentation, diagnosis and management. Primary familial hepatic neuroendocrine tumors: a case-based discussion.** The 4th Saudi neuroendocrine summit February 28- March 1st, 2014, Jeddah, Saudi Arabia **(Invited speaker)**
- 237. Treatment of castrated resistance prostatic carcinoma.** The 4th oncology meeting for Algerian Society of Medical Oncology in association with Arab Medical Association against Cancer and Euro Arab School of Oncology (EASO). December 6-7, 2013, Algeria **(Invited speaker)**
- 238. 4th Masterclass in Neuroendocrine tumors.** November 22-23, 2013, Paris. France. **(Chair of session)**
- 239. Incidence of lung cancer in the Mediterranean region.** X Mediterranean Oncology Society conference, November 11-13, 2013, Taranto. Italy **(Invited speaker)**
- 240. Evolving landscape in the first line therapy of metastatic renal cell carcinoma.** Pfizer

- regional meeting. November 9, 2013, Phoenicia Hotel, Beirut, Lebanon. **(Invited speaker)**
- 241. Lights and shadows in the Management of Prostate Cancer.** European Arab School of Oncology (EASO) course on October 25-26, 2013, Marrakech, Morocco. Skelet- related events prevention **(Invited speaker)**
- 242. Cancer registries in the region.** WHO/IRAQ meeting on cancer control in the region. October 20-22nd, 2013, Doha, Qatar. **(Invited speaker and as WHO temporary advisor)**
- 243. Neoadjuvant chemoradiation in rectal gastrointestinal CALL meeting.** September 19-21, 2013. Dubai, UAE **(Invited speaker)**.
- 244. Neuroendocrine Tumors- Multidisciplinary Disease management.** The Endocrine tumors day organized by the Lebanese Society of Endocrinology Diabetes and lipids. June 29, 2013- Hilton Metropolitan Hotel, Beirut, Lebanon **(Invited Speaker)**.
- 245. Adjuvant and systemic therapy for colorectal cancer.** The Memorial Sloan Kettering Cancer Center and the AUB inaugural joint course in Oncologic sciences. June 23-28, 2013, West Hall, AUB Beirut- Lebanon **(Invited Speaker)**.
- 246. Maintenance treatment with Caprecitabine and Bevacizumab versus Observation after induction treatment with chemotherapy and Bevacizumab in Metastatic Colorectal Cancer. The phase III CAIRO3 study of the Dutch Colorectal Cancer Group by M. Koopion , 8th Best of ASCO in Beirut June 21-22, 2013, Hilton Habtour, Beirut , Lebanon (Invited Speaker).**
- 247. Angiogenesis and extended survival in metastatic colorectal cancer with Avastin. Avastin workshop for Iraqi Oncologists.** June 20, 2013, Habtoor Hotel, Beirut- Lebanon **(Invited Speaker)**.
- 248. Role of targeted therapy in GI Cancer. Lebanese Society for General Surgery (16th Spring Congress).** June 6-7 , 2013, Lebanese Order of Physicians, Beirut- Lebanon **(Invited Speaker)**.
- 249. Targeted Therapy in Metastatic Colon Carcinoma.** Merck Serono Oncology Regional Symposium Middle East 2013. April 11-12, 2013. Prague **(Chair of Session and Invited Speaker)**.
- 250. New Advance in Medical Treatment of Neuroendocrine Tumors.** Update in Hepatobiliary and Pancreatic Cancer, the King Fahed Medical City Cancer Center and Saudi Cancer Society. April 4, 2013, Riyadh **(Invited speaker)**.
- 251. Treatment Sequencing in Castrated Resistant Prostate Cancer.** Fifth Middle East Prostate Cancer Advisory Board. March 29, 2013, Dubai, UAE **(Chair of the board and invited speaker)**.
- 252. Angiogenesis, Basic Concepts and Pathogenesis in Colorectal Carcinoma.** Iraqi Oncology Forum by Roche. March 1, 2013, Beirut, Lebanon **(Invited speaker)**.
- 253. Extending Survival in Metastatic Colorectal Carcinoma.** Iraqi Oncology Forum by Roche March 1, 2013, Beirut, Lebanon **(Invited Speaker)**.
- 254. Safety Aspects and Management of Toxicity of Angiogenesis Inhibitors.** Arab Collaborative Hematology – Oncology Group (ACHOG) Course on Angiogenesis. Feb. 22, 2013, Istanbul-Turkey **(Invited speaker)**.
- 255. Clinical Management of Neuroendocrine Tumors.** Neuroendocrine Tumors workshop for Iraqi Pathologists, organized by AUBMC CME Office. Feb. 8, 2013, Beirut-Lebanon

(Invited speaker)

- 256. Castrated Resistance Prostatic Cancer Case Presentation: Optimal management.** The 2nd Urology-Oncology National Meeting. Feb 15, 2013, Beirut – Lebanon **(Invited speaker)**
- 257. Optimal Sequencing Strategy in Second Line Treatment of Metastatic Castrated Resistance Prostate Cancer.** MDACC 2nd Joint Conference: Genitourinary Malignancies; Update Jan.31-Feb.1, 2013, Amman – Jordan **(Invited speaker)**.
- 258. New Insights and Trends in Cancer Incidence in Lebanon.** The 1st MENA Congress by the Turkish Society of Oncology, the Lebanese Society of Medical Oncology and the Arab Medical Association against Cancer. Nov. 29, 2012, Istanbul-Turkey **(Invited speaker)**.
- 259. Evidence Based Data on Prostate Cancer.** The Euro-Arab School of Oncology workshop on prostate cancer. Nov. 23, 2012, Movenpick Hotel, Beirut – Lebanon **(Invited speaker)** and (chair of session).
- 260. Multidisciplinary Approach in Management of Neuroendocrine Tumors, the 1st Middle East Forum on Neuroendocrine Tumors by ACHOG.** Nov. 17, 2012, Hilton Habtoor Hotel Beirut – Lebanon **(Invited speaker)**.
- 261. Update on Lebanese Tumor Registry.** The Xth Makassed Medical Congress. July 13, 2012, Coral Beach Hotel, Beirut – Lebanon **(Invited Speaker)**.
- 262. Recent Updates in the Management of Colorectal Cancer.** Best of ASCO in Beirut. June 22, 2012, Beirut – Lebanon **(Invited speaker)**.
- 263. Updates in the Management of Colorectal Cancer for Iraqi Oncologists.** By Roche. Beirut May 24, 2012 **(Invited speaker)**
- 264. Update in Treatment of Urologic Cancer,** 12th Pan Arab Cancer Congress, April 27-28, 2012 Cotes de carthage, Tunisia **(Chair of Session)**.
- 265. Update in Treatment of Advanced Pancreatic Cancer.** 12th Pan Arab Cancer Congress, April 27, 28, 2012, Cotes de Carthage, Tunisia **(Invited Speaker)**.
- 266. State of the Art Management of Metastatic Colorectal Cancer, Role of Oral Chemotherapy.** ROCHE meeting on Cancer Treatment Strategies and oral chemotherapies. April 13-14, 2012, Istanbul-Turkey **(Invited speaker)**.
- 267. Epidemiology of lung cancer in the Mediterranean Basin and Middle East.** Lilly Oncology forum, March 23-24, 2012, Istanbul-Turkey **(Invited speaker)**.
- 268. Role of chemotherapy in Metastatic Prostate Cancer.** The First Urology Oncology National Meeting. March 17, 2012, Beirut – Lebanon **(Invited speaker)**.
- 269. Metastatic Colorectal Cancer. Merck Serono Oncology Regional Symposium,** March 2, 2012, Beirut-Lebanon (Chair of the Session).
- 270. Safety Aspects & Management of Angiogenesis Inhibitors.** Angiogenesis: Biology, Basic Principles and Clinical Applications. 1st ACHOG meeting, Beirut – Lebanon, Feb, 24-25, 2012 **(Invited Speaker and Co-chair of the meeting)**.
- 271. Perifosine a new Horizon in Cancer Management,** Colorectal Cancer Update, Jordanian Hematology Association Meeting, Amman-Jordan, Feb.16,2012 **(Invited speaker)**.
- 272. Prostate Cancer in the MENA region.** Steering Committee meeting, Presentation of the results of actual Practice of Prostatic Cancer in Lebanon. Amman, Jordan, Oct. 29, 2011 **(Speaker)**.
- 273. State of the art and update on systemic Therapy of prostate Cancer.** 3rd EASO

- Masterclass in Clinical Oncology (European Arab School of Oncology) Meeting Oct. 27-29, 2011, Amman, Jordan. **(Invited speaker)**.
- 274. Epidemiology of lung cancer in the Mediterranean Area.** IX Mediterranean Oncology Society International Meeting. Oct. 27-29, 2011. Pamplona, Spain **(Invited speaker)**.
- 275. Changing the Roadmap to GIST Survival.** GIST GOLS Meeting. Oct. 21-23, 2011. Athens, Greece.
- 276. Update in the Management of Colorectal Cancer.** Iraqi Oncologists Forum. Oct. 20, 2011, Habtour Hotel, Beirut, Lebanon. **(Invited speaker)**.
- 277. Updates in the Management of Rectal Cancer.** 6th Best of ASCO Meeting, July 1-2, 2011, Beirut, Lebanon **(Invited speaker)**.
- 278. Decision Making in the Treatment of Non-Small Cell Lung Cancer.** Lilly Oncology Forum (Middle East & North Africa). Intercontinental Festival City Hotel Dubai, UAE. April 1-2, 2011 **(Invited speaker)**
- 279. New Epidemiologic Trends in Lung Cancer data from Lebanon and Middle East.** Hotel Vendome Intercontinental – Beirut, March 29, 2011 **(Invited speaker)**.
- 280. Recent advances in the Management of Colorectal cancer.** Oncology-Surgery forum for Near East. Phoenicia Intercontinental Hotel, Beirut, March 26, 2011 **(Invited speaker)**.
- 281. Liver metastasis in Colorectal Cancer: Is This a Surgical or Oncologic Question?** Lebanese Society of Medical Oncology Educational Conference (LSMO 8). Dec. 3-4, 2010, Royal Hotel, Beirut, **(Invited speaker)**.
- 282. Update in the Management of early Rectal Cancer** Lebanese Society of Medical Oncology Educational Conference (LSMO 8). Dec. 3-4, 2010, Royal Hotel, Beirut. **(Invited speaker)**.
- 283. Breast Cancer Management in Mediterranean Countries, Epidemiology, characteristics and Survival (Lebanon).** 8th Mediterranean Conference in Oncology “Innovations in Breast Cancer Management”. Dec. 28-30, 2010, Antalya-Turkey. **(Invited speaker)**.
- 284. Avastin Case Report Assembly Meeting for Gulf Region, Moderator, Colorectal Cancer Session.** Nov. 26, 2010, Beirut.
- 285. Recent Updates in the Management of Hormone refractory Prostatic Cancer.** United Arab Emirates Cancer Congress, Oct. 28-30, 2010 **(Invited speaker)**.
- 286. Multidisciplinary approach to treating Neuroendocrine Tumors.** NET Tour 10, Oct. 23, 2010, Beirut. **(Invited speaker)**.
- 287. Erbitux: Personalized Therapy for metastatic Colorectal Carcinoma.** 5th Oncology Regional Symposium Middle East / Africa. Sept 24, 2010, Beirut **(Invited speaker)**.
- 288. What is the role of targeted therapy in stage III Colorectal Cancer.** The wining TACTIC in adjuvant colorectal cancer meeting. July 22, 2010. **(Invited speaker)**.
- 249. K-ras status and outcome in the adjuvant setting for colorectal cancer.** Best of ASCO. June 2010, Habtoor Grand Hotel, Beirut, Lebanon **(Invited speaker)**.
- 250. New Trends in the Treatment of Advanced Lung Cancer.** A Teaching forum for Iraqi oncologists. Phoenicia Hotel, Beirut April 20, 2010 **(Invited speaker)**.
- 251. Epidemiology of Cancer in Lebanon.** First Clinical Research Symposium, AUBMC March 6, 2010, Beirut **(Invited speaker)**.
- 252. Epidemiology of Cancer.** The world day of cancer. Feb 4, 2010. Intercontinental Hotel, Beirut, Lebanon **(Invited speaker)**.

- 253. Angiogenesis Course:** (Co-chair of the course). Modifying resistance of Herceptin and chemotherapy with antiangiogenic therapy Feb.6-7, 2010, Le Royal, Beirut (**Invited speaker**).
- 254. Epidemiology and Biology of Renal Cell Carcinoma.** Levant Oncology Workshop Jan. 29-30, 2010 , Beirut , Lebanon.(**Invited speaker**)
- 255. Updates in The Treatment of Metastatic Colorectal Cancer. Military Jordanian Oncology Service, Dec. 20, 2009,** Amman, Jordan (**Invited speaker**).
- 256. Treatment of Advanced Colorectal Cancer, Adjuvant Treatment of Colon Cancer Thrombosis in Cancer Patients, Prevention and Treatment.** Dec. 6, 2009, Istanbul, Turkey (**Invited speaker**).
- 257. Update in the Treatment of Lung Cancer, Chemotherapy in Advanced Disease for Iraqi Oncologists.** Nov. 13, 2009, Habtoor Grand Hotel, Beirut Lebanon (**Invited speaker**).
- 258. Adjuvant Treatment of Stage II Colon Cancer.** 1st international conference, Assiut Clinical Oncology Department, Assiut University. Nov. 18, 2009, Luxor, Egypt (**Invited speaker**).
- 259. Advances in the Treatment of Colorectal Cancer, Adjuvant and metastatic disease.** Teaching Forum for Iraqi Oncologists. Nov. 4, 2009 Habtoor Hotel, Beirut, Lebanon (**Invited speaker**).
- 260. Update in the Treatment of Advanced Lung Cancer. 18th Annual Conference,** Kasr El-Aini Centre of Clinical Oncology, Faculty of Medicine, Cairo University. Sept. 30, 2009. Cairo, Egypt. (**Invited speaker**).
- 261. Preoperative fluorouracil-based chemotherapy + or - weekly Oxaliplatin in Locally advanced rectal cancer STAR Study.** 4th Best of ASCO 10-11 July 2009, Habtoor Grand Hotel, Beirut, Lebanon (**Invited speaker**).
- 262. Challenging Cases in Colorectal Cancer:** Rectal Cancer Case discussion MEMA The 42nd Middle East Medical Assembly. MEMA_2009 April 25, 2009. Beirut, Lebanon (**Invited speaker**).
- 263. Challenging cases in Pancreatic Cancer. Interactive Case Discussion (A panelist) MEMA** 42nd Middle East Medical Assembly. MEMA_2009 April 25, 2009. Beirut, Lebanon
- 264. Metastatic Renal Cell Carcinoma, Challenging Landscape of Managements,** 42nd Middle East Medical Assembly. MEMA 2009 April 25, 2009. Beirut, Lebanon (**Chair of Session**).
- 265. Targeted Therapy: A Paradigm shift from Standard chemotherapy in Metastatic Colorectal Cancer.** April 9, 2009. Movenpick Hotel Beirut (**Invited speaker**).
- 266. GIST Tour : Optimizing GIST Management** Case Discussion: Systemic Management of advanced GIST Movenpick Hotel, March 20, 2009 Beirut (**Invited speaker**).
- 267. Perspectives in Lung Cancer** March 6-7, 2009 Brussels Belgium (**Active participation**)
- 268. 2009 Zenith Meeting** 23-25 Jan. 2009, Melin Hotel Seville, Spain (**Active Participation**)
- 269. Breast Cancer: Prevention and early detection:** Burj El Barajneh women Association Feb. 8, 2009 , Beirut (**Invited speaker**)
- 270. Best of ASCO 2008** Highlights of colorectal and pancreatic cancers (2008)
Liver metastasis in colorectal cancer: Current and emerging approaches to treatment.
Pancreatic cancer. Adjuvant Therapy Intercontinental Mzaar, Faraya, Lebanon July 11-12, 2008
- 271. BCLC (Barcelona Clinic Liver Cancer).** Program for the advancement of therapy in

hepatocellular carcinoma. PATH 13015 October 2008. Barcelona, Spain (**Active participant**).

272. **Lebanese Society of Medical Oncology CME activity.** Integrating Biolysis in Treatment of Advanced Colorectal Cancer. Oct. 17, 2008, Rotana Hotel Beirut (**Invited speaker**).
273. **Iraqi Symposium for Targeted Therapy.** Integrating Avastin in treatment of advanced colorectal cancer. Oct. 24, 2008, Beirut (**Invited speaker**).
274. **Iraqi Symposium for Colorectal Cancer.** Eloxatin in the adjuvant treatment and metastatic setting in colorectal cancer. Oct. 26, 2008, Beirut. (**Invited Speaker**).
275. **Merck Serono Oncology Regional Meeting, Erbitux Symposium: 1st line metastatic colorectal cancer. 1st line metastatic non-small cell lung cancer in treatment of head and neck cancers** Nov. 6, 2008, Hughada, Egypt. (**Chair of Session**).
276. **The 6th International Jordan Oncology Society Conference and the Arab Medical Association against Cancer (A.M.A.A.C).** Who benefits from adjuvant therapy among patients with B₂ Stage Colorectal Cancer. Nov. 8, 2008. Amman, Jordan (**Invited speaker**).
277. **ALIMTA in first line Non-small cell lung cancer: Speakers training and expert meeting.** Nov. 27-28, 2008, Berlin, Germany (Active Participation).
278. **The Lebanese Society of Medical Oncology National Forum (LSMO 7)** Modified Resistance to chemotherapy and Trastuzumab by Bevacizumab in locally recurrent breast cancer. Le Royal Hotel Dbayeh, Beirut Lebanon. Nov. 14, 2008 (**Invited speaker**).
279. **The Lebanese Society of Medical Oncology National Forum (LSMO7)** _Lebanese Cancer Registry: Past, Present and Future (2003, 2004 data). Le Royal Hotel Dbayeh, Beirut, Lebanon. Nov. 15, 2008 (**Invited Speaker**).
280. **Lebanese Society of General Surgery Conference** Adjuvant Therapy in Gastric Cancer, Current status, March 29, 2008, Beirut (**Invited speaker**).
281. **Core Curriculum lecture for House Staff.** Update in colorectal cancer. Feb. 21, 2008, AUBMC (**Speaker**).
282. **Lebanese Society of Urologist, Annual Meeting,** chemotherapy for hormone refractory prostate cancer, March 15, 2008, Boulogne, Lebanon (**Invited speaker**).
283. **Lebanese Society of Medical Oncology CME activity:** Snap Shots from WCLC 2007. Advances in first line treatment of locally advanced or metastatic Non-small cell lung cancer, March 27, 2007, Metropolitan, Beirut (**Invited speaker**).
284. **International Breast Cancer Conference: The Practice of Breast Cancer in Lebanon** Feb. 6, 2008, Paris (**Invited speaker**).
285. **The 6th Congress of the Lebanese Society of Gastroenterology:** Update on medical treatment of pancreatic cancer. The Lebanese Order of Physicians Dec. 7-8, 2007 (**Invited speaker**).
286. **Pan-Arab Urology Meeting:** Update on chemotherapy for Hormone Refractory Prostate Cancer Nov. 1-3, 2007_Movenpick Hotel, Beirut, Lebanon (**Invited speaker**).
287. **Best of ASCO 2007:** Update in Colorectal Cancer, Cairo, Egypt. July 6-7 2007 (**Invited speaker**).
288. **Breast Course:** MEMA May 2007 (**chair of session**)
289. **Angiogenesis: A key target in Oncology: a course organized by Eticho (European Training in Clinical Hematology and Oncology)** Barcelona, May 4-5,2007 (**Active participant**)

- 290. Second Middle East & Africa Oncology Summit.** Organized by Novartis Paris, France May 3-4, 2007 **(Active participant)**
- 291. Exploring new horizons in Cancer therapy** (Nevavar Symposium) by Bayer Schering Pharma. Alexandria, Egypt April 26-27, 2007 **(Active participant)**.
- 292. "For The Sake of Our Patients"**. Generics and Copies. Organized by the Lebanese Society of Medical Oncology. March 23, 2007, Gefinor Rotana, Beirut **(Invited speaker)**.
- 293. 5th Roche Middle East Oncology Conference. "Answering the Call"**. Singapore, Feb 15-16, 2007 **(Active participant)**.
- 294. Epidemiology and Systemic therapy in Breast Cancer in Lebanon: Middle East Symposium,** Paris Feb. 6, 2007 **(Invited speaker)**.
- 295. Systemic therapy for hormone refractory prostate cancer: an update Genito-urinary cancer session, The 16th Annual Conference of Cairo University Hospital (Kasr Al Aini). Changing Standards in Cancer Treatment.** Dec. 1-4, 2006, Cairo-Egypt **(Invited speaker)**.
- 296. Breast Cancer-Early detection (lecture for the public) Marathon Beirut,** Nov-30, 2006, Lebanon. **(Invited speaker)**.
- 297. Breast friends session: A Knowledge checkup (for the journalists). Breast Cancer Dialogues, What the experts want women to know.** Nov. 17, 2006. Movenpick Hotel, Beirut, Lebanon **(Invited speaker)**.
- 298. Colorectal cancer, therapy in Advanced and Adjuvant Setting. New Approach in the Treatment of cancer: Meeting Patients' needs. Under the Patronage of the Lebanese Order of Pharmacists.** Oct. 28, 2006, Mzaar International, Lebanon **(Invited Speaker)**.
- 299. Cancer Epidemiology in Lebanon (Cancer Epidemiology Symposium) MEMA/LSMO-6 Meeting** May 11, 2006 **(chair of session and invited speaker)** Beirut-Lebanon
- 300. Treatment of colorectal liver metastasis, 2006 Iraqi Oncology workshop,** May 10, 2006. Beirut – Lebanon **(Invited speaker)**.
- 301. Angiogenesis Course.** April 28-29, 2006 Barcelona, Spain **(Active participant) organized by Accreditation Council of Oncology in Europe** (6 European CME credits) and American Medical Association.
- 302. Zenith Meeting (Zometa Expert Network: Impact the future of Bone Health.** April 24-26, 2006. Porto, Portugal. **(Active participant)**
- 303. Hormonal therapy in breast cancer and supportive treatment in patient with bone metastasis (session chair). The 5th annual meeting of the Jordanian Oncology Society.** April 13-15, 2006, Amman, Jordan
- 304. 6th International Medical Education workshop, Molecular Targeted Therapy of Cancer** April 7-8, 2006 Cracow-Poland. **(Active participant) organized by ESMO and EACCME (6 European CME Credits)**.
- 305. Chemotherapeutic agents in Thoracic Cancer. What's new? Case Discussion. Lebanese Society of Medical Oncology CME meeting. Beirut, Intercontinental Le Vendome Hotel,** March 31, 2006 **(Invited speaker)**.
- 306. Breast Cancer in Lebanon, epidemiology and clinical implications and protocols, breast cancer advisory board, Nice, France, March 23, 2006 (Invited speaker)**.
- 307. 4th Middle East Oncology Conference** March 9th-11th, 2006, Kuala Lumpur, Malaysia-Invited by Roche.

308. Lebanese Cancer Registry- past, present and future. **National meeting on Cancer in Lebanon.** Feb.25-26, 2006. Printania Hotel-Broumana, Lebanon (Invited speaker).
309. Hematology-Oncology Session, cases in gastrointestinal malignancies. The First Annual AUB-John's Hopkins Review of Internal Medicine; Beirut Feb-1-5 2006 (**Chair of Oncology Session & Speaker**)
310. New Guidelines in the Management of Febrile Neutropenia Episodes, Beirut Jan. 26, 2006 (**Chair of Session**).
311. Updates in Head and Neck cancer. **St. Etienne Clinic and Hospital.** Brussels, Belgium. December 26-30, 2005 (Invited speaker).
312. ALIMTA E.U. Thoracic Thought Leader Summit, **Hotel Krasnapolsky,** Amsterdam, Netherlands, December 8, 2005 (**Participant**).
313. Avastin in Colorectal cancer, Clinical experience at AUBMC. Pharma International Avastin Investigators meeting. Basel, Switzerland, Nov. 25-27, 2005 (**Invited**).
314. "Facing Cancer Challenges Today" Lung session chair and discussant, Sharm El Sheikh, Savoy Hotel, Nov. 24, 2005 (**invited**)
315. Role of chemotherapy in Locally Advanced and Androgen-Independent Prostate Cancer XIth **Clinical Congress American College of Surgeon-Lebanon Chapter-Urology Section.** Sept. 8, 2005, Beirut, Lebanon (Invited speaker).
316. ASCO Highlights (2005), Recent Advances in colorectal Cancer. **Lebanese Society of Medical Oncology.** July 22, 2005. (Invited speaker).
317. A. Regional Chemotherapy in pancreatic cancer.
B. Colon Cancer in Lebanon. **Gastro Intestinal Malignancies Conference, Saudi Cancer Foundation,** Feb.16-17, 2005. Al – Khobar, Saudi Arabia (Invited speaker).
318. Paradigm shift in colorectal cancer management. **Jordanian Medical Oncology Association Dead Sea,** Jordan Feb. 3-4, 2005 (Invited speaker).
319. Evidence Based Medicine (Oncology) **The first meeting of the Royal Jordanian Medical Services.** Amman Dec. 23, 2004 (Invited speaker).
320. Cancer in Lebanon. Cancer Prevention and Early Detection Meeting organized by **Private Physicians Associations of Jordan, AUB Alumni Club of Jordan. King Hussein Cancer Center and Mediterranean School of Oncology – Rome – Italy.** Amman- Jordan Nov. 24-27, 2004 (Invited speaker).
321. Epidemiology of Cancer in Lebanon (opening ceremony lecture) **The 1st Oncology Conference of the North Medical Center** Oct. 22, 2004 (Invited speaker), Zgharta, Lebanon.
322. Colon Cancer in Lebanon: Incidence and Clinical Experience at AUBMC. **The VII Makassed Congress-General Surgery Beirut,** Sept 25, 2004. (Invited speaker).
323. Regional Treatment in Pancreatic cancer (Intra-arterial chemotherapy). **The VII Makassed Congress, General Surgery Beirut,** Sept 25, 2004 (Invited speaker).
324. ASCO Highlights(2004) . Recent advances in colorectal cancer. July 15, 2004 Intercontinental Hotel, Beirut. **Lebanese Society of Medical Oncology** (Invited speaker).
325. Recent Advances in the management of Prostatic cancer Jordan July 6, 2004. (Invited speaker)- **Jordanian Society of Medical Oncology.**
326. Evidence Based Medicine – Advances in the treatment of solid tumors. Istanbul. April 30, 2004. **Eli Lilly. Regional Medical Conference** (Invited speaker).

327. Cisplatin and Navelbine in advanced breast cancer, Amman, Jordan April 16, 2004. **Hospital Committee Educational activity (Invited speaker).**
328. Chemotherapy updates in hormone refractory prostatic cancer. **Syrian Oncology Society meeting**, Tadmor, Syria, March 4, 2004. **(Invited speaker).**
329. Cisplatin and Vinorelbine in Advanced Breast Cancer, 10 years of experience, **Egyptian Oncology Society, Alexandria Egypt** Wednesday Oct. 22, 2003. **(Invited speaker)**
330. Breast Cancer Screening and Early Detection, **Joun el Shouf**, Sunday Oct. 12, 2003. **(Invited speaker)**
331. ASCO Highlights and Scientific update. Lung, Breast, Pancreatic, GU and Colorectal Cancers. **King Hussein Cancer Center** August 18, 2003, Amman, Jordan. **(Invited speaker)**
332. **ASCO Highlights**, Colon cancer July 31, 2003, Phoenicia Hotel. **(Invited speaker)**
333. Recent Advances in Colorectal Cancer, **Lebanese Society of Medical Oncology (LSMO)** Wednesday July 16, 2003, Phoenicia Hotel. **(Invited speaker).**
334. **The second Annual work shop on Prostate cancer.** Management of Advanced Prostate Cancer, Highlights on a current study protocol for chemotherapy in Advanced Prostate Cancer Thursday, July 10th, 2003, Metropolitan Hotel. **(Invited speaker)**
335. Chemotherapy for advanced prostatic cancer. **4th educational symposium of the cancer program at AUBMC**, Mzar-Faraya, Lebanon March 15-16, 2003 **(Invited speaker)**
336. **New strategies in the treatment of advanced non-small cell lung cancer.** Jan.11, 2003, Berlin Germany.
337. Breast Cancer in Lebanon. **3rd Educational Symposium of the Cancer Program at AUBMC**, Mzar – Faraya, Lebanon Sept. 14-15 , 2002. **(Invited speaker).**
338. **A step forward in cancer management** 5-6 September 2002, Sharm El Sheikh, Egypt.
339. **Tomozolomide in the treatment of brain metastasis.** Sheraton Hotel July 30, 2002. **(Invited speaker).**
340. **Chemotherapy for advanced pancreatic cancer**, Movenpick Hotel July 20, 2002.
341. **ASCO 2002 Review Session: Non-colorectal GI Cancer.** Monroe Hotel, July 18, 2002 (LSMO meeting). **(Invited speaker)**
342. **Temozolomide Global Investigator Meeting.** 20-22 June 2002, Monte Carlo, Monaco.
343. Cancer Incidence in post war Lebanon: The first population-based estimates, 1993 and 1998. **The Lebanese Cancer Epidemiology Group.** Phoenicia Hotel April 30, 2002. **(Invited speaker).**
344. Intra-arterial chemotherapy for pancreatic cancer, 2nd **Educational Symposium of the cancer program at AUBMC, Mzar-Faraya, Lebanon** April 13, 2002. **(Invited speaker).**
345. New Perspective in the Management of Metastatic Colorectal Cancer. **1st Educational Symposium of the Cancer Program at AUBMC, Mzar-Faraya, Lebanon** Sept. 15, 2001. **(Invited speaker).**
346. Breast Cancer Prevention and early detection **Joun, Shouf Lebanon** June 1, 2001. **(Invited speaker).**
347. Cancer Epidemiology in Lebanon, Hospital Based Cancer Registry, **Middle East Breast Cancer Forum Dubai** March 24-25, 2001. **(Invited speaker).**
348. Cancer Biology and Epidemiology Advanced Course EB 304 " Epidemiology of Chronic Diseases". **Department of Epidemiology and Biostatistics, Faculty of Health Sciences,**

AUB May 25, 1999. (Invited speaker).

349. Epidemiology of cancer in Lebanon AUB experiences. Presented in part at the 1st meeting of the Lebanese Medical Oncology Society Sept. 1998. (Invited speaker).

350. The role of GM-CSF in healing of pressure ulcers and extravasation due to chemotherapy July 8, 1998. The University Hospital of Gent, Belgium. (Invited speaker)

351. Chemoprevention in cancer patients (1996), Saida sponsored by the Lebanese Medical Oncology Society. (Invited speaker)

352. Cancer pain control (1995). Alumni club sponsored by the Lebanese Medical Oncology Society. (Invited speaker)

IV. SERVICES

A- TITLES

- | | |
|-----------------------------------------------------------------------------------------------------|----------------------|
| 1. Head, Tumor registry- Cancer program | 1997 - Present |
| 2. Head, Hematology Oncology Division, | Sept. 2000- Nov 2017 |
| 3. Director, Gastrointestinal and Uro-Oncology Service | April 2011 |
| 4. Director, Data Management and Clinical Research Unit at NK Basile Cancer Center Institute | Oct.2012 - Present |

B- HOSPITAL COMMITTEES

- | | |
|------------------------------------------------------------------|------------------|
| 1. MEMBER, Hospital Committee on Cancer | 1992 - 1997 |
| 2. CHAIRMAN, Hospital Committee on Cancer | 1997 – 2013 |
| 3. VICE CHAIRMAN and MEMBER, Hospital Committee on Cancer | Oct 2014-2016 |
| 4. MEMBER, Performance Improvement Subcommittee for pain. | 2001-2002 |
| 5. MEMBER, Committee of Peers | 2006 – 2008 |
| 6. MEMBER, Professional fees Committee | Oct. 2010 – 2022 |

C- FACULTY COMMITTEE

- | | |
|----------------------------------------------------------------------------------------|----------------------|
| 1. MEMBER, Committee of Bioavailability and Bioequivalence and Clinical trials. | 2007-2009 |
| 2. MEMBER, Procedure Committee as Clinical Research Conduct | Feb.2010-2011 |
| 3. MEMBER , Ad-hoc Committee for the Ambulatory Cancer Center | Feb 2010-2012 |
| 4. MEMBER, Search Committee for ENT Chair | Aug.2010- 2012 |
| 5. MEMBER, Hospital Mortality Morbidity Committee | Oct. 2012 – Sep 2014 |
| 6. MEMBER, Naef K. Basile Cancer Institute Advisory Committee | Dec 2014- present |
| 7. MEMBER, Naef K. Basile Cancer Institute Executive Committee | Oct 2010- present |
| 8. MEMBER, Naef K. Basile Cancer Institute Research Committee | Dec 2014- present |

D- DEPARTMENTAL COMMITTEES

1. **MEMBER**, Internal Medicine departmental committee Sept. 2000 -2017
2. **MEMBER**, Clinical research committee 2001 - 2009

E- EDITORIAL BOARD

- a. Member, The ARAB ONCOLOGY JOURNAL (JAN-2005)
- b. LSMO (Lebanese Society of Medical Oncology) Newsletter (Dec. 2004).
- c. Tumor Registry : 20 Years of Service (Editor in Chief)
- d. Lancet Oncology Middle East (Editorial Board, Lebanon) (August 2007)
- e. Middle East Journal of Cancer (Editorial Board) Sept 2009-present.
- f. Annals of Oncology Middle East Edition (Editorial Board) Jan. 2011
- g. Lead Guest editor, BioMed Research International Special Issue on Future Directions of Immunotherapy in Gastrointestinal Cancers. September 2019 issue
- h. BMC Cancer. Dec. 2020
- i. International Journal of Molecular Sciences. March 2020

F- REVIEWER OF PEER REVIEW ARTICLES AND RESEARCH PROPOSALS

1. Randomized Phase II Study comparing Efficacy and Safety of SOX versus MFOLFOX-6 as Neoadjuvant Chemotherapy without Radiotherapy for Locally Advanced Rectal Cancer (KSCC1301) BMC Cancer BCAN-D-20-03872.
2. Antiangiogenic Therapy: Current Challenges and Perspectives for Cancer Medicine. Dec. 2020. Manuscript ID CAM4-2020-10-4568.
3. Immunotherapy in Solid Tumors and Gut Microbiota: The Correlation. A Special reference to colorectal cancer for cancers journa; - 1034598, 2020.
4. Cell-based immunotherapy approaches for colorectal cancer: main achievements and challenges. Manuscript ID FON-2020-1218 for future Oncology. Jan. 2021.
5. Neoadjuvant Chemoradio Therapy for patients with unresectable radically locally advanced colon cancer: a potential improvement to overall survival and decrease to multivisceral

resection: an original research. BMC Cancer. IG C&C 50595 (Dec. 2020). (invited as editorial board and reviewer).

6. Complete Pathologic response after Pembrolizumab combined with radiotherapy in patients with metastatic colorectal cancer. For OncoTargets and Therapy. Feb. 2021.
7. Early change in peripheral CD4+ T cells predict the response of immune checkpoint inhibitors in gastrointestinal cancer. Immunotherapy Manuscript ID IMT-2020-0068
8. Vitamin C activates Pyruvate dehydrogenase (PDH) targeting the mitochondrial tricarboxylic acid (TCA) cycle in hypoxic KRAS mutant colon cancer. Theranostics Review request (51265v1), 2020.
9. Number of Lymph nodes, Anastomotic Leakage Incidence, Recurrence Rate and 5-year Survival OS of High and Low Ligation of the Inferior Mesenteric Artery in Colorectal Cancer Surgery. BioMed Research International Manuscript ID 2390262
10. MIXED EPITHELIAL ENDOCRINE NEOPLASMS [MEEN] OF THE COLON AND RECTUM – An evolution over time – A targeted review. World Journal of Gastroenterology, Manuscript NO: 56996
11. Continuous ascorbate infusions in the management of the patients with advanced colon cancer. Journal of Translational Medicine JTRM-D-20-00751.
12. Transarterial chemoembolization followed by radiotherapy versus sandwich treatment for unresectable or ablative hepatocellular carcinoma. Technology in Cancer Research & Treatment Manuscript ID TCRT-20-0434.
13. Resistance to anti-angiogenic therapies: a mechanism depending on the time of exposure to the drugs. Frontiers in Cell and Developmental Biology, section Molecular and Cellular Oncology 553024.
14. Review on The South Region Cancer Registry: an evaluation of its exhaustiveness in a cohort of lung cancer patients Manuscript ID TCA-BR-09-2018-2234 - Thoracic Cancer
15. Para spermatic cord proximal-type epithelioid sarcoma: a high-grade and challenging soft tissue malignancy to manage (manuscript # AJU-2020-0041) Asian Journal of Urology, February 2020.
16. Relationship between Mediterranean Diet and Colon Cancer” (manuscript # NC-12-18-3603), in Nutrition and Cancer: An International Journal. February 2019

17. A 12 Year Trend Analysis of the Incidence of Gastrointestinal Cancers from the East Azerbaijan Cancer Registry (2004-2015). BMC Cancer. BCAN-D-17-02450. May 2018.
18. Management of patients with metastatic colorectal cancer in Lebanese hospitals and associated direct cost: A multicenter cohort study. Eastern Mediterranean Health Journal. Ms No EMHJ- D- 17-00197. October 2017.
19. Understanding and targeting resistance to chemotherapy in colorectal cancer worldwide cancer research journal No. 18-0730, September 2017.
20. Results from a retrospective analysis of colonoscopies for Inflammatory bowel disease and colorectal cancer in a Lebanese tertiary care center, for BMJ Open Gastroenterology (bmjgast-2017-000167) August 2017
21. The relationship of high-fat diet, bile acid and bacterial flora with colon cancer. The European Journal of Cancer care Ms No: ECC-2017-0151, August 2017.
22. Habitual consumption of processed meat and gastric cancer risk: A meta-analysis of prospective cohort studies, for Clinical Nutrition (YCLNU-D-17-00592) August 2017
23. Epidemiology of colonic diseases in Lebanon. British medical Journal of Gastro enterology Ms. No: bmjgast-2017-000167, July 2017.
24. When no treatment is the best treatment: active surveillance strategies for low risk prostate cancers, for Cancer treatment reviews (CTR-17-00058), March, 2017.
25. Middle-distance running acutely influences the concentration and composition of serum bile acids: potential implications for cancer risk, for Oncotarget Journal (Paper #027446), February 21st 2017.
26. Molecular targeted drugs and treatment of colorectal cancer: recent progress and future perspectives, for Journal of Drug Targeting (JDT-2017-0013), February 6, 2017.
27. Lung cancer in Basrah during 2005-2012: incidence and time trend Manuscript No. 20160074/ OJS 14515, for Saudi medical journal, March 2016.
28. Detection and significance of Her-2/neu expression in gastric adenocarcinomas. Manuscript No JCRT-62-16, for Journal of cancer research and therapeutics, March 2016.
29. Recent advances in the treatment of castrate resistance prostate cancer, for cancer treatment reviews CTR-D-15-00097, May 2015.

30. Preoperative neutrophil- lymphocyte, lymphocyte-monocyte and platelets, lymphocyte ratios as predictors of overall survival in patients with bladder cancer undergoing radical cystectomy, for tumor biology journal. TUBI-D-14-02960, May 2015.
31. Second line hormonal manipulation in castration resistant prostate cancer, for expert review of anticancer therapy. ERT-2015-0183, December 2015.
32. Optimal sequencing of therapies in the treatment of metastatic prostate cancer, for Cancer treatment reviews. December 2nd 2014
33. Biologics in colorectal cancer - state of the art, for Expert Review of Gastroenterology & Hepatology. October 8th 2014
34. Platinum-based chemotherapy (PBCT) versus Capecitabine-based chemotherapy (CBCT) in patients with metastatic triple negative breast cancer pretreated with anthracyclines and taxans: a single institute experience, for Chemotherapy. November 24th 2014
35. FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer: results from FIRGEM study, for BMC Cancer Journal April 8th 2014.
36. Time trends of cancer incidence in Setif, Algeria, 1986-2010: An observational study, for BMC Cancer. April 2014
37. Cutaneous manifestations of anti-angiogenic therapy in Oncology: Review with focus on VEGF inhibitors for critical reviews in Oncology / Hematology Journal, manuscript CROH-D-B-00074. July 2013
38. The prognostic value of Ki-67 in breast cancer patients with positive axillary lymph node, for Journal of Experimental and Colinical Cancer Research. July 2013.
39. Breast Cancer screening practices among women in selected rural communities of Nigeria for Journal of Public Health and Epidemiology. JPHE- 12- 058, May 2012.
40. Chemotherapy followed by antilogous stem cell transplantation for relapsed diffuse large B-cell lymphoma. A single retrospective institutional experience for LMJ serial no. 2012/4, Feb 2013.
41. Treatment outcome of Docetaxel plus Prednisone for metastatic castration resistant prostate cancer in Korea for Journal of Cancer Research and Therapeutics, Dec. 2012.
42. Risk factors of breast cancer in Saudi females: Case – control study. MS: 2012/2816 for British Journal of Medicine and Medical Research 2012.

43. Survival after Neoadjuvant Chemoradiation in Rectal Cancers; Importance of Metastatic Recurrence as a first Event. For LMJ Serial no. 2010/59, Feb. 2011.
44. The Clinical Usefulness of Assessing VEGF and the Soluble Receptors s VEGFR-1 and S VEGFR -2 in women with Breast Cancer. For British journal of Cancer (BJC CL/2010/2270) Jan 2011.
45. Whole Body 18 F –FDG PET Predicts Progression Free and Overall Survival in Squamous Cell Carcinoma of the Esophagus: Results of a prospective Trial. For Hematology / Oncology and Stem Cell Therapy 9Ms. No HEMONSTEM-D-10-0010GR1) Nov. 2010.
46. Gemcitabine and Cisplatin as first line therapy in Metastatic Breast Carcinoma PAJO (Pan Arab Journal of Oncology) March 2010.
47. Clear Cell Sarcoma of the Axilla: for the Lebanese Medical Journal March 2010.
48. Cisplatin and Vinorelbine in unresectable malignant pleural effusion: for PAJO (Pan Arab Journal of Oncology) Oct. 2009.
49. The Emerging Role of Taxanes and Biologic Combinations in the Adjuvant Treatment of Breast Cancer. MS # 200905012: For Oncology Journal Sept. 2009.
50. Late Solitary Testicular Metastasis from Rectal Cancer: for Journal of Cancer Research and Therapeutics, August 2009.
51. Oxaliplatin and Ifosfamide, a promising combination in Platinum and Taxane-resistant ovarian cancer. MS # 2009/26: for the Lebanese Medical Journal July 2009.
52. Superior Sulcus (Pancoast) tumors of the lung for PAJO (Pan Arab Journal of Oncology Sept. 2008.
53. The first pilot study on characteristics and practice patterns of Kuwaiti breast cancer. MS # CL/2007/2031 for British Journal of Cancer (July 2007).
54. Dexradoxane for anthracycline extravasation. MS # 2007 for Expert Rev. Anticancer therapy.
55. Risk Factors of breast cancer: A report from India. Ms # THE BREAST-D -07-71 for the Breast, March 2007.
56. Chemotherapy of BRCA-1 linked Breast Cancer compared to its sporadic counterparts. MS#C-1708-05 Version 1 for Cancer, August 29, 2005.

57. Variation of chemotherapy administration for Breast Cancer and Association with Hospitalization chemotherapy related toxicity. MS # C-0147-05 Version 1: for Cancer, Feb. 2005.
58. Primary Hepatic Lymphoma: For the Lebanese Medical Journal Nov. 2003: Reference: 2003/40.
59. ANNO 2001/805: A Phase II study of Cisplatin and Vinorelbine in Patients with metastatic breast cancer by G. Mustacchi et al. For Annals of Oncology Jan. 2002.
60. Protocol 2013: Chorambucil versus 2x2 Gy involved field radiotherapy in stage III/IV previously untreated follicular lymphoma patients. A prospective randomized phase III clinical trial EORTC Trial (European Organization for Research and Treatment of Cancer) Nov. 2001.

V. PRESS RELEASES AND INTERVIEWS

1. Cancer treatment, Al –Manar TV, Feb 27, 2019.
2. Cancer in Lebanon, highest incidence rates in the Arab world. Al- Safir, 12 April 2016.
3. Cancer Data in Lebanon 2012, The World Cancer Day, Feb. 7, 2013, Hilton Metropolitan Hotel.
4. The New Cancer Trends in Lebanon Future TV, Feb 27, 2013.
5. Colon Cancer, early detection, prevention and treatment. MTV Station, Tahkik, April 15, 2011
6. Breast Cancer : Al Hurra TV Station, Dec. 16, 2010
7. Cancer in Lebanon: Aub TV Nov. 2009 Breast Cancer, early detection and Management Sumariya Iraqi TV Nov. 2009.
8. Cancer Incidence in Lebanon: Voice of Lebanon Jan. 6, 2009
9. Breast Cancer: Causes, early detection and management. Human and Health magazine, No. 4, July 2008: 9-11
10. Breast Cancer: Epidemiologic data in Lebanon, early detection Manar TV, March 2008
11. Breast Cancer: Early detection Alam Al Soha, Future TV Oct. 30, 2007
12. Breast Cancer Campaign for early detection in Arab countries Saudi T.V. Channel II Nov. 14, 2007
13. Breast Cancer: Chemotherapy and Side effects: NBN Television April 24, 2007
14. Breast Cancer : Early detection : ART Television Nov. 25, 2006
15. Breast Friends Campaign Launch press conference. Movenpick Hotel Nov. 17, 2006.
16. Cancer incidences in Lebanon, Al Afkar June 14, 2004.
17. Breast cancer, screening and early detection, New TV, Oct. 2003.

18. Cancer strategy in Lebanon. Al Bayan, 375, Feb.2003.
19. Breast Cancer, early detection campaign al Anwar August 2002.
20. 600 new cases of breast cancer per year in Lebanon. Al Diyar August 19, 2002.
21. Breast Cancer in Lebanon: Screening for early detection. Al Safir, Thursday August 8, 2002.
22. Cancer in Lebanon 1993-1998 (AUB-Research). Al Safir May 1, 2002, Daily Star May 1, 2002, L'Orient-Le Jour May 1, 2002.
23. Blood Diseases: Thalassemia and Sickle cell Diseases and Gene therapy. AL Mustakbal Feb. 6, 2002.
24. Breast and lung Cancer in Lebanon. Al Afkar 2001.
25. Breast Cancer: History, precipitating factors and preventive measures. Al Diyar, Oct. 10, 1998.